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3Abstract
Up to a third of adults attending the Queen Square UK NHS Specialised Service for
Rare Mitochondrial Disease out-patient clinic remain genetically undetermined. This
thesis describes research which aimed to establish the molecular basis of
mitochondrial disease in these patients and evaluate genotype/phenotype
correlations. Both novel clinical syndromes and molecular causes of disease were
identified. Furthermore, new insights into the respiratory chain (RC) protein structure
were elucidated.
Novel clinical phenotypes: Three previously unrecognised mitochondrial disease
phenotypes were characterised. First, m.9185T>C in MT-ATP6, encoding subunit 6
of ATP synthase (complex V), was detected in a pedigree exhibiting matrilineal
inheritance. Presentation was with axonal Charcot-Marie-Tooth (CMT2) disease.
Further screening of 270 patients with genetically unclassified CMT2 demonstrated
three additional families harbouring the same mutation, thus proving a causal link
between reduced complex V activity and impaired axonal function. Second, a severe
distal myopathy was observed in two unrelated patients with de novo dominant
POLG mutations. Finally, COX10 mutations were linked to adult cytochrome c
oxidase (COX) deficiency. Despite a complex multisystem phenotype comprising
short stature, proximal myopathy, fatigue, sensorineural hearing loss, pigmentary
maculopathy, renal Fanconi syndrome and premature ovarian failure, the patient’s
clinical severity was considerably milder than fatal COX10-related infantile disease.
Nuclear gene mutations: Three major experimental strategies were employed to
locate mutations in the nuclear genes of adults with clinically and/or biochemically
suspected mitochondrial disease. First, a candidate gene approach identified
RRM2B mutations in 2/33 patients with multiple mitochondrial DNA deletions.
Second, whole-exome sequencing confirmed COX10 mutations can cause adult
mitochondrial disease. Finally, combined homozygosity mapping/whole-exome
sequencing in a consanguineous family led to the discovery that NDUFA4 mutations
cause COX-deficient Leigh syndrome. This example of ‘back-translation’ led to the
discovery that NDUFA4, previously considered to be a complex I subunit, is actually
an important component of the COX enzyme complex.
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CHAPTER 1
1. Introductory overview
Approximately 80% of children and 50% of adults with primary disorders of the
mitochondrial respiratory chain (RC) harbour pathogenic mutations in nuclear genes
encoding mitochondrial proteins (unpublished data). This is not surprising given that
the majority of RC subunits and proteins involved with transcription and translation of
mitochondrial DNA (mtDNA), assembly of the multimeric RC enzyme complexes,
biosynthesis of mobile electron carriers within the inner mitochondrial membrane
(IMM), import of solutes and proteins into the mitochondrion, regulation of
mitochondrial membrane dynamics/composition, and mitochondrial fission and fusion
are nuclear-encoded.
Over 120 nuclear genes are linked to mitochondrial disease (Vafai and Mootha,
2012). However, an estimated 1,500 nuclear-encoded proteins (5-10% of the
genomic coding region) are targeted to mitochondria (Calvo et al., 2006). Defects in
any of these genes can potentially cause a mitochondrial disorder. Deciphering the
genetic basis for inheritable disease is essential in order to provide accurate genetic
counselling and prenatal diagnostics and to attempt to predict the subsequent clinical
course of the disorder. Fully characterising the clinical spectrum associated with
mitochondrial dysfunction and advancing current understanding concerning the
functional role of mitochondrial-related nuclear genes in both health and disease will
help facilitate future development of treatment strategies for the benefit of patients. It
is also likely that a genetic diagnosis will be an important inclusion criterion for future
clinical treatment trials.
This thesis focuses on: 1) characterising novel clinical phenotypes associated with
adult RC disease; and 2) identifying causative genetic mutations in the nuclear
genes of patients with presumed but genetically undetermined mitochondrial disease
and assessing the molecular pathogenesis of the variants. In keeping with these
aims the introduction of this thesis focuses on the following: 1) mtDNA replication,
both at the replication fork and via deoxyribonucleotide triphosphate (dNTP)
metabolism, as dysfunction of these cellular processes can generate secondary
Chapter 1 | Introduction
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multiple mtDNA deletions as occurs with POLG and RRM2B mutations; and 2)
cytochrome c oxidase (COX, complex IV) and complex V structure and function.
Specific details of the individual genes discussed are included within the introduction
of the relevant chapter headings. Finally, a general overview of next-generation
sequencing (NGS) is outlined as this technology was utilised to identify the nuclear
basis of mitochondrial disease in two unrelated families and forms an important
component of the thesis.
Chapter 1 | Introduction
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1.1 The mitochondrion
The mitochondrion is a cellular organelle present in almost every eukaryotic cell and
has a number of essential functions. The earliest recordings of mitochondria
probably date back to the 1840s (Henle, 1841). However, it was not until 1890 that
Richard Altmann recognised their universal cellular occurrence and labelled them
‘bioblasts’ (Altmann, 1890). The term ‘mitochondrion,’ derived from the Greek ‘mitos’
(thread) and ‘chondros’ (granule), was later coined by Carl Benda to describe their
appearance during spermatogenesis, when they were likened to a collection of
granules forming threads inside the cells (Benda, 1898).
Mitochondria are thought to have evolved up to two billion years ago from
endosymbiotic prokaryotes (Grivell, 1983). Shared microbial characteristics
(mitochondria contain multiple copies of a single circular genome which employs a
variant genetic code) led to the suggestion that their ancestor was a Proteobacteria
(Futuyma, 2005), possibly related to the Rickettsiales (Emelyanov, 2003), which was
originally endocytosed by another species of prokaryote thereby becoming
incorporated into its cytoplasm. The newly acquired ability of the symbiont bacteria to
conduct cellular respiration in the host cell, which had previously relied solely on
glycolysis and fermentation, enabled survival in much more diverse habitats and thus
represented a considerable evolutionary advantage.
Under the electron microscope mitochondria appear as double membrane-bound
structures in cross-section, with a diameter of approximately 0.5-1.0 m and length
of 2-5 m. The inner mitochondrial membrane (IMM) is highly convoluted forming
cristae which extend into a central matrix space (Palade, 1953). Many of the
mitochondrion’s enzymatic reactions occur on this expanded surface area. Although
frequently depicted as discrete cylindrical structures, mitochondria are highly
dynamic and move throughout the cell whilst constantly fusing and dividing (Bereiter-
Hahn and Jendrach, 2010).
In the late 1940s the mitochondrion was recognised to be a major site of cellular
energy production (Kennedy and Lehninger, 1949). It is now well-established that
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oxidation decarboxylation of pyruvate, fatty acid -oxidation and Krebs’ citric acid
cycle all occur within the mitochondrial central matrix space. The products of these
metabolic pathways, specifically the reduced cofactors NADH (reduced nicotinamide
dinucleotide) and FADH2 (reduced flavin adenine dinucleotide), are subsequently
used to generate cellular energy in the form of adenine triphosphate (ATP), from
adenine diphosphate (ADP) and inorganic phosphate (Pi), via oxidative
phosphorylation (OXPHOS).
Arguably the most important of the major functions of mitochondria, which includes
cell signalling and the metabolism of amino acids, fatty acids, and cofactors, is the
utilisation of molecular oxygen to convert the energy contained in food into ATP, the
cellular energy currency. This process relies on the mitochondrial respiratory
electron transport chain and OXPHOS system.
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1.2 The mitochondrial respiratory chain and oxidative
phosphorylation system
OXPHOS requires five multimeric enzyme complexes (complex I-IV, collectively
termed the RC, and complex V) embedded in the IMM. The sequential transfer of
electrons between each enzyme complex relies on specific electron carriers. These
include flavins, iron-sulphur (FeS) complexes, quinones, and metals such as copper
and the haem groups of cytochromes. Ubiquinone (Coenzyme Q10, CoQ10) and
cytochrome c act as mobile carriers of electrons and move electrons from complexes
I/II to III, and complexes III to IV respectively.
Complex I (NADH:ubiquinone oxidoreductase) comprises approximately 45
polypeptide subunits (at the time of writing, see Chapter 6), seven of which are
encoded by mtDNA. Complex II (succinate-ubiquinone oxidoreductase) has four
subunits, all of which are nuclear encoded. It also participates in Krebs cycle via one
of its subunits, SDHA (succinate dehydrogenase complex, subunit A). SDHA
contains a covalently attached FAD cofactor which catalyses oxidation of succinate
to fumarate in step six of Krebs cycle. In doing so, FAD (reduced flavin adenine
dinucleotide) is converted to FADH2. Electrons are subsequently passed from FADH2,
via the other three complex II SDH subunits, to ubiquinone. Complex III (ubiquinol-
cytochrome c oxidoreductase) consists of 11 subunits, one of which (cytochrome b)
is mitochondrially encoded. Complex IV (cytochrome c oxidase) has long been
considered (at the time of writing, see Chapter 6) to be composed of 13 subunits,
three of which are encoded by mtDNA. Finally, complex V (ATP synthase, F1Fo ATP
synthase) has at least 16 subunits, of which two are mitochondrially encoded.
The process of ATP production is reliant on the presence of oxygen and the reducing
equivalents NADH and FADH2 which are generated by oxidation of: 1) pyruvate,
produced in the cytosol during glycolysis and actively transported across the IMM; 2)
fatty acids; and 3) acetyl-CoA in Krebs cycle. In the absence of oxygen, pyruvate
remains in the cytosol and undergoes fermentation. NADH is oxidised to NAD to
prevent build-up in the cytoplasm and NAD is subsequently re-used for glycolysis.
The waste product of this reaction is lactic acid. When oxygen is abundant, pyruvate
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is oxidised to acetyl-CoA and carbon dioxide by the pyruvate dehydrogenase
complex within the mitochondrion. Acetyl-CoA subsequently enters Krebs cycle in
the mitochondrial matrix and is oxidised during an eight-step process, which involves
different enzymes and co-enzymes, to form carbon dioxide, the reducing equivalents
NADH and FADH2, and GTP (guanosine triphosphate).
NADH transfers electrons derived from oxidation of pyruvate and fatty acids to
complex I, whilst FADH2 transports electrons gained from oxidation of succinate to
fumarate in Krebs cycle to complex II. Flavoproteins also transfer electrons from -
oxidation of fatty acids and other organic acids directly to ubiquinone. From complex
I and II electrons are transferred to ubiquinone and then to complex III, and via
cytochrome c to complex IV where they are accepted by oxygen to produce water
(H2O). The energy released during sequential transfer of electrons is used to
generate the mitochondrial membrane potential (Δψm 150 mV) and pH gradient
(ΔpHm) by translocating protons from the mitochondrial matrix to the intermembrane
(IM) space. Proton pumping occurs at complexes I, III and IV. The resulting
electrochemical gradient is harnessed by complex V which couples proton flow
across the IMM back into the mitochondrial matrix with the synthesis of ATP from
ADP and Pi. ATP is transported across the IMM by the mitochondrial carrier protein
adenine nucleotide translocator (Ant). Although Ant was initially thought to function
as a dimeric structure, recent evidence suggests it may be present in a monomeric
form (Kunji and Crichton, 2010). Once in the cytoplasm, ATP is utilised by the cell as
an energy source. Depending on the energy status of the cell, ATP synthase can
either hydrolyse or synthesise ATP in humans.
Chapter 1 | Introduction
27
1.3 Human mitochondrial genome structure and
organisation
1.3.1 Human mitochondrial DNA
One unique property of mitochondria is that they contain DNA molecules separate to
nuclear DNA (nDNA). The mitochondrial genome is organised into a double-stranded
circle of DNA comprised of 16,569 base pairs (bp). Genes are located on both DNA
strands which are termed the heavy (H) and light (L) strand due to their relative
composition of either mainly purines (adenine and guanine) or pyrimidines (thymine
and cytosine) respectively, with the former having greater molecular weight (MW)
than the latter. It is highly compact with no introns and contains only one major non-
coding region (NCR) known as the control region (comprising 900 bp in mammals).
The control region contains the origin of replication of one DNA strand, the origins of
transcription for both DNA strands, and the Displacement loop (D-loop), a triple-
stranded region whose third DNA strand (or 7S DNA) spans approximately 650 bp
from nucleotide numbers 16,111 to 191 (Mao and Holt, 2009). In total mtDNA
contains 37 genes encoding: 13 polypeptide OXPHOS subunits; 22 tRNAs; and two
rRNAs, both of which are essential for mitochondrial protein synthesis.
MtDNA is susceptible to oxidative DNA damage due to its close proximity to reactive
oxygen species (ROS) at the IMM, lack of protective histone proteins, and limited
proof-reading and repair systems. As a result, mtDNA has a mutation rate 10-20
times that of nDNA (Lynch et al., 2006; Richter et al., 1988).
1.3.2 Mitochondrial nucleoid
In vivo, nDNA adopts a condensed structure associated with histones and other
proteins (Kornberg, 1974; Olins and Olins, 1974) called nucleosomes which form the
basic repeating units of eukaryotic chromatin. These protein-DNA complexes
compact, order, and protect the DNA, and create a degree of regulatory control to
ensure its correct expression. They also facilitate co-ordinated copying and
segregation of DNA molecules.
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MtDNA is also packaged into protein-DNA complexes known as nucleoids, which are
believed to be the units of mtDNA transmission and inheritance (Holt et al., 2007;
Malka et al., 2006). Early studies suggested a single mitochondrion, on average,
contained 3.2 nucleoids and 4.6 mtDNA molecules (Satoh and Kuroiwa, 1991). Later
work suggested that each nucleoid contained between 2-10 mtDNAs in rapidly
dividing cells (Iborra et al., 2004; Legros et al., 2004). However, more recently next-
generation imaging techniques have demonstrated nucleoids are smaller than
previously thought, containing an average of 1.4 mtDNAs (i.e. either one or two
mtDNA molecules per nucleoid) (Kukat et al., 2011).
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1.4 Replication and maintenance of mitochondrial DNA
Since mtDNA encodes only 13 of the approximately 90 essential polypeptide
OXPHOS subunits, the remaining subunits and proteins required for their
transcription, translation, post-translational modification and assembly are all
nuclear-encoded. The dependence on the nuclear genome extends to include the
apparatus required for mtDNA maintenance and repair, the proteins for which are
translated in the cytoplasm and imported into the mitochondria for mtDNA synthesis.
Accurate mtDNA replication is essential to maintain m, established across the
inner mitochondrial membrane by respiration, and is necessary for energy production
in the form of ATP. Despite the mtDNA replication machinery being nuclear encoded,
it is completely separate from its nuclear counterpart consisting of just 5 basic
enzyme components: 1) DNA polymerase gamma (POL) A and B; 2) DNA helicase
Twinkle; 3) mitochondrial single-stranded DNA-binding protein (mtSSB); and 4)
mitochondrial RNA polymerase (POLRMT). Unlike nDNA which replicates once
during cell division, mtDNA continuously replicates throughout the cell cycle in
replicating and post-mitotic cells.
1.4.1 Mitochondrial replication apparatus
1.4.1.1 DNA polymerase gamma A and B
POL is the only known DNA polymerase in animal mitochondria. It functions as a
heterotrimer (Yakubovskaya et al., 2006) composed of one catalytic subunit (POLA)
encoded by POLG, and two accessory subunits (POLB) encoded by POLG2 (Ropp
and Copeland, 1996). The catalytic subunit contains 3 functional domains; a 3’ to 5’
proofreading exonuclease domain; a linker domain; and a highly conserved carboxyl-
terminal polymerase domain (Luo and Kaguni, 2005). The accessory subunits were
first shown to confer high processivity in vitro by promoting formation of long
stretches of DNA (Carrodeguas et al., 1999). This is achieved by both increasing
binding affinity for DNA and enhancing replication rate (Lee et al., 2009, 2010; Lim et
al., 1999; Yakubovskaya et al., 2007).
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1.4.1.2 DNA helicase Twinkle
In 2001 Spelbrink et al. identified the mammalian replicative mtDNA helicase Twinkle
(acronym for T7 gp4-like protein with intramitochondrial nucleoid localisation),
encoded by C10orf2, with structural similarity to bacteriophage T7 gene 4
primase/helicase (T7 gp4) and other ring helicases required for DNA replication
(Spelbrink et al., 2001a). This was achieved by searching for open reading frames
(ORFs) in a region previously identified as being linked to autosomal dominant
progressive external ophthalmoplegia (adPEO) on chromosome 10q24 (Li et al.,
1999; Suomalainen et al., 1995). The C-terminal end of the Twinkle protein was
found to have structural similarity with the C-terminal portion of T7 gp4 and other
hexameric ring helicases, and is now known to be critical for maintenance of human
mtDNA integrity. However, human Twinkle lacks the primase domain motifs found in
the N-terminal primase region of T7 gp4 which confer primase activity. The authors
screened C10orf2 and identified 11 coding-region mutations co-segregating in 12
pedigrees with adPEO associated with multiple mtDNA deletions, thus confirming the
importance of the protein in mtDNA maintenance. Expression of human and
Drosophila Twinkle variants carrying mutations in the helicase motifs have since
been shown to cause mtDNA depletion in cells (Matsushima et al., 2008; Wanrooij et
al., 2007).
1.4.1.3 Mitochondrial single-stranded DNA-binding protein
MtSSB binds single-stranded DNA (ssDNA) as a homotetramer (Li and Williams,
1997). The ssDNA wraps around the tetrameric mtSSB protein through
electropositive channels guided by flexible loop (Bochkarev et al., 1997; Yang et al.,
1997) and prevents refolding and degradation of the nucleic acid. It also enhances
primer recognition (Thömmes et al., 1995) and processivity of POL (Farr et al.,
1999). In vitro, POL, DNA helicase Twinkle, and mtSSB can use double-stranded
DNA (dsDNA) as a template to synthesise ssDNA molecules of over 16kb (Korhonen
et al., 2004). In the absence of mtSSB protein, the ssDNA products are  2kb. No
mutations in the mtSSB gene have been associated with human mitochondrial
disease.
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1.4.1.4 Mitochondrial RNA polymerase
Mitochondrial RNA polymerase (POLRMT) is a nuclear encoded RNA polymerase
involved in transcription of mtDNA and is distinct from other nuclear RNA
polymerases. It was first discovered in yeast and found to be encoded by RPO41
(Greenleaf et al., 1986; Kelly et al., 1986), and later identified in human cells where
significant homologies with sequences corresponding to mitochondrial RNA
polymerases from lower eukaryotes, and to RNA polymerases from several
bacteriophages was shown (Tiranti et al., 1997).
The basal transcription machinery of mitochondria consists of human POLRMT and
mitochondrial transcription factor B2 (TFB2M) (Litonin et al., 2010; Shutt et al., 2010).
They are activated by mitochondrial transcription factor A (TFAM), which also
participates in mtDNA packaging and replication.
In addition to its role in transcribing mtDNA, POLRMT is essential during replication
when it provides RNA primers used to initiate mtDNA synthesis at the origin of heavy
strand DNA replication (OH) (Chang and Clayton, 1985; Chang et al., 1985;
Wanrooij et al., 2008). Primer formation required for replication starts at the light
strand promoter (LSP) in the D-loop, which is also the start point for polycistronic
transcripts later processed to form the complex I subunit ND6 and 8 of the 22 tRNAs
required for translation of the protein subunit encoding mRNAs. The primer extends
from the LSP by 100 bp from which leading strand DNA synthesis can start. Most
H-strand replication initiation events are actually prematurely terminated around 600
bp from OH. The single stranded RNA-DNA (7S DNA) hybrid anneals to the parental
DNA template forming a triple-stranded structure called the D-loop, so-called due to
the displaced parental H-strand (Arnberg et al., 1971; ter Schegget et al., 1971).
The D-loop plays a critical role in controlling mtDNA replication and transcription
(Anderson et al., 1981; Doda et al., 1981), and more recently evidence has
highlighted its interaction with the mitochondrial nucleoid whose role includes
mtDNA protection, repair, segregation and copy number control (He et al., 2007;
Wang, 2006). The precise location of OH, and therefore the start of mtDNA H-strand
replication, is debatable. Transition from RNA primer to DNA has been shown 5-10
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bp downstream of a conserved DNA sequence known as conserved sequence box II
(CSBII) (Kang et al., 1997; Pham et al., 2006), however, many believe OH to be
further downstream from CSBII as evidenced by isolation of DNA replication
intermediates, direct Sanger sequencing and primer extension analysis (Crews et al.,
1979; Fish et al., 2004; Gillum and Clayton, 1978).
According to the asynchronous strand displacement model (see section 1.4.2.1), the
replication machinery continues until two-thirds around the mitochondrial genome
before reaching a 30 bp non-coding DNA region. Here, the replication machinery
exposes the origin of light strand replication (OL) and displaces it into its single
stranded form to allow lagging strand synthesis to be initiated (Kang et al., 1997;
Martens and Clayton, 1979). The single-stranded OL region takes on a stem-loop
conformation. Primer synthesis is initiated by POLRMT which acts as a lagging
strand primase (Wanrooij et al., 2008) by recognising the origin sequence at the OL
stem-loop structure, and extends for  25 bp before being replaced by POL which
initiates lagging strand DNA synthesis. These RNA-DNA transition points have been
shown at the base of the double-stranded stem (Kang et al., 1997). RNA-DNA
transition between POLRMT and POL can be mimicked in vitro (Fusté et al., 2010),
unlike H-strand replication, suggesting OL dependent initiation is an unregulated
event (Wanrooij and Falkenberg, 2010).
1.4.2 The mitochondrial replication process
Despite the replication apparatus being relatively well characterised over recent
years, the precise mode of mtDNA replication has been intensely debated
(Bogenhagen and Clayton, 2003a, 2003b; Holt and Jacobs, 2003). For many years
mtDNA replication was thought to occur exclusively by a strand-displacement model,
where a leading strand is synthesised from OH and a lagging strand from OL in an
asymmetric and unidirectional pattern. In 2000, an alternative model was suggested
which was further expanded in 2006 suggesting duplex replication intermediates
were formed by coupled synchronous leading-lagging strand synthesis, and that the
lagging strand is initially laid down as RNA before conversion to DNA
(ribonucleotide incorporation throughout the lagging strand, so-called RITOLS model
– see section 1.4.2.2) due to the observation that the intermediates were RNase
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sensitive (Holt et al., 2000; Yasukawa et al., 2006). The main criticism of this
proposal was the experimental use of the Brewer and Fangman 2D-agarose gel
electrophoresis (2D-AGE) procedure, in which restriction enzyme-digested DNA is
exposed to native gel electrophoresis in the absence of Ethidium Bromide in the first
dimension, and in its presence in the second dimension (Brewer and Fangman,
1987). It has been suggested that when analysing mtDNA, interpreting 2D-AGE gel
displays is challenging because the replication intermediates produced by the
strand-displacement model are subject to branch migration when the DNA is cleaved
by restriction endonucleases. Unlike fully duplex replicating structures, branch
migration of triplex structures is unstable and liable to loss of the less stable nascent
strands during electrophoresis. Many of the intermediates of the strand-displacement
model would, therefore, be destabilised by 2D-AGE techniques, making rarer
structures more abundant (Clayton, 2003). The proposed mechanisms for mtDNA
replication are discussed in detail below.
1.4.2.1 Asynchronous strand displacement model
Leading strand replication is initiated from a POLRMT-synthesised primer at the LSP.
The replication machinery (consisting of POLA and B, Twinkle helicase and mtSSB)
extends this primer, with the RNA-DNA transition point at CSBII. Replication will
often cease prematurely at a 15 bp conserved sequence known as the termination-
associated sequence (TAS) at the distal end of the control region, thus forming a
stable triple-stranded structure known as the D-loop. The nascent strand of the D-
loop is known as 7S DNA. It has been shown that productive replicative
intermediates, in the process of elongation to full genomic size, have the same 5’
ends as the nascent 7S DNA strand confirming their common origin (Kang et al.,
1997; Tapper and Clayton, 1981). The D-loop is 650 bp in humans (Clayton, 1982).
The TAS may represent a regulation point for mtDNA synthesis. It has also been
suggested the D-loop is critical for mitochondrial nucleoid regulation (see 1.2.2).
When leading strand synthesis does proceed beyond the TAS it continues along the
parental L-strand leaving behind ssDNA protected by mtSSB which also prevents
primer formation of the lagging strand by non-specific binding of POLRMT to the
lagging strand (Fusté et al., 2010).
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Two-thirds of the way round the genome the replication machinery reaches OL which
is exposed by Twinkle helicase in single stranded form when it takes on a stem-loop
structure (Martens and Clayton, 1979; Tapper and Clayton, 1981). The stem
structure prevents mtSSB binding thereby allowing POLRMT to initiate primer
synthesis from a poly dT repeat in the loop region of OL (Fusté et al., 2010). POL
replaces POLRMT and initiates lagging strand synthesis. To complete mtDNA
replication, the two daughter molecules separate, RNA primers are removed from
OH and OL by RNase H1, and gaps in the molecules are filled and ligated by mtDNA
ligase (which is also involved with mtDNA repair). Finally superhelical turns are
introduced into the covalently closed circular mtDNA by mitochondrial type II
topoisomerase (Taanman, 1999). It is recognised that occasional use of secondary
origins, particularly for lagging-strand initiation, may occur (Bogenhagen et al.,
1979); however, human molecules lacking OH or OL do not appear to survive since
both origins are present in almost all deleted forms of human mtDNA.
1.4.2.2 Coupled leading/lagging strand model and RITOLS model
In 2000, Holt et al. proposed the existence of a second replication model in which
leading- and lagging-strand syntheses are coupled, on the basis of 2D-AGE which
showed significant quantities of mtDNA formed duplex replication intermediates (Holt
et al., 2000). Other replication intermediates were also present and thought to
represent simultaneous stand-displacement replication. The strand-coupled
mechanism is proposed to initiate in both directions from a broad zone, OriZ
(Bowmaker et al., 2003). Later studies demonstrated some replication intermediates
were RNase H-sensitive which led to the assumption they were derived from
ribonucleotide-rich DNA synthesis initiated unidirectionally from the non-coding
region (Yasukawa et al., 2005, 2006). According to this replication mode, referred to
as ribonucleotide incorporation throughout the lagging strand (RITOLS) model, the
lagging strand is initially laid down as RNA before being converted to DNA. In a
similar manner to the strand displacement model, RITOLS predicts delayed lagging
strand DNA synthesis, although the mtSSB is replaced by RNA. Short Okazaki-like
fragments may also be used as primers that initiate lagging-strand DNA synthesis
discontinuously (Yasukawa et al., 2006), although these have not yet been
demonstrated in-vitro.
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1.5 Deoxyribonucleotide synthesis and salvage
MtDNA synthesis is independent from nDNA replication and occurs continuously
throughout the cell cycle. This means mitochondria require a constant supply of
dNTPs, the building blocks of DNA, for mtDNA synthesis and maintenance
(Bogenhagen and Clayton, 1976). Mitochondrial and cytosolic dNTP pools are
separated by the mitochondrial inner membrane, which is impermeable to negatively
charged nucleotides (Bestwick and Mathews, 1982). This means mitochondria must
synthesise, salvage or import dNTPs. As mitochondria lack a functional de novo
deoxyribonucleotide synthesis pathway, they rely on: 1) import of cytosolic dNTPs in
replicating cells; and 2) mitochondrial nucleoside salvaging pathways in non-
replicating cells. A number of cytosolic and mitochondrial enzymes are then involved
in the dNTP salvage and synthesis process in both replicating and non-replicating
cells, and are discussed below.
1.5.1 Replicating cells
The exchange of deoxyribonucleotides between the cytosol and mitochondria is
mediated by the mitochondrial deoxynucleotide carrier (Dolce et al., 2001; Pontarin
et al., 2003; Rosenberg et al., 2002). Mitochondria rely on de novo synthesis of
cytosolic deoxyribonucleotides by ribonucleotide reductase (RNR), which catalyses
the direct reduction of ribonucleotide diphosphates to their corresponding
deoxyribonucleotides. They can also obtain them via cytosolic nucleoside salvage
from direct phosphorylation of deoxyribonucleosides by deoxyribonucleoside kinases
(dNK), nucleoside monophosphate kinase (NMPK), and nucleoside diphosphate
kinase (NDPK).
The two major cytosolic dNKs are thymidine kinase (TK1) which phosphorylates
deoxythymidine (dThy) and deoxyuridine (dUri), and deoxycytidine kinase (dCK)
which phosphorylates deoxycytidine (dCyt), deoxyguanosine (dGua) and
deoxyadenosine (dAdn). The latter can also be phosphorylated by adenosine kinase
(ADK) (Arnér and Eriksson, 1995; Jones, 1980; Reichard, 1988; Van Rompay et al.,
2000). RNR and TK1 are both regulated by S-phase and are, therefore,
downregulated in post-mitotic cells.
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1.5.2 Non-replicating cells
Until recently, mitochondrial nucleoside salvage was thought to be the only source of
dNTPs in non-dividing cells. Recycled deoxynucleosides derived from within the
mitochondria or cytoplasm, via the equilibrative nucleoside transporter 1 (hENT1)
(LAI 2004), are phosphorylated by two dNKs: TK2 is specific for dThy, dCyt and dUri,
deoxyguanosine kinase (DGUOK) for dGua, dAdn and deoxyinosine (dIno). Both are
independent of the cell cycle (Eriksson et al., 2002; Wang et al., 1999; Zhu et al.,
1998). Mitochondrial NMPK and NDPK perform the two further phosphorylation
steps for dNTP formation.
In 2000 an R2 subunit homolog encoded by ribonucleotide reductase M2 B (RRM2B)
was identified; termed p53R2 because its transcription is tightly regulated by the
tumour suppressor protein p53 (Nakano et al., 2000; Tanaka et al., 2000). Unlike the
cytoplasmic R2 subunit which is produced exclusively during S-phase in cycling cells,
p53R2 is detectable at low levels throughout the cell cycle in both proliferating and
post-mitotic cells. It is likely p53R2 has an essential role in supplementing the dNTPs
produced by the mitochondrion’s own deoxynucleotide salvage pathway by de novo
synthesis of dNTPs in non-dividing cells.
1.5.3 Maintenance of deoxyribonucleotide triphosphate pools
NMPK and NDPK phosphorylation reactions are reversible, unlike phosphorylation of
deoxynucelosides by dNKs. Dephosphorylation of dNMPs to their corresponding
nucleosides can occur, however, by 5’-nucleotidases: dNT1 is located in the cytosol
and counteracts TK1 and dCK; dNT2 is located in the mitochondrion and specific for
thymidine monophosphate and deoxyuridine monophosphate and probably has an
important role in regulating and protecting mtDNA from excess dTTP, accumulation
of which can cause mitochondrial genetic disease (Gallinaro et al., 2002).
Cellular concentrations for all four dNTPs are tightly controlled via biosynthetic and
degradation pathways (Reichard, 1988), with each dNTP maintained in proportion to
its DNA concentration. Alterations in dNTP pools in cell cultures cause dysfunctional
mtDNA replication and repair (Kunz et al., 1994; Martomo and Mathews, 2002), and
mutations in functionally important dNTP synthesis and salvage genes are
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associated with depletion and multiple deletions of mtDNA. The shortage and/or
imbalance of the dNTP pool are thought to cause reduced efficiency and accuracy of
mtDNA replication, with misincorporation of nucleotides. It may also interfere with
replication by affecting synthesis of the RNA primers necessary for initiation of
replication (Smits et al., 2010).
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1.6 Cytochrome c oxidase (complex IV)
COX, a haem-containing oxidase (Calhoun et al., 1994), is the terminal enzyme
complex (complex IV) of the mitochondrial respiratory chain. It is a large
transmembrane protein with surfaces exposed to both the mitochondrial matrix and
IM space, and exists within the IMM as either a monomer or a dimer, comprising two
monomers connected by a cardiolipin molecule (Kadenbach et al., 2000; Tsukihara
et al., 1995). The latter is considered the active form of the enzyme and catalyses
the transfer of electrons from ferrocytochrome c to oxygen. In doing so, it receives
one electron from four each of cytochrome c molecules and transfers them to one
oxygen molecule to form two molecules of water. Four protons from the inner
aqueous compartment are used to make H2O and four protons are translocated
across the IMM into the IM space, thereby establishing an electrochemical gradient
utilised by complex V to drive generation of ATP. The overall reaction is represented
as follows: 4 ferrocytochrome c + 8H+ (inside) + O2  4 ferricytochrome c + 4H+ (outside)
+ 2H2O.
1.6.1 Cytochrome c oxidase structure
Mammalian COX was originally resolved into eight polypeptide components by gel
filtration and sodium dodecyl sulphate gel electrophoresis (Steffens and Buse, 1976).
However, later experiments using a high-resolution electrophoresis system identified
13 structural subunits (Kadenbach et al., 1983). The subsequent purification of
bovine heart COX assigned all 13 subunits within the enzyme complex (Tsukihara et
al., 1996). The three largest subunits (MTCO1-3) are mitochondrially encoded and
form the catalytic core of the enzyme. The remaining ten nuclear-encoded subunits
(IV, Va, Vb, VIa, VIb, VIc, VIIa, VIIb, VIIc, and VIII) surround the core and are
thought to stabilise the enzyme, function in assembly of the enzyme complex, or
regulate enzyme activity (Taanman, 1997a). Human subunits VIa and VIIa have
heart and liver specific tissue isoforms coded for by different genes (Kadenbach et
al., 1982; Yanamura et al., 1988), thus a total of 15 genes encode the structural COX
subunits. COX has six prosthetic metal groups: two haem (a, a3); two copper (CuA,
CuB); one zinc; and one magnesium (Capaldi, 1990). The two haem A and two
copper moieties are involved in electron transfer, whilst the function of the zinc and
magnesium groups is unknown.
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Despite the historically accepted COX crystal structure, recent evidence from cell
lines, including blue-native gel electrophoresis (BN-PAGE), proteomic analysis, short
hair-pin (sh) RNA induced knock down/over expression studies, and evolutionary
data, suggest that NDUFA4, previously assigned to encode an accessory subunit of
complex I, is actually an additional complex IV subunit (Balsa et al., 2012a). The
disassociation of NDUFA4 from the COX enzyme complex during routine purification
is thought to account for previously failed attempts to identify it as a COX subunit
during crystallisation studies. Misattribution to complex I was probably related to
contamination, as it was previously only inconsistently detected in complex I
preparations and its presence correlated with contamination by another COX subunit
(VIb) (Hirst et al., 2003). As such, COX should now be considered to consist of 14
structural polypeptide subunits.
1.6.2 Cytochrome c oxidase assembly and dysfunction
COX biogenesis is thought to be a linear process in which addition of subunits and
cofactors occurs in a sequential manner. This concept was first presented using data
obtained from rat liver mitochondria in which the incorporation of subunits, labelled
with radioactive methionine, into the COX enzyme complex was recorded
(Wielburski and Nelson, 1983). Analysis of the human enzyme using Blue-native gel
electrophoresis subsequently confirmed this model (Nijtmans et al., 1998). An
assembly pathway characterised by at least three discrete assembly intermediates
(so-called S1-3) forming around core subunit MTCO1 during synthesis of the
holoenzyme, and probably representing rate-limiting steps in the process, was
proposed. The three intermediates included: 1) S1 containing COXI; 2) S2
comprising COXI and IV; and 3) S3 consisting of all the COX subunits apart from
COXVIa and VIIb, insertion of which concludes formation of the enzyme complex
(Nijtmans et al., 1998; Williams et al., 2004a). A large number of accessory proteins
(now known to number at least 46) required for COX assembly were subsequently
identified by studying COX expression in yeast mutants defective in COX assembly
(McEwen et al., 1986; Soto et al., 2012a). However, the mechanistic role of some of
these is unclear.
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At the time of writing, mutations in eleven human nuclear-encoded factors required
for assembly of the enzyme complex (SURF1, SCO1, SCO2, COX10, COX15,
LRPPRC, TACO1, FASTKD2, C2orf64/COA5, C12orf62/COX14 and
FAM36A/COX20) were linked to human COX deficiency, and typically cause severe
neonatal/childhood onset presentations with an early fatal outcome (Soto et al.,
2012b; Szklarczyk et al., 2013). Isolated COX deficiency is the second most
common enzyme deficiency following complex I (5% of 1,406 fresh muscle samples
examined in Nijmegen between 2005 and 2009) (Rodenburg, 2011). Mutations in the
structural subunits are extremely rare (Hanna et al., 1998; Rahman et al., 1999) with
only three nuclear-encoded COX subunits linked to human disease (Indrieri et al.,
2012; Massa et al., 2008; Shteyer et al., 2009). To date, most cases of isolated COX
deficiency are caused by mutations in nuclear-encoded proteins required for COX
translation, maturation or assembly (Soto et al., 2012b) or secondary to mtDNA
depletion. Furthermore, these reported nuclear gene mutations are typically
associated with severe neonatal or childhood onset presentations and an early fatal
outcome. However, many cases of COX deficiency remain undefined at the
molecular level.
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1.7 F1Fo ATP synthase (complex V)
Human mitochondrial ATP synthase is the fifth multimeric enzyme complex (complex
V) of OXPHOS.
Under physiological conditions, the ATP synthase utilises energy created by the
proton electrochemical gradient to synthesise ATP from ADP and Pi in the
mitochondrial matrix (Capaldi et al., 1994). The flux of protons which occurs down
the proton gradient generated by electron transfer occurs from the protochemically
positive (PP) to protochemically negative (PN) side of the IMM. The activity of the
enzyme is reversible, so that ATP hydrolysis generates a protein gradient by reversal
of this flux. Fermenting bacteria without an electron transport chain utilise this
function in order to create a transmembrane proton gradient which is then used to
transport nutrients into the cell, maintain ionic balance, and for flagella. The overall
reaction can be represented as follows: ADP + Pi + H+ (PP)  ATP + H+ (PN)
The enzyme complex is organised into dimers and oligomers (Wittig and Schägger,
2008) and consists of two distinct functional protein domains known as F1 and Fo.
The soluble F1 portion contains the catalytic core of the enzyme complex and is
situated within the mitochondrial matrix, whilst the Fo is bound to the IMM and
contains the membrane proton channel. F1 derives its name from ‘Fraction 1,’
whereas Fo is so-called as it binds and is subsequently inhibited by the antibiotic
oligomycin. Both of the functional regions are comprised of multiple protein subunits
which enable both ‘rotatory catalysis’ and oligomerisation to occur. The latter
mediates mitochondrial and cristae morphology.
Recently, in addition to their ATP synthesising/hydrolysing capacity, dimers of
mitochondrial ATP synthase have been suggested to form the mitochondrial
permeability transition pore (MPTP) (Giorgio et al., 2013). The MPTP is a large
conductance channel in the IMM whose opening causes an increase of permeability
to solutes with molecular masses up to 1.5kDa. This causes the mitochondrial
permeability transition, which refers to the massive swelling and depolarisation of
mitochondria that occurs under some conditions, most notably calcium overload and
stress, with uncoupling of OXPHOS and subsequent cell death.
Chapter 1 | Introduction
42
1.7.1 F1Fo ATP synthase structure
F1 comprises five polypeptide subunits: three ; three ; and one , , and . Fo
contains a c-ring subunit, composed of eight copies (Watt et al., 2010), one copy of
subunits a, b, d, F6, and the oligomycin sensitivity-conferring protein (OSCP), and
finally transmembrane accessory subunits e, f, g, and A6L. F1 subunits , , and 
form the central stalk, and Fo subunits b, d, F6, and OSCP the peripheral stalk of the
enzyme. Subunits a and A6L are encoded by the mitochondrial genes MT-ATP6 and
MT-ATP8 respectively. The remaining 14 subunits (including IF1) are nuclear-
encoded. However, as the crystal structure for complex V is not complete it is
possible additional subunits may still be characterised.
1.7.2 F1Fo ATP synthase assembly and dysfunction
As with COX, research involving assembly-deficient yeast mutants has been
extensively used to study ATP synthase assembly (Kucharczyk et al., 2009a, 2009b,
2009c, 2010, 2013). However, due to rapid turnover of Fo subunits and the stator in
these yeast mutants (the latter formed of the peripheral stalk and subunit a, thereby
linking the catalytic and membrane domains (Walker and Dickson, 2006), ATP
synthase biogenesis is not easily analysed (Rak et al., 2009). Assembly of F1, the
stator, and the c-ring is thought to occur separately, although the sequence in which
the individual subunits are inserted into each module is unclear. Mammalian ATP
synthase is subsequently thought to proceed as follows: assembly of the c-ring
followed by binding of F1, the stator, and finally subunits a and A6L (Wittig et al.,
2010). This process is dependent on numerous nuclear-encoded ancillary proteins.
Complex V deficiency is rare, and was the least frequent isolated RC enzyme defect
seen in Nijmegen between the years 2005 and 2009 (1% of 1,406 fresh muscle
samples examined) (Rodenburg, 2011). Mutations in only three structural ATP
synthase-encoding subunits are described: 1) mitochondrial-encoded MT-ATP6 (Holt
et al., 1990) and 2) MT-ATP-8 (Jonckheere et al., 2008); and 3) nuclear-encoded
ATP5E (encoding the  subunit of F1) (Mayr et al., 2010). Two additional genes have
been associated with complex V deficiency: TMEM70, which functions as an
ancillary factor of complex V biogenesis (Cízková et al., 2008); and the F1 portion
assembly factor ATP12 (De Meirleir et al., 2004).
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1.8 Whole exome sequencing
Until relatively recently, identification of causative pathogenic mutations in
monogenic disorders was reliant upon two main strategies: 1) candidate gene
analysis using automated Sanger sequencing, so-called ‘first-generation’ technology,
of known genes reported, or having potential, to cause genetic disease; and 2)
genetic linkage mapping studies, when families with multiple affected and unaffected
relatives were available. The main disadvantage of the former is that prior knowledge
is needed to enable selection of a suitable candidate gene(s) to be screened, whilst
the latter depends on the availability of large multigenerational pedigrees with DNA
required from numerous affected and unaffected relatives, and even when
successful, a region of linkage rather than a single candidate gene is identified.
Since 2005, ‘next-generation’ sequencing (NGS) platforms have been increasingly
utilised to study rare variations in different diseases and to locate novel disease
genes for both Mendelian disorders and complex traits (Metzker, 2005). Initially,
NGS technology utilised three main platforms which relied on parallel, cyclic
interrogation of sequences from spatially separated clonal amplicons, (oil-aqueous
emulsion bead [Roche: pyrosequencing chemistry], clonal beads [SOLiD:
sequencing by sequential ligation of oligonucleotide probes], or clonal bridges
[Illumina: sequencing by reversible dye terminators]) (Pareek et al., 2011), although
a number of additional platforms have since been developed. Whole exome
sequencing uses NGS technology to couple targeted exon capture with massively
parallel DNA sequencing (all NGS platforms perform both the sequencing reactions
and data capture simultaneously, unlike automated Sanger sequencing where the
sequencing reaction is performed separately to the read detection). This technique
determines all the coding variations an individual harbours. Although limited to exons,
which constitute only 1-2% of the human genome, most alleles known to underlie
Mendelian disease disrupt these protein-coding sequences, thereby making it a
powerful yet cost-effective model for the identification of mutant alleles (Stenson et
al., 2009).
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1.8.1 Next-generation sequencing workflow
Although a number of NGS platforms exist, they all share certain basic principles
required to capture a whole or subset of the mammalian genome at a scale
corresponding to massively parallel sequencing. These steps can be broadly
grouped as: 1) template preparation; 2) sequencing and imaging; 3) sequence read
alignment; and 4) variation detection. In the case of exome sequencing, an additional
step is required in order to enrich the sample for protein-coding exons alone.
Genomic DNA (gDNA) is randomly fragmented to lengths of 300-400 bp. Several
micrograms of DNA are then used to construct a shotgun library. The library
fragment ends are repaired and ligated to adaptors (or linkers) containing universal
priming sites which later allow individual fragments to be hybridised to a flowcell and
subsequently amplified and sequenced using common PCR primers (Metzker, 2010).
In the case of whole exome sequencing, the library is enriched for sequences
corresponding to exons by hybridising the fragments to biotinylated probes (or baits)
(RNA or DNA) complementing all known exons in the genome. Biotin-streptavidin
based pulldown is then used to isolate the bound exome-containing fraction, followed
by amplification and massively parallel sequencing of the enriched library. The
sequences are then aligned with the reference sequence prior to variant detection.
1.8.2 Approaches to gene identification using whole exome
sequencing
Whole exome sequencing has rapidly become the first-line molecular approach for
identification of causative, rare (minor allele frequency [MAF]  1%) and novel,
mutations in monogenic Mendelian disorders, due to the high throughput and
relatively low expenditure of this technique in comparison with the available
alternatives. The key challenge, however, is distinguishing disease-related alleles
from the background of non-pathogenic polymorphisms and sequencing errors.
Typically, exome sequencing identifies 20,000-30,000 single nucleotide variants
(SNVs) to the reference exome in each individual (Bamshad et al., 2011). As such, it
is important to adopt a clear bioinformatic approach prior to exome sequencing in
order to maximise the likelihood of identifying the causal mutation(s). The following
strategies can be utilised to aid identification of disease-causing alleles using whole
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exome sequencing data: 1) filtering genes with rare or novel variants predicted to be
pathogenic that are shared by multiple, unrelated, probands with identical clinical
phenotypes; 2) sequencing the exomes of both parents and the affected child when
spontaneous disease exists for de novo heterozygous mutations (so-called ‘trio’
analysis); and 3) linkage analysis (if sufficient affected individuals are available for
study) prior to exome sequencing of the interval identified if access is limited to one
or two small families or homozygosity mapping if parents of the proband are
consanguineous.
Novelty is assessed by filtering the variants against recorded polymorphisms
available in public databases, such as dbSNP and 1000 Genomes Project, and/or
those found in a cohort of unaffected controls. This filtering step assumes that an
allele found to harbour variants that occur in the filter set cannot be causative. This
approach is powerful because only a small proportion (~2%) of the SNVs identified in
any one individual is novel (Bamshad et al., 2011). However, there are limitations.
First, dbSNP is known to be contaminated with pathogenic alleles. Second, as the
number of sequenced exomes and genomes increases, filtering for observed
variants independent of their MAF risks eliminating pathogenic alleles which occur in
the general population at relatively high frequencies. This is of particular importance
in recessive disorders in which the carrier does not exhibit a phenotype which would
usually result in exclusion from a control database, for example the 1000 Genomes
Project (Ng et al., 2010b). As such, searching for variants with a MAF of  1% in
addition to novel variants, particularly in rare recessive disorders, is recommended.
Candidate alleles can be further divided according to their predicted pathogenicity.
For instance, stop codons gained, frameshift, and missense mutations would be
weighted more heavily than synonymous mutations. However, the risk is that
variants which do not alter protein-coding sequences, such as splice site mutations,
could be overlooked. The deleterious impact of the variant can also be quantitated
using various algorithms. For example phyloP (Cooper et al., 2010), SIFT (Kumar et
al., 2009), and Polymorphism Phenotyping v2 (Adzhubei et al., 2010) consider
factors such as the sequence conservation of a particular genomic region, or the
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physiochemical alterations that might be caused by an amino acid substitution and
how these might affect protein function.
Finally, candidate genes can be identified using prior knowledge of their biological
and functional characteristics which are shared with other genes or proteins,
dysfunction of which is known to cause a similar clinical phenotype. In the case of
mitochondrial disorders, filtering for an inventory of genes whose protein products
are primarily localised to the mitochondria (the so-called mitochondrial proteome
(Calvo and Mootha, 2010)) is a powerful albeit imperfect (in view of the extra-
mitochondrial or double localisation of many gene products) tool to reduce the list of
candidate alleles when a primary disorder of the RC is suspected. One such
example of an inventory of mammalian mitochondrial genes is Mitocarta, a
compendium of over 1000 human genes (compiled using mass spectrometry of
mitochondria isolated from different tissue types, protein tagging/microscopy, and
integration of other genome-scale datasets of mitochondrial localisation, using a
Bayesian approach) with strong support of mitochondrial localisation (Pagliarini et al.,
2008a).
1.8.3 Limitations of whole exome sequencing
Despite significant benefits to whole exome sequencing there are some limitations.
Firstly, non-coding intronic regions are not interrogated and although most variants
known to underlie Mendelian disorders are thought to disrupt protein-coding
sequences (Stenson et al., 2009), the contribution of non-coding regions to disease
has not yet been determined. Secondly, exome sequencing only captures what we
currently know exists. Thirdly, not all known genes are properly captured and
sequenced using exome sequencing. Examples include repetitive regions,
sequences which are highly homologous for other locations in the genome, and AT-
or GC-rich sequences. The first two examples make mapping the resulting reads
back to the reference exome difficult, whilst GC and AT-rich target sequences may
show PCR amplification bias in product yield during template preparation which
results in their underrepresentation in exome alignments and assemblies (Dohm et
al., 2008; Harismendy et al., 2009; Hillier et al., 2008; Metzker, 2010). Fourthly, in
addition to the repeat expansion and intronic mutation mechanisms, copy number
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variations (CNVs) are not detected. This is because PCR-based sample preparation
methods are used, thus all targets eventually achieve similar concentrations.
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1.9 Aims of thesis
The aims of this thesis were to: 1) characterise novel adult clinical phenotypes
associated with primary dysfunction of the RC; and 2) identify causative genetic
mutations in the nuclear genes of patients with presumed but genetically
undetermined mitochondrial disease, and to assess their molecular pathogenesis.
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CHAPTER 2
2. Materials and Methods
Materials and methods shared amongst multiple chapters are outlined in detail below.
Methods used only once are included under the relevant chapter headings within a
separate methods section.
2.1 Histopathology and electron microscopy
Muscle and nerve biopsies were performed following informed consent. Muscle was
snap frozen at the bedside and stored at -80°C until use. Standard histological and
histochemical stains were used on cryostat sections as previously described
(Rahman et al., 2000). The sural nerve was fixed in 3% glutaraldehyde with 0.1 M
sodium cacodylate buffer, post fixed in 1% osmium tetraoxide and embedded in
Araldite CY212 resin. One µm resin sections were cut and stained with methylene
blue, azure II and basic fuchsin. Seventy nm resin sections of areas of interest were
cut and contrasted with uranyl acetate and lead citrate for electron microscopy (EM).
Teased fibres were prepared as previously described (Low et al., 1978).
Muscle and nerve histopathology and EM was performed in the University College
London Hospitals (UCLH) National Hospital for Neurology and Neurosurgery
(NHNN) National Commissioning Group (NCG) Neuropathology diagnostic
laboratory and results were interpreted by Dr Janice Holton and Dr Rahul Phadke.
2.2 Cell culture methods
2.2.1 Cell incubation
Skin biopsies were performed following informed consent. Human fibroblasts were
established from skin explants and cultured routinely in Dulbecco’s modified Eagle’s
medium, 4.5 g/L D-(+)-glucose, Glutamax™-I (Life Technologies) supplemented with
10% fetal bovine serum, 110 g/ml of sodium pyruvate, 50 U/ml of penicillin, 50
g/ml of streptomycin and 50 g/ml of uridine. Medium was changed every 4 days.
The cell density was monitored by phase-contrast microscopy and cultures
approaching 80-90% confluency were harvested and re-plated at a lower density.
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Cells were grown routinely in plastic dishes at 37°C in a humidified atmosphere of
5% CO2 in air, but cultured onto glass coverslips for 3 days prior to
immunocytochemical investigations (Taanman et al., 2003). Cultures were checked
for mycoplasma infection by 4',6-diamidino-2-phenylindole staining prior to all
experiments.
Cell incubation was performed by Dr Jan-Willem Taanman at the Department of
Clinical Neuroscience, University College London Institute of Neurology.
2.2.2 Harvesting cells
Fibroblasts were washed with sterile phosphate-buffered saline (PBS) and
trypsinisation was then performed. Culture medium was added to the dislodged,
trypsinised cells to stop further trypsin activity. The resulting fibroblast suspension
was then collected, and was pelleted by centrifugation at 200 × g for 10 minutes in a
Thermo Scientific Heraeus Megafuge 16 centrifuge. The cell pellet was subsequently
resuspended with culture medium.
2.3 Biochemical methods
Spectrophotometric analysis of haem absorption spectra was performed using crude
mitochondrial pellets from muscle tissue (see section 2.5.1). All other RC enzyme
assays used mitochondria isolated from cultured skin fibroblasts by differential
centrifugation (see section 2.5.2). The one exception to this was the RC enzyme
assay performed on cultured skin fibroblasts grown on galactose-containing medium
(Chapter 6) in which whole cell lysates were used (see section 2.5.3).
Spectrophotometric analyses of RC enzymes extracted from muscle tissue were
performed in the UCLH NHNN NCG Neurometabolic diagnostic laboratory by Dr Iain
Hargreaves.
2.3.1 Sample preparation
Whole cell lysates or mitochondrial fractions were used. For whole cell lysates,
cultured skin fibroblasts, grown on galactose-containing medium (Chapter 6), were
harvested. Pellets of harvested cells (see section 2.5.3) and mitochondrial fractions
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(see sections 2.5.1 and 2.5.2) were resuspended in isolation medium (320 mM
sucrose, 10 mM Tris, pH 7.4 and 1 mM EDTA) with three protease inhibitors (1 mM
PMSF, 1 μg/ml leupeptin and 1 μg/ml pepstatin A). Snap-freezing was performed on
samples for 3 cycles using liquid nitrogen to disrupt the cells and expose
mitochondrial enzymes. A bicinchoninic acid (BCA) protein assay (see section 2.5.4)
was then carried out on the samples (2 l) in triplicate to determine the protein
concentration and the remainder of the samples were used in spectrophotometric
activity assays.
2.3.2 Spectrophotometric analysis
All measurements were made at 30°C using the HITACHI U-3310
spectrophotometer (apart from citrate synthase [CS] where a 96-well plate and a
plate reader was used) and quadruplicated measurements were recorded. Complex I
and complex IV were measured in the cultured skin fibroblasts of the adult patients
with COX deficiency discussed in Chapter 5 and 6, whereas complex II+III was
measured in the cultured skin fibroblasts of the adult patient with COX deficiency
discussed in Chapter 5 only.
2.3.2.1 Complex I (NADH: ubiquinone reductase)
The oxidation of NADH was measured spectrophotometrically at 340 nm in 1 ml
solution of 20 mM potassium phosphate (KPi) buffer (pH 7.2), 8 mM MgCl2, 150 M
NADH, 1 mM KCN, and 2.5 mg/ml bovine serum albumin (BSA) prewarmed at 30ºC.
An additional 10 μl of H2O was added to the reference cuvette, whereas 10 μl of
mitochondrial extract was added to the sample cuvette. Approximately 30 seconds
after initiating the measurement, ubiquinone-1 stock solution (~5 mM in ethanol) was
added to a final concentration of 50 M to start the reaction. When the time scale
reached 380 seconds, 10 μl of 10 mM rotenone stock solution (in ethanol) was
added to inhibit complex I. Measurement was continued for another 340 seconds to
allow the evaluation of non-rotenone sensitive NADH dehydrogenase activity.
2.3.2.2 Complex II+III (succinate: cytochrome c reductase)
The succinate cytochrome c reductase assay measures the rate of reduction of
cytochrome c and was performed as described by King (King, 1967) . The assay was
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measured in 1 ml solution of 100 mM KPi buffer (pH 7.4), 0.3 mM EDTA, 0.1 mM
cytochrome c, 1 mM KCN, 20 mM Na+ succinate, and 2.5 mg/ml BSA, at a
wavelength of 550 nm. Two cuvettes with KPi buffer, EDTA, cytochrome c and BSA
were prewarmed at 30ºC, whilst 7.5 μl of mitochondrial extract was incubated with
40 l of 500 mM Na+ succinate and 10 l of 100 mM KCN at 30°C for 5 min to
activate the enzyme. After 4 min, both the reference and test cuvettes were loaded
into the spectrophotometer. When the full 5 min had elapsed, the mitochondrial
extract (along with Na+ succinate and KCN) were added to the test cuvette, whilst 40
l of 500 mM Na+ succinate, 10 l of 100 mM KCN and 7.5 l of H2O were added to
the reference cuvette. Both cuvettes were mixed thoroughly and the absorbance at
550 nm was measured for 5 mins. After this time 10 μl of 2 mM antimycin A was
added to the test cuvette and mixed and measurements continued for a further 4-5
mins. The antimycin A halts the reaction because cytochrome c reductase is
antimycin A sensitive.
2.3.2.3 Complex IV (cytochrome c oxidase)
Spectrophotometric analysis was performed in 0.1 M KPi (pH 7.0) prewarmed at
30ºC according to Wharton and Tzagoloff (Wharton and Tzagoloff, 1967). Two
cuvettes (for reference and sample) were identically loaded with KPi buffer.
Cytochrome c was reduced by dithionite and added to a final concentration of 50 μM
and a total volume of 1 ml. The cytochrome c in reference cuvette was then oxidised
with 10 μl of 0.1 M potassium ferricyanide and 5 μl of mitochondrial sample was
added to the sample cuvette 30 seconds after initiating the measurement by the
spectrophotometer, which measured the absorbance difference at 550 nm between
the reference and the sample. The entire measurement cycle lasted for 5 minutes
and the absorbance values were recorded for every one-minute interval.
2.3.2.4 Citrate synthase
CS activity was measured using a previously described method (Coore et al., 1971).
The activity of the mitochondrial citric acid cycle enzyme was used as an indication
of the relative mitochondrial enrichment of the sample. CS catalyses the reaction
between oxaloacetate (OAA), the substrate, and acetyl CoA resulting in the
production of citrate and liberation of ‘free’ thiol groups (CoA-SH). DTNB (‘Ellman’s
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reagent’, 5,5’-dithio bis-2-nitrobenzoid acid) binds free thiol groups to produce
DTNB-CoA which is yellow and absorbs at 412 nm. A master mix was made up as
follows (for 1 sample to make a total volume of 1000 l): 500 l of 200 mM Tris; 20 l
of 10 mM acetyl-CoA; 20 l of 10 mM DTNB ; 10 l of 10% (w/v) Triton X-100; 10 l
of 10 mM oxaloacetate ; 430 l of H2O. The master mix was pre-warmed to 30°C. 10
l of the sample was added to 990 l of the mastermix and 240 l was pipetted into 4
separate wells on the 96-well plate in order to perform the assay in quadruplicate,
along with four blanks (replacing the sample with 10 l of H2O). The increase in
absorbance at 440 nm was recorded over a 10 min period on a plate reader.
2.3.3 Respiratory chain enzyme activity calculations
The NADH dehydrogenase of complex I is the only rotenone-sensitive NADH
dehydrogenase in the cell. To measure complex I activity the difference in
absorbance change per minute before (activity of all NADH dehydrogenases) and
after addition of rotenone (activity of all NADH dehydrogenases excluding complex I)
was measured. The rotenone-sensitive activity of complex I can then be calculated
via the Beer-Lambert Law with the ubiquinone extinction coefficient (=6.81 mM-1).
Likewise, the activities of Complex II + III and CS were calculated via the Beer-
Lambert Law with the cytochrome c (19.2 mM-1) and DTNB (13.6 mM-1) extinction
coefficients, respectively. The specific enzyme activities (nM/mg/min) were
calculated by dividing the rate by the protein concentration obtained from the BCA
protein assay.
For COX the rate constant (k) was calculated from a programmed spreadsheet by
taking the logarithm of change in absorbance per min (Wharton and Tzagoloff, 1967).
The specific COX activity (k/mg/min) was calculated by dividing the rate constant by
the protein concentration obtained from the BCA protein assay.
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2.4 Genetic methods
2.4.1 DNA extraction from whole blood and muscle tissue
DNA extraction was performed from whole blood using the Qiagen Flexigene DNA
extraction kit and muscle tissue using the Promega Wizard Genomic kit according
the manufacturer’s instructions in the UCLH NHNN NCG Neurogenetics diagnostic
laboratory by Ms Cathy Woodward.
2.4.2 DNA and RNA quantification
DNA and RNA quantification was carried out on a NanoDrop® ND-1000
spectrophotometer (NanoDrop). A 2 µl sample was loaded onto the machine.
Nucleotides, RNA, single-stranded DNA, and double-stranded DNA all have an
absorbance maximum at 260 nm, whereas proteins that may contaminate the
sample have an absorbance maximum at 280 nm. The ratio of absorbance at 260
nm compared to that at 280 nm is therefore used to assess the purity of DNA and
RNA. A ratio of approximately 1.8 is generally considered acceptable for DNA, whilst
a ratio of approximately 2.0 is acceptable for RNA. All samples used in the
experiments presented in this thesis were in the acceptable range of purity.
2.4.3 Polymerase chain reaction
DNA fragments were amplified using polymerase chain reaction (PCR) (Mullis et al.,
1986; Saiki et al., 1988). The standard PCR mix per 1 l DNA template (200 ng/l)
consisted of: 12.5 l Amplitaq Gold 360 mastermix (Applied Biosystems); 9.5
l nanopure H2O; 1 l of 10 pmol forward; and 1 l of 10 pmol reverse primer, to
make a total mastermix volume per well of 25 l. The standard cycling conditions
consisted of an initial denaturation step at 95°C for 10 min, followed by 30 cycles of
denaturation at 95°C for 30 sec, annealing at 58°C for 30 sec, and extension at 72°C
for 30 sec. The final extension step at 72°C was for 7 min. PCR products and RFLP
fragments were separated on a 2% agarose gel that contained 0.25 g/ml of
ethidium bromide and then visualised under UV illumination. Five hundred ng of a
100 bp ladder (Invitrogen) was used as a size standard. To monitor for
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contamination a negative control containing 1 l of ddH2O instead of template DNA
was used for each reaction.
2.4.4 Automated Sanger sequencing
Sanger sequencing involves the selective incorporation of chain-terminating
dideoxyribonucleotide triphosphates (ddNTPs) by DNA polymerase during in vitro
DNA replication. The process requires a single-stranded DNA template, a DNA
primer, a DNA polymerase, normal dNTPs and modified ddNTPs that terminate DNA
strand elongation. Chain-terminating nucleotides lack the 3'-OH group necessary for
formation of a phosphodiester bond between two nucleotides. As such, when
ddNTPs are incorporated into the growing DNA chain they prevent DNA polymerase
from any further extension. The ddNTPs may be radioactively or fluorescently
labelled for detection in automated sequencing machines.
In this thesis, amplification of DNA fragments for sequencing was performed using
specific overlapping primers (the oligonucleotide sequences for each primer are
listed under the relevant chapter heading), and BigDye Terminator v.1.1 cycle
sequencing kit (Applied Biosystems). The samples were run on a 3730xl DNA
Analyzer, assembled and analysed using Seqscape v.2.5 software (Applied
Biosystems) and were compared to the reference sequence.
2.4.5 Whole exome sequencing
Whole exome sequencing was performed within the UK10K project. DNA (1-3 μg)
was sheared to 100-400 bp using a Covaris E210 or LE220 (Covaris, Woburn, MA,
USA). Sheared DNA was subjected to Illumina paired-end DNA library preparation
and enriched for target sequences (Agilent Technologies; Human All Exon 50 Mb -
ELID S02972011) according to manufacturer's recommendations (Agilent
Technologies; SureSelectXT Automated Target Enrichment for Illumina Paired-End
Multiplexed Sequencing). Enriched libraries were sequenced using the HiSeq
platform (Illumina) as paired-end 75 base reads according to the manufacturer's
protocol. The mean coverage of the exomes was 74 times. The Burrows-Wheeler
Aligner (BWA) (Li and Durbin, 2009) was used for alignment to the human reference
genome build UCSC hg19 (Grch37). To improve raw alignment BAMs for single
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nucleotide polymorphism (SNP) calling, we realigned around known (1000 Genomes
pilot) indels, and recalibrated base quality scores using Genome Analysis Toolkit
(GATK) (DePristo et al., 2011). BAQ tags were added using SAMtools calmd. BAMs
for each sample were merged and duplicates marked using Picard. Variants (SNPs
and Indels) were called on each sample individually with both SAMtools mpileup
(0.1.17) (Li et al., 2009) and GATK UnifedGenotyper (1.3.21) (McKenna et al., 2010),
restricted to exon bait regions plus or minus a 100 bp window. Various quality filters
were applied to each of the callsets separately. Calls were then merged, giving
preference to GATK information when possible. Calls were annotated with 1000
Genomes allele frequencies, dbSNP132 rsids and earliest appearance in dbSNP.
Functional annotation was added using Ensembl Variant Effect Predictor v2.2
against Ensembl 64 and included coding consequence predictions, SIFT, PolyPhen
and Condel annotations, and GERP and Grantham Matrix scores. Variant filtering of
the single nucleotide variants and indels was done as previously described on the
basis of autosomal recessive inheritance. The filtering of the variants was done very
stringently, excluding variants in dbSNP132, 1000 Genomes, synonymous and other
non-coding variants apart from essential splice site changes. Variants were also
excluded if present in either the remaining UK10K rare disease cohort (823 exomes
at the time of the analysis) or the NHLBI Exome Sequencing Project (ESP) database.
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2.5 Protein methods
2.5.1 Isolation of mitochondria from muscle tissue using
differential centrifugation
Frozen muscle tissue was ground in homogenisation buffer (320 mM sucrose, 1 mM
EDTA, 10 mM Tris-HCl pH 7.4) in a glass homogenizer manually. Muscle
homogenates were centrifuged at 600 × g for 10 min at 4°C. The supernatants were
stored on ice and the pellets were resuspended in homogenising buffer,
homogenised and centrifuged at 600 × g for 10 min at 4°C. Both the supernatants
were pooled and centrifuged at 12000 × g for 10 min at 4°C. The mitochondrial
enriched protein pellets were subsequently used for RC enzyme assays (performed
in the Neurometabolic diagnostic laboratory by Dr Iain Hargreaves), haem-
absorption spectra analysis, in-gel activity staining, and western blot analysis of
sodium dodecyl sulphate (SDS)-denaturing and blue-native polyacrylamide gels.
Protein concentrations were determined by BCA protein assay.
2.5.2 Isolation of mitochondria from cultured skin fibroblasts
using differential centrifugation
Twenty 10 cm plates with confluent cultures of fibroblasts (~10 × 106 cells) were
harvested by trypsinisation. Cell pellets were washed in 50 ml of PBS supplemented
with 1 mM phenylmethysulfonyl (PMSF), 1 g/ml of leupeptin, and 1 g/ml pepstatin
A (all Sigma). These protease inhibitors were added to the ice-cold buffer shortly
before use. Cell pellets were frozen at -80°C. After storage at -80°C cell pellets were
thawed and put on ice. All procedures (including centrifugations) were carried on ice
or at 4°C. Each cell pellet was resuspended in 1 ml ice-cold homogenisation buffer
(10 mM Tris-HCl pH 7.4, 1 mM sodium EDTA, 250 mM sucrose, 1 mM PMSF, 1
g/ml leupeptin, 1 g/ml pepstatin). Cells were pelleted by centrifugation at 4000 x g
for 5 mins. The supernatant was discarded and the cell pellet resuspended in 2 ml
ice-cold homogenisation buffer and transferred to an ice-cold, 2 ml Teflon® pestle
PYREX® Potter-Elvehjem tissue homogeniser. Cells were homogenised (20 strokes
at 1000 rpm) and the homogenate was transferred to a centrifuge tube. Nuclei, cell
debris, and unbroken cells were pelleted by centrifugation at 1500 x g for 10 mins.
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The supernatant was transferred to a new tube and kept on ice. The pellet was
resuspended in 2 ml ice-cold homogenisation buffer and transferred to back to the
glass tissue homogeniser. The pellet was homogenised, transferred to a centrifuge
tube, and centrifuged at 1500 x g for 10 mins as before. The two supernatants were
combined and centrifuged again at 1500 x g for 10 mins. The supernatant was
transferred to a clear centrifuge tube and the mitochondria were pelleted by
centrifugation at 11,500 x g for 12 mins. The supernatant was discarded and the
mitochondrial pellet was resuspended in 100 l homogenisation buffer. The
resuspended mitochondria were stored at -80°C until use.
Mitochondria were isolated from all fibroblast cultures (apart from the cells grown on
galactose-containing medium discussed in Chapter 6, where whole cell lysates were
used for RC enzyme assay) using this previously described method of differential
centrifugation (Rickwood et al., 1987). The isolated mitochondria were subsequently
used for RC enzyme assays and western blot analysis of SDS-denaturing
polyacrylamide gels. Protein concentrations were determined by BCA protein assay.
As the mitochondrial enrichment by the differential centrifugation procedure may vary
between samples, spectrophotometric assays of CS activity were performed (see
section 2.3.2.4), so that the RC enzyme activities could be expressed relative to the
mitochondrial marker enzyme CS and, thus, allow correction for different levels of
mitochondrial enrichment of the samples.
2.5.3 Whole cell lysates
Two 10 cm plates with confluent cultures of fibroblasts (~106 cells) were harvested
by trypsinisation. Cell pellets were washed in 5 ml of PBS supplemented with 1 mM
PMSF, 1 g/ml of leupeptin, and 1 g/ml pepstatin A. Protease inhibitors were added
to the ice-cold buffer shortly before use. Cell pellets were frozen and stored at -80°C.
Cell pellets were thawed and put on ice. All procedures (including centrifugations)
were carried on ice or at 4°C. The cell pellet was resuspended in 1 ml ice-cold
homogenisation buffer and the cells were pelleted by centrifugation at 16,000 × g for
10 minutes at 4°C. The supernatant was removed and the cell pellet resuspended in
a volume of homogenisation buffer relative to the size of the pellet (75 l for a small
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size pellet, 150 l for a medium size pellet, and 200 l for a large size pellet). Protein
concentrations were determined by BCA protein assay.
Whole cell lysates of fibroblasts grown on galactose-containing medium were used
for RC enzyme assay of complexes I and IV in Chapter 6.
2.5.4 Bicinchoninic acid protein assay
The BCA protein assay was performed according to the instructions provided by the
Thermo Scientific Pierce BCA Protein Assay Kit. A serial dilution was made of the
bovine serum albumin (BSA) standard provided and resulted in a final BSA
concentration ranging from 0 to 2000 μl/ml. To estimate the protein concentration 25
μl of the BSA solution at varying concentrations and 25 μl of diluted mitochondrial
extracts were mixed with 200 μl of Working Reagent (50:1 ratio of BCA Reagent A to
Reagent B) in wells of a 96-well plate. The 96-well plate was subsequently incubated
at 37˚C for 30 minutes, followed by the detection of the absorbance at 562 nm of the
BSA standard and samples. A linear plot of absorbance against concentration was
constructed for BSA standard and the protein concentration of samples could then
be interpolated from the plot.
2.5.5 SDS denaturing polyacrylamide gel electrophoresis
A 12.5% and 15% separating gel mix and a 3% stacking gel mix were made up using
the reagents below for the western blots performed in Chapters 4 and 5. The gel
mixtures were filtered at 0.2 m prior to addition of ammonium parsulphate (APS)
and tetramethylethylenediamine (TEMED). After adding APS and TEMED the gel
was poured between two glass plates separated by a 0.75 mm spacer (BIORAD mini
PROTEAN II system) and overlaid with ddH2O. Once polymerised, the ddH2O was
removed and APS and TEMED were added to the 3% stacking gel mix which was
then poured on top of the separating gel. A comb was then inserted and the gel left
to polymerise for 45 min.
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3% stack 12.5% separating 15% separating
3.75 M Tris-HCl (pH 8.6) - 920 l 920 l
0.5 M Tris-HCl (pH 6.5) 500 l - -
40% acrylamide/bis (37.5:1) 450 l 3.1 ml 3.7 ml
20% SDS 25 l 46 l 46 l
Urea 1.8 g 3.25 g -
ddH2O 3.25 ml 3.5 ml 2.9 ml
10% ammonium persulphate 25 l 44 l 44 l
TEMED 3 l 6 l 6 l
In Chapter 6, a 4-20% Tris-Glycine gel (Thermo scientific) pre-cast gel was used.
Based on the BCA protein assay results, samples were diluted to the same
concentration using PBS and 2x Dissociation Buffer (2x DB – 100 mM Tris-HCl, pH
6.5, 24% [v/v] glycerol, 8% [w/v] SDS, 4% [v/v] -mercaptoethanol, 0.02% [w/v]
bromophenol blue). Additional volumes of 1x DB were added to the samples
(including blanks) to ensure each lane contained equal volumes of DB. Samples
were incubated at 37°C for 30 mins and then centrifuged at 16,000 × g. The
supernatant was transferred to a new tube prior to loading. Wells were rinsed and
the samples loaded. Gels were run at 100 V for 15 min and then 200 V for further 45
min.
Western blotting was performed in a BIORAD Mini Trans-Blot® Electrophoretic
Transfer Cell. Labelled polyvinylidene difluoride (PVDF) membranes (Millipore) were
soaked in methanol then equilibrated in Towbin’s buffer (TB 25 mM Tris-base, 192
mM Glycine, and 20% methanol). The transfer sandwich was made in the gel holder
cassette and consisted of a sponge pad, followed by a sheet of Whatmann 3MM
paper, the separating gel, the wet PVDF membrane, a second sheet of Whatmann
3MM paper and finally a second sponge pad. The transfer sandwich was assembled
whilst submerged in TB, ensuring that there were no air bubbles between any of the
different layers. The transfer sandwich was put in the transfer cell with the separating
gel side facing the cathode and the PVDF membrane side facing the anode. An ice
pack and a small magnetic stir bar were placed in the transfer cell which was then
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filled with TB. The transfer was performed at 100 V for 75 min after which the
sandwich was disassembled and the membranes left to dry overnight.
Once dried the membrane was briefly soaked in methanol and equilibrated in PBS. It
was then blocked with 10% (w:v) milk powder in PBS. A falcon tube was also
blocked with 5 ml of 10% milk powder. The milk was discarded and the blots and the
falcon tube were washed briefly with PBS/Tween (1x PBS, 0.3% Tween 20) three
times. The blots were then placed into the blocked falcon tubes with the protein side
facing inwards. The primary antibody was added to 3 ml of PBS/Tween in the falcon
tube and the blot was incubated for two hours on a roller mixer. Blots were then
washed three times in PBS/Tween for 10 mins. The secondary antibody was then
added and the blot incubated for one hour before being washed a further three times
in PBS/Tween. The specific primary and secondary antibodies used for each
experiment are included under the relevant chapter heading.
The Thermo Scientific Pierce ECL Western blotting substrate kit and Amersham
Hyperfilm ECL was used to detect chemiluminscent signals with exposure times from
7 sec to 16 min.
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2.5.6 Blue-native polyacrylamide gel electrophoresis
2.5.6.1 One-dimensional blue-native gel electrophoresis
Separating 8-16% acrylamide gradient gels with a 4% acrylamide stacking gel were
used in Chapters 4 and 5, whereas a 3-12% acrylamide gel with a 3% acrylamide
stacking gel was additionally used in Chapter 6. Acrylamide-bis (48% acrylamide,
1.5% bis), 3x gel buffer (1.5 M 6-aminocaproic acid, 150 mM bistris) , ddH2O,
glycerol, 10% APS, and TEMED were used to make the gels in the ratios listed
below.
High
(16%)
High
(12%)
Low
(8%)
Low
(3%)
Stack
(4%)
Stack
(3%)
Acrylamide/bis
(37.5:1)
3.25 ml 2.44 ml 1.98 ml 0.744 ml 0.5 ml 0.38 ml
3x gel buffer 3.30 ml 3.3 ml 3.96 ml 3.96 ml 2 ml 2.0 ml
ddH2O 1.70 ml 2.51 ml 5.86 ml 7.098 ml 3.5 ml 3.12 ml
Glycerol 1.98 g 1.98 g - - - -
10% ammonium
persulphate
35 l 35 l 70 l 70 l 50 l 50 l
TEMED 3.5 l 3.5 l 7 l 7 l 5 l 5 l
The mixtures were filtered at 0.2 m prior to addition of APS and TEMED. Once APS
and TEMED had been added to the high and low percentage mixtures for the
separating gel, 7 ml of each were pipetted into the wells of the gradient mixer. A
peristaltic pump at a constant speed was used to pour four gels between two glass
plates separated by a 0.75-mm spacer (BIORAD mini PROTEAN II system). The
gradient gels were overlaid with H2O-saturated butanol which was removed after the
gels had polymerised. APS and TEMED were added to the stacking gel mix which
was then poured on top of the separating gels. Combs were inserted and the gels
were sealed with clingfilm and left overnight (or for up to one week) at 4°C.
The concentration of the mitochondrial enriched fraction of muscle tissues (~10 g/l
of protein) was determined using a BCA protein assay and equalised by diluting by
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adding homogenising buffer (320 mM sucrose, 1 mM EDTA, 10 mM Tris-HCl pH 7.4)
with protease inhibitors. Ten l of the samples with a protein concentration of 10
g/l were then suspended in 150 l of protein solubilising solution (1 M -amino-n-
caproic acid, 50 mM Bis-Tris [pH 7.0]) and 25 l 20% n-dodecyl--D-maltoside
(DDM). After incubation on ice for 30 minutes, the samples were centrifuged at
16,000 × g for 20 minutes at 4°C. To the supernatant 25 l 1 M -amino-n-caproic
acid, 5% Serva Blue G was added before loading 20 l in each lane of the gradient
polyacrylamide blue-native gel (Schägger, 1995; Williams et al., 2004b). Cathode
buffer A (50 mM tricine, 15 mM bistris, 0.02% Serva blue G, pH 7.0) and anode
buffer (50 mM bistris, pH 7.0) were added to the electrophoretic tank and
electrophoresis was performed at 100 V for 20 min, then constant at 4 mA per gel.
Electrophoresis was stopped 5 mins after the blue front had run off the bottom of the
gel. If the gel was to be used for enzyme activity staining, the cathode buffer A was
replaced with cathode buffer B (50 mM tricine, 15 mM bistris, 0.002% Serva blue G,
pH 7.0) halfway through the run. Immunoblotting was performed as described in
section 2.5.5 except that two additional washes of the PVDF membrane in methanol
prior to blocking were performed in order to remove excess Serva blue G. The
specific primary and secondary antibodies used for each experiment are included
under the relevant chapter heading.
2.5.6.2 In-gel activity staining
In-gel enzyme activity staining of complex I and IV (Chapter 6) was performed as
previously described (Zerbetto et al., 1997). The gel strips were first destained for a
few minutes in anode buffer and rinsed in ddH2O. The NADH:ubiquinone
oxidoreductase (10 ml of 2 mM Tris·HCl pH 7.4, 25 mg nitroblue tetrazolium and 1
mg NADH) or the COX stain (1 ml 0.5 M NaPi buffer pH 7.4, 5 mg diaminobenzidine,
10 mg cytochrome c, 10 l catalase solution at 2 g/ml and 9 ml ddH2O) were added
and the gel strips incubated overnight at 37°C. Gel strips were soaked in ddH2O to
halt the reactions. The staining intensity of each band was quantified using
AlphaEase FC software from Alpha Innotech.
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2.5.6.3 Two-dimensional blue-native gel electrophoresis
For two-dimensional blue-native gel electrophoresis (Chapter 6), lanes excised from
the blue-native gel were soaked in 3 ml of reducing buffer (RB: 1% [v:v] -
mercaptoethanol, 1% [w:v] SDS) for 15 mins in a sealed tube under a fume hood as
a denaturing step. The gel slices were then soaked in 3 ml of equilibrating buffer
(EB: 50 mM tris, 1% [w:v] SDS, pH 6.8) twice for 10 min. Glass plates were
assembled sandwiching the gel slice within the top third of the plates where the
stacking gel is poured. Approximately 3-4 mm was left between the top of the gel
slice and the top of the plates in order to completely seal the gel slice within the
stacking gel. A 15% SDS-denaturing separating gel was poured with sufficient space
between the top of the separating gel and the gel slice for the stacking gel. The
separating gel was overlaid with ddH2O. Once polymerised, the ddH2O was removed
and a 3% stacking gel was poured ensuring the gel strips were completely
surrounded. A single toothed comb was inserted between the gel strip and the edge
of the gel plate to enable a BioRad Precision plus Protein Standard to be used as a
molecular size marker. The stacking gel was left 30 mins to polymerise and then
electrophoresis was performed at 100 V. When the gel front had entered the
separating gel the voltage was increased to 200 V (run at constant voltage) until the
front reached the bottom of the gel. The gels were blotted and probed as described
in section 2.5.5. The specific primary and secondary antibodies used are included in
Chapter 6.
2.5.7 Immunocytochemistry
2.5.7.1 Polylysine Coating of Coverslips
Lyophilised poly-L-lysine (5 mg), purchased from Sigma, was resuspended in 5 ml of
sterile 0.1 M sodium borate buffer, pH 8.1; and 200 μl of the polylysine mixture was
incubated on the surface of 22-mm sterile coverslips for an hour, followed by two
rinses with sterile H2O.
Chapter 2 | Materials and Methods
66
2.5.7.2 Cell-seeding on coverslips
Polylysine coated coverslips were seeded with approximately 7.5 × 103 cultured skin
fibroblasts in 500 μl medium at 37˚C, 5% CO2 in wells of a 6-well plate. After 1 hour,
1.8 ml of medium was added to each well.
2.5.7.3 Immunofluorescence Staining of Cultured Cells
Cells were fixed by incubating with 4% w/v paraformaldehyde in PBS at room
temperature for 20 min. The coverslips were subsequently incubated with methanol
at -20˚C for 15 min for further fixation and membrane solubilisation. The coverslips
were incubated with 300 μl of 10% normal goat serum (NGS) in PBS at 37˚C for 30
min to prevent non-specific antibody binding. Coverslips were probed with 80 l of
diluted primary antibody (anti-NDUFA4 and anti-MTCO1) and 2% NGS in PBS for 45
min at 37ºC. For secondary incubation, the coverslips were incubated with 80 l of
100-fold diluted secondary antibody tagged with an Alexa fluorophore (Molecular
Probes) and 2% NGS in PBS for 45 min at 37ºC. Prior to the paraformaldehyde
fixation step, some samples were also counterstained with 5 μM MitoTracker Red
CM-H2XRos (Invitrogen) by incubation in the culture medium at 37˚C for 45 minutes,
followed by a further 30 minutes of incubation at 37˚C in plain culture medium. The
coverslips were mounted with Agar Scientific citifluor/PBS/glycerol supplemented
with 1 μg/ml of 4’,6-diamidino-2-phenylindole (DAPI) from Sigma and sealed with nail
varnish. Fluorescent images were obtained with a Zeiss Axioplan confocal
microscope. The optimal concentration of anti-NDUFA4/anti-MTCO1 used was
determined by direct observation of fluorescent signal strength of diluted 1 mg/ml
anti-NDUFA4/anti-MTCO1 (dilutions included 50-1, 100-1, 200-1, 400-1 and 800-1).
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CHAPTER 3
3. m.9185T>C in MT-ATP6 causes axonal Charcot-
Marie-Tooth disease
3.1 Introduction
Mitochondrial ATP generation by OXPHOS underpins key molecular processes that
are essential for normal central and peripheral nervous system axonal function.
Axonal peripheral neuropathies are a well-recognised complication of primary
mtDNA mutations. However, the neuropathy is rarely the presenting or predominant
clinical manifestation of the disease (Croft et al., 1977; Peyronnard et al., 1980;
Gemignani et al., 1982; Yiannikas et al., 1986; Mizusawa et al., 1991; Schröder,
1993; Bouillot et al., 2002; Kärppä et al., 2003). In contrast, mutations in the nuclear-
encoded mitochondrial genes MFN2 (Chung et al., 2006) and GDAP1 (Baxter et al.,
2002), which encode outer mitochondrial membrane proteins, usually present with
isolated peripheral neuropathy, and are now recognised to be important causes of
both axonal and demyelinating forms of Charcot-Marie-Tooth (CMT) disease.
An extended family in which the index case presented with a pure motor neuropathy
in childhood evolving into motor-predominant CMT2 in later life was investigated.
Additional multi-system clinical features and a matrilineal inheritance pattern
prompted mtDNA sequencing in one individual. The known pathogenic missense
mutation m.9185T>C in MT-ATP6 was identified and shown to segregate with
disease in affected members of the pedigree. MT-ATP6 encodes the ATP6 subunit
of the mitochondrial ATP synthase (OXPHOS complex V). The ATP6 subunit is a
component of Fo and involved in the translocation of protons across the IMM, a
process which is coupled to ATP generation within the catalytic domain of F1. In view
of the striking neuropathic features observed in this family, a large cohort of 442
unrelated probands with genetically undefined CMT2 and dHMN was screened for
mutations in MT-ATP6 and MT-ATP8, encoding two components of complex V.
Mitochondrial mutations that impair the function and stability of complex V are shown
to be an important but previously unreported cause of CMT2.
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3.2 Patient cohort
A cohort of patients from the Medical Research Council (MRC) Centre for
Neuromuscular Diseases inherited neuropathy database was selected. These were
patients presenting with a clinical phenotype compatible with either CMT2 (a
progressive peripheral motor and sensory neuropathy, n=270) or dHMN (a
progressive peripheral motor neuropathy without sensory involvement, n=172).
Diagnosis was based on clinical and electrophysiological phenotypic evaluation.
Patients were excluded from the study if inheritance was consistent with paternal
transmission. All patients with CMT2 were negative for mutations in MFN2. The
majority of patients with CMT2 were also screened for mutations in MPZ, HSPB1,
HSPB8, TRPV4 and GJB1 where appropriate. Patients with dHMN were negative for
mutations in HSPB1, HSPB8, TRPV4, and selected patients were negative for
mutations in BSCL2 and GARS. These genes were sequenced in the UCLH NHNN
Neurogenetics diagnostic laboratory.
3.3 Methods
3.3.1 Automated Sanger sequencing of MT-ATP6/8
Amplification of DNA fragments for sequencing was performed using specific
overlapping primers, Amplitaq Gold 360 mastermix (Applied Biosystems) and BigDye
Terminator v.1.1 cycle sequencing kit (Applied Biosystems). The workload was
shared with Sinéad Murphy and Ellen Cottenie (MRC Centre for Neuromuscular
Diseases, UCL Institute of Neurology). The samples were run on a 3730xl DNA
Analyzer, assembled and analysed using Seqscape v.2.5 software (Applied
Biosystems) and were compared to the rCRS reference sequence (NCBI accession
number NC_012920). Full mitochondrial genome sequencing was performed in one
patient (Family 3.1, Patient III-6). Targeted sequencing of MT-ATP6/8 was performed
in all remaining patients (Table 3.1 for primer sequences).
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Table 3.1: Primer sequences used for targeted analysis of MT-ATP6/8
Fragment Forward primer Length
(nucleotides)
Nucleotide
locationReverse primer
1 5’-ACAGTTTCATGCCCATCGTC-3’ 530 8196-8726
3’-GTTCGTCCTTTAGTGTTGTG-5’
2 5’-CCGACTAATCACCACCCAAC-3’ 598 8646-9244
3’-GGTTTTACTATATGATAGGC-5’
3 5’-ATCCAAGCCTACGTTTTCAC-3’ 593 9151-9744
3’-CTGAGGCTTGTAGGAGGGTA-5’
3.3.2 Restriction endonuclease analysis to quantitate m.9185T>C
mutant load
Restriction endonuclease analysis was used to quantitate mutant load in m.9185T>C
positive cases. The workload was shared with Ellen Cottenie (MRC Centre for
Neuromuscular Diseases, UCL Institute of Neurology). To introduce a BSP12OI
restriction site (GGGCCC) into the mutant but not the wild-type mtDNA, a fragment
of MT-ATP6 containing the mutation site was amplified using the mismatch sense
primer (9,161-9,184) ACGTTTTCACACTTCTAGTGGGCC and antisense primer
(9,273–9,253) AGAGGGCCCCTGTTAGGGGTC. In order to calculate heteroplasmy,
a FAM fluorophore (6-carboxyfluorescein) was used at the 5’ end of the antisense
primer. To amplify the fragment initially an annealing temperature of 58°C and 17
PCR cycles was used. The temperature, PCR cycle number and primer
concentration was subsequently optimised so that sufficient PCR product was
obtained. The PCR cycle number was then reduced to the lowest possible number to
ensure that amplification occurred only in the linear phase to enable accurate
quantitation of mutant load. The final PCR reaction was as follows: 1) initial
denaturation (10 min, 95°C); 2) denaturation (30 sec, 95°C); 3) primer annealing (30
sec, 57°C); 4) elongation (30 sec, 72°C); 5) final elongation (7 min, 72°C). Steps two
to four were repeated 18 times. The composition of the PCR reaction was as follows:
Amplitaq Gold 360 Mastermix (12.5 l); ddH2O (5.5 l); forward primer (3 l, 10
pmol/l); reverse primer (3 l, 10 pmol/l); DNA template (1 l, 50ng/l). Following
the amplification phase, restriction enzyme digestion using 10 units of BSP12OI was
Chapter 3 | m.9185T>C in MT-ATP6 causes axonal Charcot-Marie-Tooth disease
71
performed to cleave the 113 nucleotides mutant PCR product into 89 and 24
nucleotide fragments. The enzyme digest reaction mix was composed of: restriction
enzyme (2 l); restriction enzyme buffer (2 l); and PCR product (16 l). The
reaction mix was subsequently incubated for two hours at 37°C. The PCR products
were finally denatured by adding 12 μl of formamide to 1 μl of digested product. 0.3
μl of Liz 600 (ABI) was used a size standard. The resulting mixture was heated at
95°C for 3 min after which it was immediately put on ice before being loaded onto a
3730xl DNA analyser. The ratio of cut to uncut DNA was calculated with the
GeneMapper (ABI) program. The experiment was performed in triplicate and the
mean mutant mtDNA level calculated.
3.3.3 Clinical and electrophysiological characteristics for patients
harbouring pathogenic m.9185T>C mutation in MT-ATP6
Detailed clinical assessment was performed for all patients harbouring the
pathogenic m.9185T>C mutation in MT-ATP6. Data ascertained where possible
included: age of symptom onset; clinical history and examination findings; CMT
examination (CMTES2) and neuropathy (CMTNS2) scale, as an indicator of
neuropathy severity (Murphy et al., 2011); nerve conduction studies (NCS) and
electromyography (EMG).
3.3.4 Laboratory, imaging, histological and biochemical findings
for patients harbouring pathogenic m.9185T>C mutation in
MT-ATP6
Laboratory investigations, including plasma creatine kinase (CK) and
plasma/cerebrospinal (CSF) lactate, brain magnetic resonance imaging (MRI) and
muscle histological studies were performed for all patients found to harbour the
pathogenic m.9185T>C mutation in MT-ATP6 where possible. Spectrophotometric
analysis of respiratory chain enzyme complexes I, II+III and IV and BN-PAGE of
complex V were performed in the UCLH NHNN NCG Neurometabolic laboratory by
Dr Annapurna Chalasani in cases where muscle tissue was available.
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3.4 Results
3.4.1 Automated Sanger sequencing of MT-ATP6/8
Disease-causing m.9185T>C mutations were detected in three additional unrelated
probands (Family 3.2, 3.3 and 3.4 discussed below) from the 270 CMT2 index cases
analysed, representing a specific mutation frequency for this variant in MT-ATP6 of
1.1%. No pathogenic MT-ATP6 variants were found in patients with dHMN (172),
and no pathogenic mutations in MT-ATP8 were found in either the CMT2 or dHMN
groups. All synonymous and non-synonymous single nucleotide variants (SNVs)
detected in MT-ATP6 and MT-ATP8 are outlined in Table 3.2. Following removal of
synonymous/non-coding SNVs and known polymorphisms, the potential
pathogenicity of each variant was evaluated using control databases: mitowheel
(http://mitowheel.org/mitowheel.html); mtDB (http://www.mtdb.igp.uu.se); and HmtDB
(http://www.hmtdb.uniba.it:8080/hmdb). The following steps were used to exclude
non-pathogenic variants: 1) SNVs detected in more than five control patients; 2)
SNVs detected in less than five control patients but known to associate with specific
haplotypes; 3) poorly conserved nucleotides (assessed using the mtSNP search tool:
mtsnp.tmig.or.jp/mtsnp/search_mtSAP_evaluation_e.html). After applying this
filtering strategy, one patient with CMT2 was found to harbour the novel variant
m.8828A>G which causes a missense change from Asparagine to Serine at amino
acid position 101 of the ATP6 protein (Asn101Ser). Unfortunately, there was no
muscle tissue available from the patient for BN-PAGE, thus the potential pathogenic
nature of this variant remains uncertain.
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3.4.2 Restriction endonuclease analysis to quantitate m.9185T>C
mutant load
Quantitation of the m.9185T>C mutant load showed segregation with disease
severity and phenotype (Figure 3.1 and 3.3, Table 3.3), and allowed patients to be
broadly classified into four clinical groups according to m.9185T>C mutant load:
(Group 1) unaffected individuals (<64% mutant load); (Group 2) asymptomatic
individuals with upper motor neuron (UMN) signs detectable on examination only
(such as a spastic increase in tone, pyramidal pattern of muscle weakness, brisk
reflexes and/or positive Babinski sign) (64-79% mutant load); (Group 3) affected
individuals with clinical symptoms and signs of UMN involvement without neuropathy
(80-91% mutant load); (Group 4) affected individuals with symptoms and signs of
motor-predominant CMT2 (92-100% mutant load).
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Table 3.2: Synonymous and non-synonymous MT-ATP6 (nucleotide positions 8527-
9207) and MT-ATP8 (nucleotide positions 8366-8572) nucleotide variants detected
in probands with CMT2 (n=270) and dHMN (n=172)
Synonymous variants Non-synonymous variants
8545G>A: S-S (1) 8381A>G: T-A (1)
8572G>A: St-St (3) 8388T>C: V-A (1)
8598T>C: I-I (2) 8396A>G: T-A (1)
8679A>G: L-L (1) 8461C>A: N-K (1)
8740C>T: L-L (1) 8477T>G: S-A (2)
8754C>T: I-I (1) 8489A>C: M-L (1)
8769A>G: T-T (2) 8490T>C: M-T (2)
8772T>C: T-T (1) 8502A>G: N-S (1)
8805A>G: T-T (1) 8516T>C: W-R (1)
8820A>G: L-L (4) 8519G>A: E-L (1)
8889T>C: I-I (1) 8545G>A: A-T (1)
8925A>G: W-W (1) 8572G>A: A-T (3)
8940C>T: I-I (2) 8578C>T: P-S (1)
8955T>C: I-I (1) 8605C>T: P-S (2)
8958C>T: I-I (1) 8620C>T: P-S (1)
9006A>G: L-L (2) 8698A>G: M-V (1)
9015C>T: N-N (1) 8699T>C: M-T (1)
9042C>T: H-H (2) 8704A>C: M-L (2)
9060C>A: T-T (1) 8704A>G: M-V(1)
9061C>T: L-L (1) 8725A>G: T-A (1)
9075C>T: T-T (1) 8765C>T: A-V (1)
9078T>C: I-I (1) 8794C>T: H-Y (1)
9117T>C: I-I (3) 8828A>G: N-S (1)
9120A>G: L-L (2) 8836A>G: M-V (1)
9123G>A: L-L (5) 8839G>A: A-T (1)
9126T>C: T-T (1) 8864T>C: V-A (1)
9168C>T: F-F (1) 8875T>C: F-L (2)
8887A>G: I-V (1)
8950G>A: V-I (2)
Chapter 3 | m.9185T>C in MT-ATP6 causes axonal Charcot-Marie-Tooth disease
75
9025G>A: G-S (1)
9067A>G: M-V (1)
9101T>C: I-T (1)
9139G>A: A-T (1)
9185T>C: L-P (3)
Abbreviations: Bold = known pathogenic variant; bold italics = novel variant; brackets
= number of patients with variant.
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3.4.3 Clinical and electrophysiological characteristics for index
family harbouring m.9185T>C in MT-ATP6
Family 3.1 (Figure 3.1, Table 3.3): The index case (Patient III-8) presented with
recurrent falls and foot drop aged 6 years following normal early development.
Clinical examination aged 21 years showed distal muscle wasting of the legs, pes
cavus, and clawing of the toes (Figure 3.2). Formal manual muscle strength testing
(MRC graded) was normal in the upper limbs with mild proximal lower limb
weakness (hip flexion 4+ bilaterally) and moderate distal lower limb weakness (ankle
dorsiflexion 3, plantarflexion 4+, inversion 5, and eversion 2 bilaterally). Ankle jerks
were absent. Plantar responses were extensor. Pin prick sensation was normal but
vibration detection was reduced to the knees. Additional multi-system clinical
findings in some family members and a matrilineal inheritance pattern prompted
mtDNA sequencing in an older sibling (Figure 3.1, Family 3.1, Patient III-6). This
revealed m.9185T>C (Haplogroup V), a homoplasmic (i.e. mutant load 100%)
pathogenic mutation in MT-ATP6, causing a missense change from leucine to
proline at amino acid position 220 of the ATP6 protein (Leu220Pro). Presence of the
m.9185T>C mutation was confirmed in the index case and was shown to segregate
with disease within the family. All affected individuals were homoplasmic, whilst the
mutational load was present at much lower levels in an unaffected relative (Family
3.1, Figure 3.1, Patient II-4). Clinical features in addition to a pure motor/motor-
predominant axonal neuropathy included: learning difficulties (Patients II-3, II-5, III-4,
III-5, III-6, III-7, III-8, IV-1 and IV-2); sensorineural hearing loss (SNHL) (Patient III-7);
and retinal degeneration (Patient III-8). Early proximal lower limb weakness was
evident in three patients (with no evidence of myopathy either neurophysiologically
or on muscle biopsy) despite a relatively mild neuropathy (patients III-6, III-7 and III-
8). Two patients suffered rapid decompensation following a febrile illness (Patient III-
5 and Patient IV-1). The available clinical data suggests a sudden onset Leigh-like
illness in one patient (Patient III-5). Electrophysiologically the neuropathy was a pure
motor neuropathy/neuronopathy in three individuals (Patients II-1, III-7 and III-8).
However, sensory signs have since developed in one patient, making the diagnosis
clinically compatible with motor-predominant CMT2 (Patient III-8). The neuropathy
was particularly severe in two adults with wheelchair dependence in the third decade
(Patient II-3 and Patient III-4).
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Family 3.1
Figure 3.1: Pedigree of Family 3.1 (index family) harbouring the m.9185T>C
mutation in MT-ATP6. Filled symbols indicate individuals with CMT2; light grey
shaded symbols indicate individuals with unknown phenotype; square symbols
indicate male gender; round symbols indicate female gender; numbers in symbols
indicate multiple individuals; symbols with slashes indicate deceased. Abbreviations:
(b) = blood; (u) = urine; (m) = muscle; yo = year old; % = percentage m.9185T>C
mutant load detected in each patient.
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Figure 3.2: Photograph demonstrating distal lower limb muscle wasting and pes
cavus in a patient with the m.9185T>C mutation in MT-ATP6 (Family 3.1, Patient III-
8).
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3.4.4 Clinical and electrophysiological characteristics for the three
additional families harbouring m.9185T>C in MT-ATP6
Family 3.2 (Figure 3.3, Table 3.3): Patients with CMT2 (Patients II-8, III-6, and IV-3,
all with 100% mutant load) presented in their first and second decades with typical
features of inherited neuropathy. Patient III-6 had a pure motor
neuropathy/neuronopathy electrophysiologically aged 29, although repeat studies
aged 45 revealed reduced sensory nerve action potentials compatible with motor-
predominant CMT2. Despite a gradually progressive clinical course, two patients
suffered a rapid decline in mobility in their fifth and sixth decades with wheelchair
dependence from unaided walking over a 5-year period (Patients II-8 and III-6). In
these severe cases there was upper limb and proximal lower limb weakness without
evidence of myopathy on EMG. However, early proximal lower limb weakness was
also present in a mildly affected individual (Patient IV-3) without upper limb
involvement.
Family 3.3 (Figure 3.3, Table 3.3): Symptom onset was in the first and second
decades (Patients III-13 and IV-2, both with 100% mutant load).
Electrophysiologically patients with homoplasmic mutant loads had a pure motor
neuropathy/neuronopathy (Patient IV-2) or sensorimotor axonal neuropathy (Patient
III-13). Those with lower mutant levels were asymptomatic (Patient III-5 with 75%
mutant load and Patient IV-1 with 45% mutant load). Patient IV-2 had a severe
neuropathic phenotype associated with learning difficulties, behavioural problems,
and wheelchair dependence by early adulthood. Patient III-13 had motor-
predominant CMT2 with pyramidal tract signs and proximal muscle weakness which
developed in later life.
Family 3.4 (Figure 3.3, Table 3.3): Unlike Family 3.1, 3.2 and 3.3, Patient III-1
initially appeared to be a sporadic case of motor-predominant CMT2 (92% mutant
load). He presented in the first decade with recurrent ankle sprains and falls and was
diagnosed with CMT2 aged 11 years. NCS demonstrated a length-dependent
sensorimotor axonal neuropathy and EMG showed proximal and distal lower limb
denervation with no evidence of myopathy.
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Family 3.2
Family 3.3
Family 3.4
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Figure 3.3: Pedigrees of three additional unrelated families harbouring the
m.9185T>C mutation in MT-ATP6. Filled symbols indicate individuals with CMT2;
dark grey shaded symbols indicate individuals with upper motor neuron signs only;
light grey shaded symbols indicate individuals with unknown phenotype; square
symbols indicate male gender; round symbols indicate female gender; diamond
symbols indicate gender unknown; numbers in symbols indicate multiple individuals;
symbols with slashes indicate deceased; a small square with a slash indicates still
birth; a small triangle indicates miscarriage; asterisks indicate affected individuals not
examined by authors. Abbreviations: (b) = blood; (u) = urine; (f) = fibroblasts; (m) =
muscle; yo = year old; % = percentage m.9185T>C mutant load detected in each
patient.
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Table 3.3: Clinical and electrophysiological findings for patients with the m.9185T>C mutation in MT-ATP6
Family Patient Sex
Age onset
(years)
Symptoms at
onset
Age
last
exam
(years)
Pes
Cavus
Motor
weakness
Sensory
loss
UMN
signs
Other features Mobility
CMTES2(28)/
CMTNS2(36)
Summary of
NCS/EMG/CMCT
3.1 II-1 F 2nd decade Falls 42 Y Distal LL N N Blackouts Unaided ND Pure motor neuropathy
(no further data available)
II-3 F 2nd decade Unsteady 30 Y Distal LL N N Mild LD, ataxia Wheelchair
(3rd decade)
ND ND
II-4 F Asymptomatic
II-5 M 1st decade Late walker,
falls
31 N Distal LL N N *Dysmorphic, LD Unaided ND Axonal neuropathy
(no further data available)
III-4 F U Unsteady, falls 32 N Distal UL
and LL
N N Mild LD,
migraine, ataxia
Wheelchair
(3rd decade)
ND Motor
neuropathy/neuronopathy
SAPs within normal limits
III-5 F 16 Rapid decline
following viral
illness with
Leigh-like
syndrome.
Died aged 16
years.
16 N N N N LD Unaided ND ND
III-6 M 11 Tripping 27 Y Mild prox
and mod
distal LL
Knees N Mild LD, foot
surgery
Unaided
with ankle
support
9(28) Sensorimotor axonal
neuropathy
SAPs mildly reduced
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III-7 M 9 Unsteadiness,
poor
concentration
15 Y Mild prox
LL
N N Mod LD, SNHL,
kyphoscoliosis,
Unaided ND Pure motor axonal
neuropathy
(no further data available)
III-8 M 6 Falls, weak
ankles
21 Y Mild prox
and mod
distal LL
Knees Extensor
plantars
Mild LD,
tapetoretinal
degeneration,
foot surgery
Unaided
with leg
irons
9(36) Aged 18: Pure motor
axonal neuropathy. SAPs
within normal limits.
Aged 21: Sensory
involvement clinically
IV-1 M 6 Deterioration
in gait.
Sudden death
following viral
illness aged 9
years.
8 N N N Hyper-
reflexia
LD Unaided ND ND
IV-2 F 10 Painful legs,
tripping
10 N N N N Febrile seizure,
mild LD
Unaided ND ND
3.2 II-3 F Asymptomatic 54 N None None N None Unaided ND ND
II-8 M 2nd decade Slow running 60 N Mild prox
and distal
UL,
severe
prox and
distal LL
Distal
UL and
LL
N Late-onset DM Wheelchair
(6th decade)
21(28) Aged 31: Pure motor
axonal neuropathy
SAPs within normal limits
III-1 F Asymptomatic
III-2 M 1-2nd decade Foot drop U Hammer
toes
U U U None Unaided ND ND
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III-3 F 5th decade Leg cramps,
reduced
exercise
tolerance, toes
extend whilst
walking
49 Y Mild distal
LL
N Hyper-
reflexia,
clonus,
extensor
plantars
None 0(36) Normal NCS/EMG/CMCT
III-5 F Asymptomatic 44 N N N Hyper-
reflexia,
clonus,
extensor
plantars
Migraine Unaided ND Normal NCS/EMG/CMCT
III-6 F 2nd decade Slow walking
and flapping
feet
40 N Mild distal
LL
None N Migraine, late-
onset DM
Unaided Aged 29: Pure motor
axonal neuropathy
SAPs within normal limits
45 N Mild prox
UL, mild
prox and
mod distal
LL
Distal
UL/LL
Extensor
plantars
Wheelchair
(5th decade)
20(28)/
24(36)
Aged 45: Sensorimotor
axonal neuropathy
SAPs within normal limits
IV-3 F 3 Falling, clumsy 19 Y Mild prox
and distal
LL
Ankles None Kyphoscoliosis,
focal seizures
Unaided 9(28)/
11(36)
Sensorimotor axonal
neuropathy
SAPs mildly reduced
IV-4 F Asymptomatic 21 N N N N None Unaided ND Normal
3.3 II-4 F Asymptomatic 83 N Mild distal
LL
N Y Late onset SNHL Rollator ND ND
III-5 F Asymptomatic 49 N N N U None Unaided ND Sural SAPs mildly
reduced
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III-13 M 17 Weak legs 43 Y Mod prox
and distal
LL
N Catch,
hyper-
reflexia
and
extensor
plantars
None Walking
stick
ND Aged 43: Sensorimotor
axonal neuropathy
SAPs mildly reduced
IV-1 M Asymptomatic
IV-2 M 4 Falls, delayed
motor skills,
toe walking
19 Y Distal LL Distal LL N Mild LD, ADHD,
OCD
Wheelchair ND Motor axonal neuropathy
SAPs within normal limits
3.4 II-1 M 1st decade Recurrent
ankle sprains,
falls
45 N Mild distal
UL, mild
prox and
mod distal
LL
Knees Pout
reflex
Foot surgery Two sticks 15(28)/
17(36)
Sensorimotor axonal
neuropathy
SAPs mildly reduced
Abbreviations: ADF = ankle dorsiflexion; ADHD = attention deficit hyperactivity disorder; BG = basal ganglia; CMCT = central motor
conduction times; CMTES2 = Charcot-Marie-Tooth examination score 2 (total score 28); CMTNS2 = Charcot-Marie-Tooth
neuropathy score 2 (total score 36, mild neuropathy: 0-10; moderate neuropathy: 11-20; severe neuropathy: >20); DM = diabetes
mellitus; F = female; LD = learning difficulties; LL = lower limbs; M = male; mod = moderate; N = no; ND = not done; OCD =
obsessive compulsive disorder; prox = proximal; SAPs = sensory nerve action potentials; SNHL = sensorineural hearing loss; U =
unknown; UL = upper limbs; UMN = upper motor neuron; Y = yes. Asterisk (*) denotes not examined by author.
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3.4.5 Laboratory, imaging, histological and biochemical findings
for patients harbouring pathogenic m.9185T>C mutation in
MT-ATP6
Laboratory investigations, brain MRI, muscle histological and biochemical studies for
all four families harbouring the pathogenic m.9185T>C mutation in MT-ATP6 are
summarised in Table 3.4. BN-PAGE (Figure 3.4) was performed on four muscle
samples and revealed both impaired assembly (demonstrated by multiple bands
indicative of abnormal assembly intermediates) and/or activity (demonstrated by
reduced band intensity) of complex V when patients were compared with control
muscle tissue (Family 3.1, Patients III-5, III-6, IV-2 and Family 3.2, Patient III-6).
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Table 3.4: Laboratory, imaging, muscle histological and biochemical findings for patients with the m.9185T>C mutation in MT-ATP6
Family Patient CK
(<140IU/L)
Plasma
lactate
(<1.7mmol/L)
CSF lactate
(<2.0mmol/L)
MRI Muscle biopsy RCEA BN-PAGE V
3.1 I-1 ND ND ND ND ND ND ND
II-1 ND ND ND ND ND ND ND
II-4 ND ND ND ND ND ND ND
II-5 U U ND ND ND ND ND
III-4 U U ND Brain:
Cerebellar
atrophy
ND ND ND
III-5 U U ND ND LM: Mild increase lipid content. No RRF/COX-ves. Normal  assembly and
activity
III-6 U U Normal Brain: Normal LM: Neurogenic changes only ND  assembly
III-7 U 1.2 2.4 Brain: High
signal BG
bilaterally
LM: Non-specific myopathic, neurogenic changes.
No RRF/COX -ves.
EM: Prominent subsarcolemmal aggregates
ND ND
III-8 168 0.9 2.1 Normal U ND ND
IV-1 Normal ND ND Normal Normal ND ND
IV-2 ND ND ND ND Normal Normal  assembly
3.2 II-8 ND ND ND ND ND ND ND
III-3 37 0.8 ND ND ND ND ND
III-5 ND ND ND Brain: Normal
Spine: Normal
ND ND ND
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III-6 79 2.8 3.0 Brain: Mild
cerebellar
atrophy
LM: Neurogenic changes. Excess lipid content. No
RRF/COX-ves.
Normal  activity
IV-3 99 1.51 ND Normal ND ND ND
IV-4 60 0.8 ND ND ND ND ND
3.3 III-5 U U ND ND ND ND ND
III-13 U U ND ND ND ND ND
IV-1 ND ND ND ND ND ND ND
IV-2 Normal ND ND ND LM and EM normal ND ND
3.4 II-1 132 1.3 ND ND ND ND ND
Abbreviations: ND = not done; U = unknown; CK = creatine kinase; CSF = cerebrospinal fluid; CMCT = central motor conduction
times; MRI = magnetic resonance imaging; LM = light microscopy; EM = electron microscopy; BG = basal ganglia; b = blood; m =
muscle; f = fibroblasts; u = urine; COX = cytochrome c oxidase; RRF = ragged red fibres; RCEA = respiratory chain enzyme
analysis; BN-PAGE V = Blue-native polyacrylamide gel electrophoresis of complex V; normal reference ranges in our laboratory:
CK < 140IU/L; plasma lactate <1.7mmol/L; and CSF lactate <2.0mmol/L.
Chapter 3 | m.9185T>C in MT-ATP6 causes axonal Charcot-Marie-Tooth disease
89
Figure 3.4: Blue-native polyacrylamide gel electrophoresis (BN-PAGE) using muscle
tissue from patients with the m.9185T>C mutation compared with control muscle
tissue. BN-PAGE was also performed in a patient with the m.8993T>G mutation as a
positive control. Abbreviations: P = patient; C = control; V (Fo + F1) = complex V
holoenzyme; F1 = F1 catalytic site of complex V only; * indicates reduced complex V
activity in patient compared to control muscle tissue (demonstrated by reduced band
density); ** indicates impaired complex V assembly in patient compared to control
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muscle tissue (demonstrated by multiple bands indicative of abnormal assembly
intermediates); */** indicates both impaired complex V activity and assembly in
patient compared to control muscle tissue (demonstrated by co-existence of reduced
band density and multiple bands indicative of abnormal assembly intermediates). (A)
Patient with the pathogenic mutation m.8993T>G (disease control). (B)-(D) Family
3.1, Patients III-5, III-6 and IV-2 respectively. (E) Family 3.2, Patient III-6.
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3.5 Discussion
In this genetically undefined CMT2 cohort the disease-causing MT-ATP6
m.9185T>C variant was identified in three unrelated probands, in addition to the
index family in which the mutation was originally detected. Some affected family
members were also classified as having dHMN. That 1.1% of this genetically
undefined CMT2 cohort harboured the m.9185T>C mutation in MT-ATP6 is
important given that molecular defects are currently only detected in approximately
35% of patients with CMT2 and in 15% of patients with dHMN (Dierick et al., 2008;
Reilly and Shy, 2009; Reilly et al., 2011; Saporta et al., 2011). Patient m.9185T>C
mutant load correlated with disease severity within each pedigree.
Patients could be broadly divided into four clinical severity-related groups according
to their m.9185T>C mutant load: (Group 1) unaffected individuals (<64% mutant
load); (Group 2) asymptomatic individuals with UMN signs detectable on
examination (64-79% mutant load); (Group 3) affected individuals with clinical
symptoms and signs of UMN involvement without neuropathy (80-91% mutant load);
(Group 4) affected individuals with symptoms and signs of motor-predominant CMT2
(92-100% mutant load).
BN-PAGE was used in muscle tissue to demonstrate the deleterious effects of the
m.9185T>C; p.Leu220Pro mutation on complex V structure and function. The
complex V assay measures the ATP synthase activity in the reverse direction. ATP
is hydrolysed to produce ADP and Pi In the presence of Pi the lead ions used in the
buffer (lead (II) nitrate) form a precipitate which correlates with the degree of ATP
hydrolysis. This technique has not been used to assess complex V in patients with
m.9185T>C previously. It has been shown that the m.8993T>G mutation associated
with LS and NARP not only impairs assembly and stability of complex V, but also
reduces intrinsic activity of the ATP synthase holoenzyme (Nijtmans et al., 2001).
Impaired complex V assembly (Figure 3.4, Family 3.1, Patients III-6 and IV-2),
reduced complex V activity (Figure 3.4, Family 3.2, Patient III-6) or both (Figure 3.4,
Family 3.1, Patient III-5) was confirmed in patients who were homoplasmic for
m.9185T>C. These data support the pathogenicity of m.9185T>C and indicate that
this mutation impairs both complex V assembly and activity. In view of the previously
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published data documenting impaired assembly and stability of complex V
associated with the NARP m.8993T>G mutation (Nijtmans et al., 2001), the
m.9185T>C mutation may also be expected to result in a poorly assembled and
unstable complex V holoenzyme. The variation in both complex V activity and
assembly observed on BN-PAGE for patients with identical m.9185T>C mutation
loads may, therefore, be attributable to holoenzyme disassembly occurring during
sample preparation. The muscle histology and histochemistry of patients with the
m.9185T>C mutation were either normal or exhibited subtle non-specific
mitochondrial abnormalities on EM as is frequently the case for mutations involving
mtDNA protein encoding genes.
The findings reported here add to increasing evidence that mitochondrial dysfunction
is an important cause of CMT2. Mutations in MFN2, a critical nuclear gene that
regulates mitochondrial fusion, have been identified as the major cause of CMT2.
Evidence is emerging that MFN2 has a distinct role aside from mitochondrial fusion
in mitochondrial axonal transport, and is an important component of the
linker/adaptor complex between mitochondria and kinesin/microtubules (Misko et al.,
2010). Disruption of this complex may explain the length-dependent nature of the
neuropathy seen with MFN2 mutations. More recently, a novel MFN2 mutation
causing optic atrophy, axonal neuropathy and mitochondrial myopathy was found to
cause multiple mtDNA deletions in skeletal muscle. This finding was thought to result
from mtDNA instability, caused by the variability of repair protein content across the
mitochondrial population as a consequence of impaired mitochondrial fusion, and
expands current knowledge of the pathogenic basis of MFN2-related neurological
disease (Rouzier et al., 2012). It has also been shown that nerves expressing mutant
forms of neurofilament (which causes CMT2E) can also alter mitochondrial dynamics,
suggesting that dysfunctional axonal transport might precipitate axonal degeneration
in a number of other CMT subtypes (Tradewell et al., 2009). These observations
imply that impaired ATP dependant axonal transport is a candidate for axonal
damage in other mitochondrial diseases.
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MT-ATP6 should be considered in the molecular diagnostic evaluation of patients
with CMT2, together with MFN2, MPZ, RAB7, HSPB1, HSPB8, GDAP1, TRPV4,
NEFL and GARS, especially in pedigrees where there appears to be no paternal
transmission (Reilly et al., 2011; Saporta et al., 2011). These findings have important
clinical implications, particularly for genetic counselling. Diagnosis can be made in
DNA extracted from blood, using restriction fragment length polymorphism genetic
analysis, since m.9185T>C mutant load appears to be high in peripheral blood
leucocytes in all affected cases reported to date. An invasive muscle biopsy is not
required for diagnostic purposes, and histology is usually unhelpful. However, if
muscle tissue is available BN-PAGE demonstrates both the structural and functional
impairment caused by the effects of m.9185T>C; p.Leu220Pro on the ATP6 subunit.
The clinical and electrophysiological phenotype in these families was typical of
CMT2/dHMN. However, the following features should be used to help prioritise MT-
ATP6 for mutation analysis in patients with neuropathy: (1) disease onset in the first
or second decades; (2) variable clinical severity within a family with wheelchair
dependence as early as 19 years; (3) an initial slowly progressive neuropathy, which
may accelerate in the fifth and sixth decades from unaided walking to wheelchair
dependence within a relatively short time frame; (4) an evolving clinical phenotype
from a pure motor to a motor-predominant axonal neuropathy in the third and fourth
decades; (5) early proximal lower limb muscle involvement despite mild distal
weakness; (6) multi-system involvement in the patient or relatives; (7) UMN signs in
affected or asymptomatic relatives; (8) rapid clinical decompensation in affected
individuals following viral or septic illness.
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CHAPTER 4
4. Novel POLG and RRM2B-related clinical phenotypes
4.1 Introduction
Mutations in nuclear genes encoding proteins involved in replication, maintenance
and repair of mtDNA may cause sporadic, autosomal dominant and autosomal
recessive mitochondrial disease associated with multiple large-scale deletions and/or
depletion and/or point mutations in mtDNA (Cohen et al., 1993; Longley et al., 2005).
To date, almost all known causative nuclear genes in this group fall into one of two
categories: genes whose products function directly at the mtDNA replication fork, or
genes encoding proteins important for supplying the mitochondria with
deoxynucleotide triphosphate pools needed for DNA replication.
4.1.1 Polymerase gamma and mitochondrial DNA replication
DNA polymerase gamma is the only known DNA polymerase in animal mitochondria.
It functions as a heterotrimer (Yakubovskaya et al., 2006) composed of one catalytic
subunit polymerase gamma, encoded by POLG, and two accessory subunits,
encoded by POLG2 (Ropp and Copeland, 1996). The catalytic subunit contains 3
functional domains: a 3’ to 5’ proofreading exonuclease domain; a linker domain; and
a highly conserved carboxyl-terminal polymerase domain (Luo and Kaguni, 2005).
The accessory subunits confer high processivity on the protein complex by
increasing binding affinity for DNA (Lim et al., 1999). Diseases caused by mutations
in POLG are highly heterogeneous, and include: sporadic PEO; autosomal dominant
or recessive PEO; cataracts; Alpers syndrome; mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE); premature menopause and ovarian failure; ataxia
neuropathy spectrum (previously labelled as mitochondrial recessive ataxia
syndrome, sensory ataxic neuropathy with dysarthria and ophthalmoplegia, and
spinocerebellar ataxia epilepsy syndrome); and myoclonic epilepsy myopathy
sensory ataxia syndromes (Cohen et al., 1993; Stumpf et al., 2013). More than 150
mutations have been reported in POLG (http://tools.niehs.nih.gov/polg/) since the
first disease-causing mutations within the gene were identified in 2001 (Van
Goethem et al., 2001a). The most common mutation in POLG is c.1399G>A, which
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results in an alanine to threonine substitution at codon 467 (p.Ala467Thr) within the
linker region of polymerase gamma, causes reduced DNA polymerase activity and
inefficient interaction with the accessory subunit (Chan et al., 2005).
4.1.2 Ribonucleotide reductase and deoxyribonucleotide synthesis
There is increasing recognition that genetic disruption of the molecular processes
that control the maintenance (replication and repair) of mtDNA, including those that
regulate nucleotide pools, are an important cause of human mitochondrial disease.
Approximately half of all adult mitochondrial disease results from genetic dysfunction
of the nuclear-encoded mitochondrial genes. A significant number of these cases are
due to disruption of genes involved in maintenance of mtDNA, leading to qualitative
(accumulation of multiple mtDNA deletions) and/or quantitative (depletion of mtDNA
copy number) downstream mitochondrial genomic effects. To date, almost all known
nuclear maintenance genes fall into one of two categories: 1) genes whose protein
products function directly at the mtDNA replication fork (Fratter et al., 2011; Longley
et al., 2006; Spelbrink et al., 2001b); or 2) genes which encode proteins involved in
supplying mitochondria with dNTP pools required for DNA replication (Bourdon et al.,
2007a; Fratter et al., 2011; Kaukonen et al., 2000; Mandel et al., 2001; Nishino et al.,
1999; Ostergaard et al., 2007; Saada et al., 2001). The most common presenting
neurological feature seen in adults with mtDNA maintenance disorders is PEO and
ptosis, although the clinical phenotype is not necessarily restricted to the extra-ocular
muscles.
Ribonucleotide reductase M2B (TP53 inducible, RRM2B) encodes the p53-inducible
small subunit of ribonucleotide reductase (RNR) known as p53R2. RNR is a
heterotetrameric enzyme, comprised of two small (p53R2) and two large (R1)
components, which catalyses the rate-limiting step in the de novo synthesis of
dNTPs by direct reduction of ribonucleotide diphosphates to their corresponding
deoxyribonucleotides. p53R2 is so-called because its transcription is tightly regulated
by the tumour suppressor protein p53 (Nakano et al., 2000; Tanaka et al., 2000). It
was initially suggested that p53R2 translocates to the nucleus during DNA damage-
induced cellular arrest and was important for local DNA repair (Tanaka et al., 2000;
Yamaguchi et al., 2001). However, the observation of constant low levels of both R1
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and p53R2 in post-mitotic cells, and the clear correlations between depletion of
mtDNA and functionally important mutations in the RRM2B have expanded the role
of p53R2 beyond that of nDNA replication and repair to include an essential role in
the supply of dNTPs for the synthesis of mtDNA. This process supplements the
dNTPs produced by the mitochondrion’s own deoxynucleotide salvage pathway.
Mutations in RRM2B are reported to cause severe mtDNA depletion in children with
encephalomyopathy and lactic acidosis frequently associated with renal tubulopathy
(Acham-Roschitz et al., 2009; Bornstein et al., 2008; Bourdon et al., 2007b; Kollberg
et al., 2009). Patients with mtDNA depletion syndromes typically die in infancy or
childhood (Rahman and Poulton, 2009). RRM2B mutations have also been shown to
cause MNGIE with mtDNA depletion (Shaibani et al., 2009), and a heterozygous
truncating mutation in RRM2B has been found to associate with adPEO with multiple
mtDNA deletions (Tyynismaa et al., 2009). Depletion and deletions of mtDNA may
result from unbalanced dNTP pools with subsequent misincorporation of nucleotides
into mtDNA.
This chapter reports genetic investigations performed in a cohort of 50 adult patients
with significant levels of multiple mtDNA deletions detectable in skeletal muscle
tissue. Fourteen individuals were found to harbour POLG mutations, and a novel
clinical phenotype exhibited by two of these patients was characterised. In addition,
two patients with RRM2B mutations were identified, including one with Kearns-Sayre
syndrome (KSS).
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4.2 Patient cohort
Fifty unrelated adults with suspected mitochondrial disease and multiple mtDNA
deletions detectable in skeletal muscle were identified using the UCLH NHNN NCG
Neurogenetics diagnostic laboratory database. Multiple mtDNA deletions had
previously been confirmed by the UCLH NHNN NCG Neurogenetics diagnostic
laboratory using long-range PCR and/or Southern blot genetic analysis techniques.
Sanger sequencing of POLG and targeted regions of C10orf2 was initially performed
by the Oxford NCG Neurogenetics diagnostic laboratory as mutations in both genes
are known to be a common cause of multiple mtDNA deletion formation in adults.
Fourteen of the 50 patients were found to harbour pathogenic mutations in POLG,
whilst C10orf2 mutations were detected in three patients.
Two unrelated patients (Patient 4.1 and Patient 4.2) with upper limb predominant
distal myopathy caused by novel heterozygous missense mutations in POLG are
reported here. One patient had marked cachexia. These findings expand the clinical
phenotype associated with POLG-related adult mitochondrial disease with multiple
mtDNA deletions, and indicate that POLG mutation analysis should be considered in
cases of distal myopathy.
RRM2B was subsequently sequenced in the remaining 33 patients in whom the
underlying nuclear gene defect had not been identified to determine the prevalence
of RRM2B mutations in this adult population. Two patients (Patient 4.3 and Patient
4.4) were found to harbour pathogenic RRM2B mutations and are discussed in detail
below.
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4.3 Case histories
4.3.1 Patient 4.1
A 26 year old white European man was referred to the neurology clinic with
longstanding progressive distal upper limb muscle wasting and weakness. Symptom
onset was in early adolescence. Past medical history included rapid development of
bilateral cataracts requiring removal aged 3 years. There was no family history of
neuromuscular disease. At initial assessment he was ambulant but exhibited marked
upper limb distal muscle wasting and weakness (Figure 4.1A).
Laboratory evaluation revealed raised serum creatine kinase of 373 to >1000 IU/L
(reference range 38-204 IU/L). Thyroid function and plasma lactate levels were
normal. Median, ulnar, sural and superficial peroneal sensory NCS and ulnar,
common peroneal and posterior tibial motor NCS were normal with no
electrophysiological evidence for a large fibre peripheral neuropathy. However, EMG
revealed myopathic changes in all muscles sampled (deltoid, first dorsal
interosseous, vastus medialis and tibialis anterior). Brain MRI was unremarkable.
MRI of the thighs, calves, and forearms demonstrated severe fatty atrophy of both
upper and lower limb musculature (Figure 4.2A-C). There was a distinct proximal-
distal gradient with forearms and calves being more severely affected than the thighs.
This pattern of distal predominant fatty infiltration was also apparent within partially
affected muscles, such as tibialis posterior and vastus medialis. Striking selectivity
existed between muscles, with some being severely affected whilst others, such as
adductor magnus, showed normal signal intensity and even compensatory
hypertrophy. A left quadriceps muscle biopsy of vastus lateralis aged 41 years
revealed 3.7% ragged red fibres (RRF) on Gomori trichrome and SDH stains and
4.2% COX negative fibres (Figure 4.1C-F). Ultrastructural examination showed
collections of abnormal mitochondria with ring forms and others containing type I
paracrystalline inclusions (Figure 4.1G, H). Activity of respiratory chain complexes I,
II+III and IV, expressed as a ratio to citrate synthase activity to correct for
mitochondrial enrichment, were normal.
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Most recent examination aged 49 years showed a high stepping gait and
hyperlordosis resulting from anterior leg and axial muscle weakness (Figure 4.1B),
bilateral aphakia and ptosis, PEO, and dysphonia. Formal manual muscle strength
testing was MRC graded bilaterally as follows: shoulder abduction/adduction 5/5;
elbow and wrist flexion/extension 2/5; finger flexion 2/5; finger extension 0/5; intrinsic
hand muscles 2/5; hip and knee flexion/extension 5/5; ankle
dorsiflexion/inversion/eversion 0/5; and ankle plantarflexion 3/4. Reflexes were
normal and plantar responses down-going. Sensory examination was normal. The
patient was markedly cachexic and had a static Body Mass Index (BMI) of 16.3
(normal male range 20-25). A formalised 3-day diet diary undertaken by a dietetic
consultant confirmed adequate oral caloric intake (96.6% of predicted reference
nutrient intake, CompEat© Nutrition Systems). Blood and urinary deoxyuridine and
thymidine levels were undetectable and thymidine phosphorylase activity in white
cells and platelets was normal, thereby excluding MNGIE.
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Figure 4.1: Clinical, muscle histological and Southern blot findings for Patient 4.1. Upper limb muscle wasting (A) and
hyperlordosis secondary to axial muscle weakness (B). Ragged red fibres visualised in haematoxylin and eosin (C), Gomori
trichrome (D) and succinate dehydrogenase (E) preparations. Histochemical staining for cytochrome c oxidase revealed significant
numbers of fibres with deficient enzyme activity (F). Ultrastructural examination confirmed structurally abnormal mitochondria with
type I paracrystalline inclusions (G) and ring forms (H). Bar in A represents 50µm in C – F and 500nm in G & H. Southern blot
analysis of mitochondrial DNA (mtDNA) extracted from muscle tissue using PvuII restriction endonuclease showing normal control
subject in lane 1 (C1); patient with single deletion of mtDNA in lane 2 (C2); and Patient 4.1 with multiple deletions of mtDNA in lane
3 (P) (I).
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Figure 4.2: Axial T1 weighted MRI of thighs, calves and forearms of Patient 4.1. Proximal (top) and distal (bottom) thigh (A): severe
fat infiltration and atrophy is seen in most muscles including quadriceps, gracilis and biceps femoris, with sparing of adductor
magnus (AM) and semimembranosus (SM). A proximal-distal gradient is noted in muscles which are incompletely affected such as
vastus medialis (VM). Proximal (top) and distal (bottom) calf (B): severe fatty atrophy of all muscles except tibialis posterior (TP)
proximally. Mid-forearm (C): severe fatty atrophy of all muscles. R = right; L = left.
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4.3.2 Patient 4.2
A 54 year old man of European descent presented to the adult neurology clinic with
worsening dysarthria and dysphagia. He had developed progressive distal upper and,
to a lesser extent, lower limb weakness in his early thirties and required bilateral
frontalis slings for ptosis aged 43 years. Past medical history included surgical
removal of bilateral cataracts during childhood. Skeletal muscle biopsy of vastus
lateralis aged 40 years was compatible with a mitochondrial disorder; however,
residual muscle tissue was unavailable for further molecular genetic testing. There
was no reported family history of neuromuscular disease, but his daughter had
congenital cataracts.
At initial assessment BMI was normal. Gait was high stepping due to bilateral foot
drop. Cranial nerve examination revealed bilateral aphakia, ptosis, PEO, facial
weakness, and neck flexor/extensor weakness (MRC grade 4/5). There was marked,
predominantly upper limb, distal muscle wasting. MRC grading of muscle power was
symmetrical and as follows: shoulder abduction/adduction 4/5; elbow flexion 2/5;
elbow extension 4/5; wrist flexion/extension 0/5; finger flexion/extension 1/5; intrinsic
hand muscles 0/5; hip flexion/extension 4/5; knee flexion 2/5; knee extension 4/5;
ankle dorsiflexion/inversion/eversion 2/5; and ankle plantar flexion 5/4. Reflexes
were all present and plantar responses flexor. Sensory examination was normal.
Laboratory tests, sensory NCS (median, ulnar, sural and superficial peroneal nerves
tested), and motor NCS (median, ulnar and posterior tibial nerves tested) were
normal. EMG confirmed evidence of a myopathy proximally (sternocleidomastoid,
trapezius, deltoid and triceps) and distally (first dorsal interosseous) in the upper
limbs. Lower limbs were affected to a lesser extent with some myopathic units
evident proximally (iliopsoas and rectus femoris). Brain MRI was normal.
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4.3.3 Patient 4.3
Patient 4.3 was born following normal pregnancy by assisted breech delivery to non-
consanguineous parents of European descent. There were no neonatal problems
and development was normal up to the age of four years when she developed
bilateral SNHL. Over the next two years she developed PEO, proximal muscle
weakness and poor weight gain, associated with malaise and tiredness. During
adolescence the fatigue prevented her from keeping up with peers during exercise.
She had short stature and delayed puberty. Parents are now in their late sixties and
do not have PEO or clinical symptoms suggestive of mitochondrial disease, and
there is no other relevant family history.
On examination aged 14 Patient 4.3 was found to have pigmentary retinopathy,
sensorineural deafness, PEO and proximal fatiguable myopathy MRC grade 4/5.
Serum CK was 281 IU/L. Blood lactate was normal (1.1 mmol/L) but CSF lactate was
mildly elevated at 2.6 mmol/L and CSF protein was raised at 1.60 g/L. The
combination of PEO and pigmentary retinopathy with onset before 20 years of age,
in association with raised CSF protein and sensorineural deafness led to a clinical
diagnosis of KSS.
Electrocardiogram did not reveal any conduction abnormalities. Echocardiogram
(ECHO) showed increased thickness of the interventricular septum and left posterior
ventricular wall with normal left ventricular function. She was found to have a right
hydronephrosis but there was no suggestion of renal tubulopathy (tubular
reabsorption of phosphate was normal at 98% at 15 years). Cranial MRI
demonstrated abnormal high signal in the deep cerebral white matter, posterior limbs
of the internal capsules and the region of the anterior commissure and diffuse
changes in the lower half of the midbrain dorsally.
Continued enlargement of the kidney necessitated nephrectomy two years later.
During the procedure a biopsy of the rectus abdominus was taken which showed
fibre size variation and frequent necrotic fibres (Figure 4.3A). Numerous fibres
showed enhanced SDH activity (Figure 4.3B) some of which showed classical
morphology of RRF (7.8% of fibres) (Figure 4.3C-E). Most RRF and fibres with
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enhanced SDH activity stained negatively for COX (10.3% of fibres) (Figure 4.3F).
EM demonstrated mitochondrial aggregates, many with abnormal morphology
including type I paracrystalline inclusions (Figure 4.3G). There were continuing
problems with appetite and nutrition, and despite nutritional supplements body mass
index aged 16 was 12.9 (weight 33.7 kg, height 161.5 cm). Patient 4.3 died aged 22
years following an episode of severe pneumonia.
4.3.4 Patient 4.4
Patient 4.4 presented aged 58 years with a 3-year history of diplopia on a
background of longstanding fatigue, having been born to non-consanguineous
parents of European descent. Birth history and early development were normal and
there was no history of neurological or neuromuscular disease in her parents, two
siblings or other relatives. Cranial nerve examination revealed mild bilateral ptosis,
restricted extra-ocular movements and slowing of saccades with no evidence of
retinopathy. Other than slight wasting of biceps there were no abnormal findings on
motor and sensory assessment of limbs.
Investigation showed normal CK. MRI brain revealed areas of T2 high signal
bilaterally in the pons and some further small foci in both frontal lobes in the anterior
limb of the left internal capsule thought to be vascular in nature. NCS and EMG were
normal. Muscle histology aged 58 years showed five RRF (0.6% of fibres) and
frequent COX-deficient fibres (4.1% of fibres), compatible with a mitochondrial
myopathy (Figure 4.3H). Similar to Patient 4.3, fibre necrosis was also observed with
two necrotic fibres in the small biopsy available, a feature not usually reported in
mitochondrial disease (Figure 4.3H, inset) (Shoffner and Shoubridge, 2001). She
died aged 66 years of urinary sepsis.
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Figure 4.3: Muscle histopathology from Patient 4.3. The muscle biopsy showed
increased variation in fibre diameter and fibre necrosis (A, arrow) confirmed by acid
phosphatase histochemistry (A, inset). Frequent fibres showed increased succinate
dehydrogenase (SDH) activity (B, arrows). Ragged red fibres were readily apparent
(C & D, **) and these displayed an increase in SDH activity (E, **) with cytochrome c
oxidase (COX) deficiency (F, **). Many of the fibres with a normal appearance in the
haematoxylin and eosin (C, *) and Gomori trichrome (D, *) preparations showed
enhanced SDH activity (E, *) and COX deficiency (F, *). Ultrastructural examination
revealed abnormal mitochondria containing type I paracrystalline inclusions (G).
Examination of the muscle biopsy from Patient 4.4 also showed increased numbers
of COX deficient fibres (H, arrows) and a small number of necrotic fibres (H, inset).
Bar in A represents 50μm in A, C-F and insets in A & H; 100 μm in B & H; 800 nm in
G. A & C haematoxylin and eosin, B & E succinic dehydrogenase, D Gomori
trichrome, F & H cytochrome oxidase, insets in A & H acid phosphatase.
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4.4 Methods
4.4.1 Long-range polymerase chain reaction and Southern blot
analysis of mitochondrial DNA
Multiple mtDNA deletions had previously been confirmed using long-range PCR
and/or Southern blot genetic analysis techniques in all 50 patients by the UCLH
NHNN NCG Neurogenetics diagnostic laboratory.
4.4.2 Automated Sanger sequencing of POLG and RRM2B
Sanger sequencing of the coding region and exon-intron boundaries of POLG and
targeted regions of C10orf2 to include nucleotides c.690-1592 (3’ end of exon 1,
exons 2 and 3) was performed by the Oxford NCG Neurogenetics diagnostic
laboratory.
The nine exons and flanking intronic regions of RRM2B were amplified from total
gDNA using specific primers (Table 4.1). PCR cycling conditions were: initial
denaturation at 95°C for 10 min, followed by 30 cycles of 95°C for 30 sec, 58°C for
30 sec, and 72°C for 30 sec, and a final extension at 72°C for 7 min.
Table 4.1: Oligonucleotides used for RRM2B PCR amplification and sequence
analysis
Forward primers (5’ to 3’) Reverse primers (5’ to 3’)
Exon 1 GGAGAAACCCTTAGGCCGC CGCGGCGAATAACATTTCCTA
Exon 2 CAGGCTCTCAAACCAATGCC GTAAAACAAGAAGGAACACTGC
Exon 3 GTGCTAACATCTTTCTTTTTCCA AGACATCTTGTCTTTGGCTGAA
Exon 4 CCATAAGGTCTTTCTGACCTGTTT TGCTCAGAAACTTCCATACTTGA
Exon 5 CTAGCTACTCGGGAGGCTGA TTTGTACTCCTTTTCCATGCTG
Exon 6 TTTGGCCATGGCACTAACTT AGCAAGCCATGATCGTGCC
Exon 7 ACCCCTCTTCCATTTTCCAG TTGGTATTGTCAGGCTGACC
Exon 8 GGACATCATTTGCCACATTG TTACCAGCCTCCTACTTCAGTT
Exon 9 CCTGACCTCTGTTTTGGTCA GGTTTTGGATTTCCTTTTGAGC
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4.4.3 Multiplex ligation-dependent probe analysis of POLG and
RRM2B
Multiplex ligation-dependent probe analysis (MLPA) was used to exclude trans-
acting large-scale genomic rearrangements when a monoallelic mutation alone was
detected using automated Sanger sequencing. POLG MLPA was performed for
Patient 4.1 and Patient 4.2 by the Oxford NCG Neurogenetics diagnostic laboratory.
The SALSA MLPA kit P089-A1 TK2 (MRC-Holland) was used in Patient 4.4 to
exclude a large-scale genomic rearrangement in RRM2B. DNA was mixed with TE
(10 mM Tris, 1 mM EDTA, pH 8) and denatured by heating to 98°C for 5 minutes,
followed by incubation at 25°C for 1 min. The P089-A1 probe mix was added to the
DNA and heated to 95°C for 1 min followed by incubation at 60°C for 16 h for
hybridisation. Annealed probes were then ligated by adding Ligase-65 at 54°C for 15
min. Ligation products were amplified by PCR (35 cycles of 95°C for 30 sec, 60°C for
30 sec and 72°C for 1 min) with SALSA PCR primers (labelled with Cy4.0). The
resulting PCR fragments were separated by capillary electrophoresis on an ABI
3730XL using ‘GeneMapper Generic’ protocol. Data were analysed using
GeneMarker analysis software. Relative copy number was obtained after
normalisation of peaks against controls with values between 0.75 and 1.25
considered to be within the normal range.
4.4.4 Quantitative real-time polymerase chain reaction
Assessment of mtDNA copy number in muscle tissue was performed using a
quantitative real-time PCR assay using an ABI Step One real-time PCR system and
power SYBR green PCR master mix (ABI, part no. 4367659). The following primers
(Bai and Wong, 2005) were used: mtDNA D-loop (forward 5’-
CATCTGGTTCCTACTTCAGGG, reverse 5’-TGAGTGGTTAATAGGGTGATAGA);
single copy nuclear gene 2-Microglobulin (forward 5’-
TGCTGTCTCCATGTTTGATGTATCT, reverse 5’-TCTCTGCTCCCCACCTCTAAGT).
Pipetting for amplification in one well (20 l total volume) was as follows: 10 l of
master mix (2x); 7.4 l of ddH2O; 0.3 l of 20 M forward primer (either for mtDNA or
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nDNA); 0.3 l of 20 M reverse primer (either for mtDNA or nDNA); and 2 l of 4
ng/l DNA.
Each DNA sample was analysed in quadruplicate. Eleven DNA samples from control
subjects were included to reveal the normal range. DNA samples from age-matched
rho0 cells (cells whose mitochondria are depleted of mtDNA by prolonged incubation
with ethidium bromide, a chemical which inhibits mtDNA replication) and a known
mtDNA depletion patient were used as negative and patient control, respectively.
PCR cycling was as follows: 1) enzyme activation step: 10 min, 95°C; 2) denaturing
step: 15 sec, 95°C; 3) annealing and elongation step: 60 sec, 60°C; 4) repeat
denaturing and annealing/elongation steps 45 times.
In addition to the DNA samples, a 10-fold serial dilution of the mtDNA amplicon (35
to 351809732 molecules) and the nDNA amplicon (26 to 257812896 molecules)
were included in each experiment. The serial dilution was prepared from a very
precisely known concentration of DNA (NanoDrop) so that the number of molecules
per 2 l could be calculated accurately. The 10-fold dilution series for both amplicons
was 10-12 to 10-18 g per 2 l.
The mtDNA amplicon is 104 bp and an average bp is 660 Da. Therefore, 1 mol =
68640 g = 6.022 × 1023 molecules (Avogadro’s number). Thus, 20 ng amplicon DNA
per l = (20x10-9 g/l ÷ 68640 g) × 6.022·1023 molecules = 1.755 × 1011 molecules
per l. The nDNA amplicon is 86 bp and an average base pair is 660 Da. Therefore,
1 mol = 56760 g = 6.022 × 1023 molecules.
The Ct values of the mtDNA and nDNA amplicon dilution series were used to
construct standard curves (number of amplicons versus Ct value). The equations of
the standard curves were used to calculate the number of amplicons in the DNA
samples. The Ct values of the serial dilutions (Y-axis) were plotted against the
number of original amplicons (X-axis) in Microsoft Excel. The logarithmic trend line
and the equation and R2 value of the trend line were displayed. The experiment was
rejected when the R2 of a standard curve was <0.98. The equations of the trend lines
(y = -a ln(x) + b  x = e(y - b)/-a) and the Ct values of the DNA samples (y) were used
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to calculate the number of mtDNA and nDNA molecules in 2 l of DNA sample (x).
The following equation was used to calculate the number of mtDNA molecules per
diploid nuclear genome (i.e. per single cell) in the DNA samples:
(Number of mtDNA amplicons) / [(Number of nDNA amplicons) / 2]
4.4.5 Protein analysis
Western blot analysis was performed on 10 µg of muscle protein extracted from total
cell lysate from Patients 4.3 and 4.4. The p53R2 and GAPDH proteins were detected
using specific anti-p53R2 rabbit polyclonal (1:1,000, cat. no. ab8105) and anti-
GAPDH mouse monoclonal (1:60,000) antibodies (Abcam) and visualised using
secondary mouse anti-rabbit and goat anti-mouse antibodies conjugated to
horseradish peroxidase (Dako).
Assembled heterotetrameric R1/p53R2 RNR protein complexes were detected using
BN-PAGE, performed as previously described for respiratory chain complexes (see
section 2.4.6), modified to examine total cell extracts (Williams et al., 2004c).
Samples were obtained from the muscle biopsies of Patient 4.3 and two controls. No
further muscle tissue was available from Patient 4.4 for BN-PAGE studies. Skeletal
muscle tissue was pulverized in liquid nitrogen. After thawing, the powder was
immediately mixed with 0.75 M 6-aminocaproic acid, 37.5 mM bistris (pH 7.0), 2.5%
(w/v) n-dodecyl-beta-D-maltoside and protease inhibitors, followed by centrifugation
at 16,000 g, 4°C for 20 min. The supernatant was transferred to a new tube and
mixed with 0.1 volume of 1 M 6-aminocaproic acid and 5% (w/v) Serva blue G. The
samples (15-20 µl) were then loaded, resolved on 4-12% polyacrylamide gels,
electrotransferred to Hybond-P membrane (GE healthcare) and probed with specific
polyclonal antibodies to p53R2 (1:1,000, Abcam, cat. no. ab8105). The secondary
antibody was mouse anti-rabbit conjugated to horseradish peroxidise (Dako). A
loading control was performed in parallel using SDHA, a major subunit of the
nuclear-encoded Krebs cycle enzyme succinate dehydrogenase (SDH; also known
as complex II).
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4.4.6 Protein function prediction
The three mutations observed in these two patients were modelled by Dr Michael
Sadowski, MRC National Institute for Medical Research (NIMR), using the published
p53R2 crystal structure (pdb code 3hf1) (Smith et al., 2009), monomers A and B for
the mono- and di-iron bound forms, respectively. Residues 1-29 and 318-351 were
not observed in the crystal structure and these regions were therefore omitted from
the model. Models were built using the automodel routine of the MODELLER
software package (version 9v3) (DeLano, 2002) with no additional refinement.
4.5 Results
4.5.1 Long-range polymerase chain reaction and Southern blot
analysis of mitochondrial DNA
Patient 4.1 (Figure 4.1I) and Patient 4.3 (Figure 4.4A, B) had multiple mtDNA
deletions detectable in skeletal muscle tissue using both long-range PCR and
Southern blot analysis techniques. Multiple deletions of mtDNA were detectable only
by long range PCR in Patient 4.4 (Figure 4.4A and B).
4.5.2 Automated Sanger sequencing of POLG and RRM2B
Genetic analysis of POLG in Patient 4.1 revealed a novel heterozygous missense
mutation c.2687T>G; p.Leu896Arg (Figure 4.5A) within the polymerase domain of
the protein (Figure 4.5C). The mutation was absent in both parents, who are healthy;
thus inheritance was considered de novo dominant. Since the clinical phenotype of
Patient 4.2 strikingly resembled that of Patient 4.1, genetic sequence analysis of
POLG in gDNA extracted from blood was performed without repeating the muscle
biopsy to confirm whether multiple mtDNA deletions were present. This revealed a
novel heterozygous missense mutation c.2851T>C; p.Tyr951His (Figure 4.5B) within
the same functional polymerase domain of the polymerase gamma protein (Figure
4.5C).
Sanger sequencing of RRM2B revealed deleterious mutations in RRM2B in two of
the 33 patients, whilst the remaining 31 patients were not shown to have pathogenic
RRM2B variations. Patient 4.3 had two novel heterozygous missense mutations in
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RRM2B: c.122G>A; p.Arg41Gln in exon 2 (Figure 4.6A) and c.391G>A; p.Glu131Lys
in exon 4 (Figure 4.6B). The c.122G>A; p.Arg41Gln change in exon 2 segregated to
the paternal allele (Figure 4.6C), and the c.391G>A; p.Glu131Lys in exon 4 to the
maternal allele (Figure 4.6D). The c.122G>A; p.Arg41Gln change was not present in
332 ethnically matched control chromosomes and c.391G>A; p.Glu131Lys was not
present in 308 ethnically matched control chromosomes.
Patient 4.4 had a heterozygous three base pair deletion in exon 3:
c.253_255delGAG; p.Glu85del (Figure 4.6E). No DNA samples from other family
members were available for study. The c.253_255delGAG; p.Glu85del mutation has
previously been reported in compound heterozygous state with the missense
mutation c.707G>T; p.Cys236Phe and also as a homozygous mutation (R. Van
Coster et al., July 2010, Acta Myologica, abstract) in neonates with a very severe
mtDNA depletion. This mutation has previously been shown to be absent from over
220 ethnically matched control chromosomes. These amino acid residues occur in
highly conserved regions across species (Figure 4.7A-C).
4.5.3 Multiplex ligation-dependent probe analysis of POLG and
RRM2B
Patient 4.1 and 4.2 were reported to have normal POLG MLPA by the Oxford NCG
Neurogenetics diagnostic laboratory. Patient 4.4 had normal copy numbers for all 8
RRM2B MLPA probes at the default threshold level (0.75-1.25), excluding a large-
scale rearrangement of this gene on the other allele in this patient.
4.5.4 Quantitative real-time polymerase chain reaction
Patients 4.3 and 4.4 had a normal mtDNA copy number compared to age-matched
controls, measured by quantitative real-time PCR (Figure 4.4C).
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Figure 4.4: Long-range PCR, Southern blot and real-time PCR data for Patient 4.3
and 4.4. Long range PCR analysis showed multiple mtDNA deletions in muscle
samples of Patients 4.3 and 4.4 (P1 and P2 respectively) compared with ladder (L)
and normal control subjects (C1 and C2) (A). Southern blot analysis using PvuII
restriction endonuclease shows multiple mtDNA deletions (with common 5kb mtDNA
deletion annotated) in muscle sample of Patient 4.3 (P1) compared with control (C1)
and only wild-type mtDNA band in muscle sample of Patient 4.4 (P2) compared with
control (C2) (B). MtDNA copy number is normal in muscle samples of Patient 4.3
and Patient 4.4 compared to age-matched healthy controls, disease controls, and
cells depleted of mtDNA (Rho0) measured by quantitative real-time PCR (C).
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Figure 4.5: POLG sequencing data for Patient 4.1 (A) and Patient 4.2 (B) compared
with control. Diagramatic representation of POLG transcript demonstrating novel
heterozygous mutations c.2687T>G and c.2851T>C (C). Amino acid alignment of the
human polymerase gamma catalytic subunit reference sequence versus sequences
of various species with Leu896Arg and Tyr951His substitutions highlighted (D).
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Figure 4.6: RRM2B sequencing data for Patient 4.3 showing: c.122G>A; p.Arg41Gln
in exon 2 (A) segregating to the paternal allele (C), and c.391G>A; p.Glu131Lys in
exon 4 (B) segregating to the maternal allele (D). RRM2B sequencing data for
Patient 4.3 showing: c.253_255delGAG; p.Glu85del in exon 3 (E).
Figure 4.7: Amino acid alignment of the human p53R2 enzyme reference sequence
versus p53R2 enzyme sequences of various species for: (A) p.Arg41Gln in exon 2;
(B) p.Glu131Lys in exon 4; and (C) p.Glu85del in exon 3.
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4.5.5 Protein analysis
4.5.5.1 SDS-denaturing gel electrophoresis
Immunoblot analysis of both patients revealed normal steady state levels of p53R2,
indicating that none of the three RRM2B mutations had any effect on p53R2 stability
(Figure 4.8A, B).
Figure 4.8: Western blot analysis of p53R2 and GAPDH proteins in muscle samples
of Patient 4.3 (A, P1) and 4.4 (B, P2) shows normal p53R2 levels versus controls
(C1 and C2).
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4.5.5.2 Blue-native gel electrophoresis
BN-PAGE analysis demonstrated reduced levels of the heterotetramer R1p53R2 in
the muscle sample from Patient 4.3 when compared with control muscle tissue
(Figure 4.9A), suggesting impaired heterotetramer assembly despite the normal
p53R2 levels seen on Western blot and BN-PAGE. BN-PAGE of Complex II in the
muscle sample from Patient 4.3 when compared with control muscle tissue showed
equal protein loading (Figure 4.9B).
Figure 4.9: Blue-native polyacrylamide gel electrophoresis of p53R2 subunit,
R1/p53R2 heterotetramer (A) and complex II (B) in muscle sample of Patient 4.3
(P1) shows reduced native R1/p53R2 levels despite normal p53R2 levels versus
controls (C1 and C2).
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4.5.6 Protein function prediction
All three RRM2B mutations were modelled on the previously published p53R2
crystal (Smith et al., 2009) (Figure 4.10A) in order to illustrate their structural
implications. This enabled significant insight into the likely functional effects on RNR
function, particularly as a result of an impaired interaction between the two p53R2
monomers within the heterotetrameric protein complex. Residue Arg41 is located
within the N-terminal swivel region as defined by Smith et al. at the most N-terminal
visible portion of the protein (Figure 4.10B). Conformational change of this region is
associated with the formation of a salt-bridge between residues Arg41 and Glu119
and the stabilization of residues in helix B in the required conformation for formation
of the di-iron bound monomer as a prerequisite for generation of the active tyrosyl-
radical-bearing form of the subunit. Since glutamine would be unable to form a salt-
bridge, the mutant would not be stable in the di-iron form and this would result in
significant reduction of the active form of the enzyme. Glu131 is found in the centre
of the iron-binding pocket (Figure 4.10C). In the wild-type p53R2 this residue bridges
both ferric irons and is therefore required for binding one or possibly both ions.
Mutation to the larger, positively-charged lysine would abolish di-iron binding
completely and might prevent iron binding altogether. The effect of both mutations on
RNR activity explains the clinical phenotype and is most likely the reason for the
multiple mtDNA deletions observed in Patient 4.3.
Glu85 is located at the top of helix B at the opposite end to Glu119, the partner of
Arg41 in the swivel mechanism (Figure 4.10D). It forms a salt bridge to Arg211 in
helix D. Deletion of the Glu85 residue would preclude the formation of this salt-bridge
and cause a significant loss of stability, of the order of a few Kcal mol-1, potentially
reducing levels of correctly folded protein. Correctly folded proteins might also be
functionally impaired: removal of the link might favour translocation of helix B over
conformational change in helix D in response to movement of the swivel region,
strongly destabilising the di-iron form and leading to a loss of native function;
alternatively it may interfere with the adoption of the conformation of helix D required
to form the channel leading to the iron-binding site. Since the mutant protein appears
to exert a dominant effect, it is likely to compete with wild-type p53R2 to form the
heterotetrameric R1/p53R2 RNR complex. The result of this competitive binding
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would be a dominant-negative effect on R1/p53R2 function. The heterozygous
nature of the defect is likely to account for the milder phenotype seen in our patient
when compared to the two previously reported cases of the same mutation observed
in compound heterozygous and homozygous (R. Van Coster et al., July 2010, Acta
Myologica, abstract) states. The presence of the normal allele would be expected to
partially compensate for impaired RNR activity.
Figure 4.10: Mutations visualised on the p53R2 structure (PDB code 3hf1) showing
details for all three mutations (A), Arg41Gln (B), Glu131Lys (C) and Glu85del (D)
respectively.
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4.6 Discussion
4.6.1 Distal myopathy caused by de novo dominant mitochondrial
polymerase gamma mutations
Two unrelated patients with distal, predominantly upper limb, myopathy due to novel
heterozygous missense mutations in POLG are described. Both mutations reside in
the polymerase domain of the DNA polymerase catalytic subunit: c.2687T>G;
p.Leu896Arg in Patient 4.1; and c.2851T>C; p.Tyr951His in Patient 4.2. Evolutionary
conservation data confirmed that Leu896 and Tyr951 are invariant at these amino
acid positions (Figure 4.5D). The Leu896Arg substitution occurs in the highly
conserved motif A region of the polymerase domain, critical for nucleotide
recognition and catalysis, and any alteration is highly likely to be pathogenic and
cause impaired enzyme acitivity. Indeed, the majority of adPEO mutations in POLG
are located in this region (Chan and Copeland, 2009). The mutation appears to be de
novo dominant in Patient 4.1, since neither parent harboured the variant. A mutation
involving the adjacent amino acid, c.2684A>G; p.Glu895Gly, has been associated
with a neonatal-onset mtDNA depletion syndrome with 5% and 20% residual mtDNA
in skeletal muscle and liver respectively (Spinazzola et al., 2009a). Tyr951 is one of
three key amino acids, together with Tyr955 and Glu895, which form a hydrophobic
pocket within the polymerase domain of polymerase gamma (Graziewicz et al.,
2006). Tyr955Cys was the first reported mutation in POLG, causing adPEO in a
Belgian pedigree (Van Goethem et al., 2001a). The heterozygous nature of the
Tyr951His mutation, in the absence of any family history of neuromuscular disease,
suggests this mutation is also de novo. Unfortunately, no other family members were
available for genetic testing.
Patient 4.1 had an extremely low but static BMI despite normal dietary caloric intake.
There was no evidence of malabsorption on laboratory testing and MNGIE was
excluded. Gastrointestinal symptoms are not uncommon in patients with
mitochondrial disease and include dysphagia, cachexia, weight loss, constipation,
pseudo-obstruction, nausea and vomiting (Rahman, 2013). Weakness of the bulbar
and facial muscles can cause significant swallowing difficulties, and this may be
compounded by ataxia (Rahman and Hanna, 2009). In Patient 4.1, the degree of
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weight loss was disproportionate to muscle wasting and dysphagia, and caloric
intake adjusted for age and activity levels was normal. It is possible he has metabolic
dysfunction as a direct consequence of his underlying mitochondrial disorder, such
as uncoupling of oxidative phosphorylation. In Luft’s first description of mitochondrial
disease, the patient had a RRF myopathy with ‘severe hypermetabolism of
nonthyroid origin’ and a BMI of 16.6 (normal female range 18.5-25) (Ernster et al.,
1959; Luft et al., 1962). Disruption of the same biological pathway may account for
the severe cachexia documented in Patient 4.1. Further work, such as measurement
of the basal metabolic rate, would be required in order to clarify the underlying
aetiology of the weight loss.
4.6.2 RRM2B mutations cause Kearns-Sayre syndrome
This is the first case of KSS to result from a nuclear genetic defect: two novel
missense mutations in RRM2B. Single large scale deletions of mtDNA are normally
found to be the cause of KSS and were first reported in this condition in 1988
(Zeviani et al., 1988). It was subsequently shown that the causative mtDNA deletions
may differ considerably in size and location, although a 5kb ‘common’ deletion is
present in approximately one third of patients (Moraes et al., 1989). The mechanism
for the formation of deletions is poorly understood. An initial hypothesis proposed
that slipped replication occurs between homologous base-pair repeat sequences
within mtDNA (Shoffner et al., 1989), since most deletions appear to occur within the
major arc between the two origins of mtDNA replication. The validity of this model
has since been questioned (Krishnan et al., 2008). Irrespective of the mechanism,
single large-scale deletions are generally considered sporadic events with a low
inheritance risk. The present discovery suggests that KSS can also follow Mendelian
inheritance patterns as a result of a nuclear gene mutation associated with multiple
mtDNA deletions. This potentially has significant clinical implications, particularly
during genetic counselling, and analysis of RRM2B should be a priority in KSS when
multiple mtDNA deletions are present.
There are currently 60 adults from 41 families reported to harbour pathogenic
mutations in RRM2B characterised by either autosomal-recessive mtDNA depletion
syndrome (Shaibani et al., 2009) or recessively- and dominantly-inherited mutations
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that cause accumulation of multiple mtDNA deletions (Tyynismaa et al., 2009; Fratter
et al., 2011; Pitceathly et al., 2011a; Takata et al., 2011; Pitceathly et al., 2012). The
data presented here indicates that RRM2B mutations are an important cause of
multiple mtDNA deletions in adults (4% of this cohort of 50 adult patients with
multiple mtDNA deletions). It is also important to note that a significant number of
this cohort do not harbour mutations in POLG, C10orf2 or RRM2B.
In mammalian cells RNR exists as a heterotetrameric enzyme consisting of one
large homodimeric R1 subunit which contains the catalytic site, and one small
homodimeric R2 subunit which supplies the tyrosyl free radical required for catalysis.
The R2 subunit is produced exclusively during S-phase in cycling cells when RNR
provides the nucleus with dNTPs required for DNA replication (Tanaka et al., 2000).
The R2 homologue p53R2, however, is detectable at low levels throughout the cell
cycle in both proliferating and post-mitotic cells. It is thought that it is the R1/p53R2
heterotetramer which is important in providing dNTPs for nDNA repair and/or mtDNA
synthesis. A recent study localised p53R2 exclusively to the cytosol during both cell
proliferation and DNA damage, suggesting that the RNR enzyme itself does not
translocate into the nucleus or mitochondrion to effect DNA repair locally as was
initially thought, but rather that dNTPs diffuse into the nucleus and mitochondria to
provide building blocks for DNA repair/synthesis (Pontarin et al., 2008). The role of
RNR in repair was also challenged since DNA damage does not lead to significant
increases in dNTP pools (Håkansson et al., 2006) and induction of p53R2 by p53
peaks around 24 hours, yet repair of damaged DNA is complete in a much shorter
time period (Nordlund and Reichard, 2006; Tanaka et al., 2000). It is possible that
p53R2 increases flux through the dNTP pool, rather than the absolute size of the
dNTP pool itself (Tyynismaa et al., 2009). Furthermore, posttranslational modification
of p53R2 by phosphorylation at Ser72 by the ataxia telangiectasia mutated (ATM)
protein kinase confers p53R2 protein stability and resistance to DNA damage within
30 minutes of genotoxic stress (Chang et al., 2008). This would allow rapid repair of
DNA by activating existing pools of p53R2 protein without reliance on slow
transcriptional induction of p53R2.
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BN-PAGE was used to demonstrate the deleterious effects of RRM2B mutations on
heterotetramer assembly. This is a technique previously used to assess intact
mitochondrial respiratory chain complexes. Data is presented that not only expands
the application of this method to include analysis of cytosolic multiprotein complexes,
but that also provides greater understanding of mutational effects on protein complex
assembly. Impaired R1/p53R2 heterotetramer assembly is a potential pathogenic
mechanism by which mutations in RRM2B cause disease. It is important that further
attempts are made to replicate this experiment in patients with RRM2B mutations to
fully understand the frequency of impaired R1/p53R2 assembly in the pathogenesis
of these disorders. BN-PAGE should also be considered to demonstrate native
multiprotein complexes when impaired assembly is suspected.
The presence of necrotic fibres alongside the more typical histopathological features
of mitochondrial disease in both patients with RRM2B mutations is intriguing,
particularly since both patients exhibit this finding. They may be a consequence of
impaired nDNA repair caused by the defective p53R2; it has been shown that
p53R2-null mice demonstrate enhanced frequency of spontaneous mutations and
activation of p53-dependent apoptotic pathways (Kimura et al., 2003). Identification
of necrotic fibres in muscle could be a useful guide when prioritising which nuclear
genes to sequence in patients with multiple mtDNA deletions.
In conclusion, this work shows that mutations in RRM2B are an important cause of
multiple mtDNA deletions in adults, and reports the first case of KSS related to
nuclear genomic dysfunction, as a result of two novel RRM2B mutations. The
heterotetrameric structure of R1/p53R2 RNR means that disease may arise from
heterozygous, homozygous or compound heterozygous mutations which reduce
RNR activity, and from impaired assembly of the heterotetramer. In addition, there is
a dosage effect, dependent on the presence or absence of wild-type p53R2. Finally,
BN-PAGE is shown to be a valuable method in the structural analysis of native
R1/p53R2 RNR, allowing mechanistic insight into the effect of dysfunctional RRM2B
on R1/p53R2 RNR assembly.
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CHAPTER 5
5. COX10 mutations link to severe adult cytochrome c
oxidase deficiency
5.1 Introduction
The COX10 protein is required to farnesylate protohaem (haem B) to haem O in the
haem A biosynthetic pathway (Moraes et al., 2004). Two haem A moieties (a and a3)
are essential prosthetic groups of the MTCO1 subunit of COX and are involved in
electron transfer (Taanman, 1997b).
In this study, an adult patient with a complex clinical phenotype, marked reduction of
COX activity in almost all muscle fibres on biopsy, and isolated biochemical COX
deficiency was investigated. In contrast to most patients with such profound COX
deficiency, disease progression was milder and the patient is clinically stable aged
37 years. The aim of this work was to elucidate the molecular genetic basis of this
disease and understand the milder clinical phenotype exhibited by this patient
compared with previous reports.
5.2 Case history
Patient 5.1 is a 37-year-old woman of European descent. She was born at term to
non-consanguineous parents and presented aged 12 months with poor weight gain
for which no cause was found. Aged 10 years short stature and mild exercise
intolerance was present. By 21 years, proximal muscle weakness and fatigue were
prominent features and at 25 years renal Fanconi syndrome and metabolic acidosis
were detected. She subsequently developed premature ovarian failure (POF). There
was no family history of neuromuscular disease (Figure 5.1). Currently, exercise
tolerance is limited to 200 yards with a walking aid. Recent clinical examination
showed short stature (height 4 ft 10 in) and a proximal myopathic gait, with upper
and lower limb proximal muscle weakness (MRC grade 4/5) and absent tendon
reflexes, but no other signs of neuropathy. There is an asymptomatic pigmentary
maculopathy and mild right-sided SNHL.
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Figure 5.1: Pedigree of Patient 5.1
Laboratory evaluation demonstrated an elevated serum lactate of 3.8 mmol/L, with a
normal CSF lactate. Brain MRI was normal at 12 years. Neurophysiology revealed
slowing of motor and sensory nerve conduction (left median compound motor action
potential [CMAP] at wrist 12.3 mV, motor conduction velocity [MCV] 30 m/s; left ulnar
CMAP at wrist 8.3 mV, MCV 33 m/s; left ulnar sensory action potential 4 µV, sensory
conduction velocity 43 m/s) and polyphasic units of brief duration in deltoid and
iliopsoas, compatible with a demyelinating peripheral neuropathy and proximal
myopathy.
Sural nerve biopsy showed moderate depletion of myelinated fibres with relative
greater loss of small diameter axons. Many of the surviving myelinated fibres had
inappropriately thin myelin sheaths for their diameter in the absence of regeneration
clusters (Figure 5.2A, arrows). Morphometry confirmed a significant number of large
calibre axons (≥ 8 µm diameter) had higher g-ratios compared to an age-matched
control (45% versus 27% of axons had a g-ratio of ≥ 0.7; normal range for large
calibre axons 0.55-0.65 age 10-60 years) (Jacobs and Love, 1985). Remyelination
causes generation of a thinner myelin sheath. This phenomenon is demonstrated in
the g-ratio (the ratio of axon to myelin circumference). Thus, remyelinated axons
tend to have a g-ratio closer to one than those myelinated naturally. The difference in
g-ratio between a normal and remyelinated nerve fibre is less apparent in small
calibre axons.
EM confirmed frequent demyelination (Figure 5.2B, C). Membrane-bound 8-nm wide
filament-containing inclusions were identified closely associated with and probably
arising within the Golgi complex cisternae of some myelinated fibre Schwann cells
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(Figure 5.2D, E). Redundant Schwannian cytoplasmic profiles were in keeping with
myelinated fibre loss. Unmyelinated fibres were well preserved.
Teased fibres showed frequent segmental demyelination. Occasional larger
mitochondria were noted in a few Schwann cells, but the cristae were of normal
density and architecture, and no inclusions were seen.
Muscle biopsy revealed global reduction in COX histochemical staining but no RRF
(Figure 5.2F).
Spectrophotometric activity assay confirmed severe COX deficiency in skeletal
muscle (0.004 COX/CS; controls 0.014-0.034) but low-normal activity in cultured skin
fibroblasts (0.015 COX/CS; controls 0.013-0.026). Mitochondrial respiratory chain
complex I and complex II+III activities were normal. Polarographic studies
demonstrated normal oxygen uptake of intact muscle mitochondria (Hargreaves et
al., 2002).
Genetic analysis of POLG, performed because of POF (Duncan et al., 2012;
Pagnamenta et al., 2006), was normal, as were sequences of the entire
mitochondrial genome, SURF1 (encoding the surfeit locus protein 1), SCO1
(encoding protein SCO1 homolog), SCO2 (encoding protein SCO2 homolog) and
TACO1 (encoding translational activator of cytochrome c oxidase 1).
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Figure 5.2: Sural nerve and muscle histopathology of Patient 5.1. Sural nerve biopsy: high magnification view of one fascicle (resin
semi-thin section stained with methylene blue, azure II and basic fuchsin) shows moderate depletion of myelinated fibres with
several large diameter axonal profiles displaying inappropriately thin myelin sheaths for their diameter, suggesting demyelination (A,
arrows). Electron microscopy demonstrates two examples of demyelinating axons (B and C) and tightly packed inclusions within a
myelinated fibre Schwann cell cytoplasm (D, star). Inspection at higher magnification shows membrane bound filamentous
inclusions (stars) closely associated with the Golgi cisternae (E, arrows). Muscle biopsy: decreased cytochrome c oxidase staining
in the majority of fibres (F). Ragged red fibres were not present. Bar in A and F represents 100 µm.
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5.3 Methods
5.3.1 Spectrophotometric analysis
Complex I, complex II+III and complex IV were measured in the muscle tissue of
Patient 5.1 in the UCLH NHNN NCG Neurometabolic diagnostic laboratory by Dr Iain
Hargreaves and in cultured skin fibroblasts of Patient 5.1 as described in section
2.3.2.
5.3.2 Oxygen polarography
Polarographic studies were performed on a mitochondrial enrichment fraction
isolated from the Vastus Lateralis muscle according to the method of Cooper et al
(Cooper et al., 1992) in the UCLH NHNN NCG Neurometabolic diagnostic laboratory
by Dr Iain Hargreaves. In these studies oxygen consumption rates were determined
in the presence of the following substrates: glutamate/malate; pyruvate/malate;
succinate and TMPD (N,N,N,N-tetramethyl-p-phenylenediamine)/ascorbate.
5.3.3 Whole exome sequencing
Genomic DNA (1-3 μg) was sheared to 100–400 bp using a Covaris E210 or LE220
(Covaris, Woburn, MA, USA). Sheared DNA was subjected to Illumina paired-end
DNA library preparation and enriched for target sequences (Agilent Technologies;
Human All Exon 50 Mb - ELID S02972011) according to manufacturer’s
recommendations (Agilent Technologies; SureSelectXT Automated Target
Enrichment for Illumina Paired-End Multiplexed Sequencing). Enriched libraries were
sequenced using the HiSeq platform (IIIumina, Inc., San Diego, CA, USA) as paired-
end 75 base reads according to the manufacturer’s protocol (see section 2.4.5).
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5.3.4 Whole exome sequencing bioinformatic analysis
Autosomal recessive inheritance was assumed in view of the non-consanguineous
lineage, because parents were unaffected, and because all reports of COX
deficiency result from loss-of-function genetic defects. The filtering pathway
searched for novel (absent from dbSNP132, 1000 Genomes Project, the UK10K rare
disease cohort [823 exomes at the time of the analysis]), compound heterozygous,
functional (non-synonymous coding [NSC] or loss-of-function [LOF] i.e. frame-shift
coding, stop gained or splice site mutations) SNVs and/or coding indels in genes
predicted to play a role in COX biogenesis. Across the entire exome no novel
candidate SNVs/genes were identified. The stringency was therefore relaxed to
include SNVs and coding indels reported to dbSNP132 and/or 1000genomes, still
assuming recessive inheritance.
5.3.5 Automated Sanger sequencing of COX10
Confirmation and segregation of the mutations identified by whole exome
sequencing analysis was assessed using standard dideoxynucleotide chain
termination (see sections 2.4.3. and 2.4.4). Amplification of COX10 fragments for
sequencing was performed using specific primers: 5’-
ATTCTTTGGAAATCTCTGGTGATGAC-3’ (forward primer), and 5’-
CTCGTACAACACCATTAAGACCT-3’ (reverse primer), designed using Primer3
(http://frodo.wi.mit.edu/primer3/), Amplitaq Gold 360 mastermix (Applied Biosystems)
and BigDye Terminator 246 v.1.1 cycle sequencing kit (Applied Biosystems). The
samples were run on a 3730xl DNA Analyser, assembled and analysed using
Seqscape v.205 software (Applied Biosystems).
5.3.6 Western blot analysis of SDS denaturing polyacrylamide gels
and immunocytochemistry
Western blot analysis of SDS denaturing gels (see section 2.5.5) were performed on
10 µg of muscle protein extracted from muscle tissue and developed with specific
mouse monoclonal antibodies (anti-SDHA and anti-MTCO1) from Abcam. The
affinity purified rabbit anti-COX10 antibody was purchased from Proteintech Group
Inc. (1:500, cat. no. 10611-1-AP). Proteins were visualised using secondary mouse
Chapter 5 | COX10 mutations link to severe adult COX deficiency
131
anti-rabbit and goat anti-mouse antibodies conjugated to horseradish peroxidase
(Dako).
Immunocytochemistry of MTCO1/MitoTracker Red CM-H2XRos (Life Technologies)
stained cells was performed as described in section 2.5.7. Anti-MTCO1 (clone
1D6E11A8, Abcam) was detected with goat anti-mouse IgG Alexa Fluor 488 (Life
Technologies) and nuclei were counterstained with 1 g of 4’,6-diamidino-2-
phenylindole (Sigma) per ml of Citifluor-glycerol-PBS solution (Agar Scientific).
5.3.7 Western blot analysis of one-dimensional blue-native
polyacrylamide gels
Western blot analysis of blue-native gels (see section 2.5.6) were performed on 10
µg of muscle protein extracted from muscle tissue and developed with specific
mouse monoclonal antibodies (anti-SDHA, anti-MTCO1, anti-MTCO2, anti-COX4,
and anti-UQCRC2) from Abcam. Proteins were visualised using secondary mouse
anti-rabbit and goat anti-mouse antibodies conjugated to horseradish peroxidase
(Dako).
5.3.8 Haem spectrophotometry
Air-oxidised versus sodium dithionite-reduced haem spectra of 1.5% DDM extracts
of muscle mitochondrial fractions were recorded as described (Capaldi et al., 1995).
The haem electron carriers of the respiratory chain give characteristic visible
absorption spectra in their reduced state. Haem spectra can be used to identify COX
and to assess its concentration in cell extracts or mitochondria. Spectral shifts or low
absorbance indicate disturbances of the catalytic centre in the enzyme. Light
scattering can be avoided by solubilising the respiratory chain complexes in 1.5%
(w/v) dodecyl maltoside or 1% (v/v) Triton X-100.
The mitochondrial samples were incubated at a concentration of 0.5 to 5 mg
protein/ml in 100 mM potassium phosphate buffer, pH 7.2, 25 mM NaCl, and 1.5%
(w/v) DDM for 5 min on ice. Insoluble material was removed by centrifugation in a
micro-centrifuge for 1 min. Air-oxidised versus sodium dithionite-reduced difference
spectra was recorded between 400 and 650 nm in order to detect the , , and 
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bands. A few crystals of sodium dithionite in the cuvette were used to reduce the
haems fully. Spectra were recorded using a double-beam spectrophotometer.
Absorption maxima of the RC haems are shown in Table 5.1.
Table 5.1: Haem absorption maxima in air-oxidised versus sodium dithionite-
reduced difference spectra, adapted from (Capaldi et al., 1995)
Cytochrome c
oxidase
Cytochrome c reductase Cytochrome c
Band Haem aa3 Haem b Haem c1 Haem c
 605 562 553 550
 520 532 520 521
 445 430 418 416
5.3.9 Yeast studies
Yeast studies were performed by Dr Brigitte Meunier (Centre de Génétique
Moléculaire, UPR3404, CNRS, Avenue de la Terrasse, 91198, Gif-sur-Yvette,
France). The mutant yeast cox10 and the centromeric plasmid carrying the human
COX10 gene were kindly received from Professor A. Tzagoloff and are previously
described (Glerum and Tzagoloff, 1994; Valnot et al., 2000). The mutations were
introduced using the Quikchange site-directed mutagenesis procedure (Stratagene)
according to the manufacturer's recommendation. The plasmids, carrying the control
or mutated human COX10 gene, were used to transform the mutant yeast cox10.
Transformants, after growth on selective medium, were inoculated on
nonfermentable medium, containing glycerol and ethanol as carbon source.
5.3.10 Modelling of COX10 protein from predicted contacts
Since the crystal structure for the COX10 protein is undetermined, the here reported
novel Arg339Trp, in addition to the previously reported COX10 amino acid
substitutions Thr196Lys, Asp204Lys, Pro225Leu, Asp336Gly, and Asp336Val
(Antonicka et al., 2003; Valnot et al., 2000), were mapped to a hypothetical COX10
protein model predicted using computational analysis by Dr Michael Sadowski, MRC
National Institute for Medical Research (NIMR). The resulting structural
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consequences were subsequently analysed to generate hypotheses for potential
mechanisms underlying the pathogenicity of these mutations. The full-length COX10
sequence was used as a query to search the Uniref100 database with 3 iterations of
JackHammer from the HMMer3 package (Eddy, 2011). The resulting alignment was
used to predict contacts between residues using covariance matrix inversion as
previously described (Jones et al., 2012; Taylor et al., 2012). Predicted contacts
were then used to provide restraints for ab initio modelling of the transmembrane
bundle. Several transmembrane prediction packages were run (MEMSAT3,
MEMSAT-SVM, OCTOPUS) and found to disagree on the transmembrane topology
and locations of the transmembrane helices. It was therefore decided to use the
curated Uniprot transmembrane annotations as the basis for the model. Predicted
contacts were implemented as harmonic restraints between alpha carbons with
mean distance 8 Å and standard deviation of 3 Å. Restraints within a single element
of secondary structure were removed to prevent distortion of the transmembrane
helices owing to noise in the predictions. The model was built using MODELLER 9v3
(Sali and Blundell, 1993) with a custom script defined as follows: first the sequence
is built as an extended chain and the normal stereochemical restraints are
implemented at this stage. Following this the ‘secondarystructure.alpha’ routine was
used to define the 9 transmembrane segments as detailed in the UNIPROT entry.
The bundle was then folded sequentially by adding one restraint at a time and
refining with 100 steps of conjugate gradient minimisation using the ‘refine.slow()’
protocol. Restraints were added in order of sequence distance starting with the
closest. Restraints involving coil residues were added after restraints between
elements of secondary structure. The process was repeated several times with
varying numbers of restraints from 1000 to 5000 and the model which was most
compact, with the most nearly parallel bundle and with the most hydrophobic surface
was chosen. Figures were rendered in PyMOL (DeLano, 2002).
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5.4 Results
5.4.1 Whole exome sequencing bioinformatic analysis
A total of 138,006 SNVs were identified (Table 5.2). Of these 9,456 were predicted to
be functional and 404 of these were novel. When these variants were filtered under a
recessive model, searching for two mutations within genes predicted to play a role in
COX biogenesis, no candidate genes were detected. However, when the filtering
stringency was relaxed to include variants reported to dbSNP132 and 1000
Genomes under a recessive model, three missense SNVs in COX10 were identified:
one reported pathogenic mutation (c.1007A>T; p.Asp336Val); one novel mutation
(c.1015C>T; p.Arg339Trp); and one SNP (c.476G>A; p.Arg159Gln, dbSNP132
rs8077302). The SNP was subsequently discounted from further analysis. No other
compound heterozygous (or homozygous) variants were detected in any other genes
predicted to play a role in COX biogenesis.
5.4.2 Automated Sanger sequencing of COX10
COX10 Sanger sequencing of gDNA from Patient 5.1 confirmed the presence of
c.1007A>T and c.1015C>T (Figure 5.3A). The unaffected parents both carried one
mutation (Figure 5.3B), thus confirming the compound heterozygous nature of the
mutations in Patient 5.1. Evolutionary conservation studies demonstrated invariance
of Asp336 and p.Arg339 across species.
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Table 5.2: Identification of candidate genes for cytochrome c oxidase deficiency in
Patient 5.1 using exome resequencing
Filter SNVs Genes
Total 138,006 13,268
SC 9,465 5,825
NSC/LOF 9,456 5,445
Novel NS/LOF 404 376
Novel homozygous NSC/LOF 24 21
Novel heterozygous NSC/LOF 380 358
Novel compound heterozygous NSC/LOF 39 17
With predicted mitochondrial localisation 0 0
With predicted role in COX biogenesis 0 0
Homozygous NSC/LOF 3749 2,597
Heterozygous NSC/LOF 5,707 3,596
Compound heterozygous NSC/LOF 3,211 1,100
With predicted mitochondrial localisation 104 43
With predicted role in COX biogenesis 3 1 (COX10)
Among the identified SNVs, non-synonymous coding and loss of function variants
were subsequently filtered for a predicted role in cytochrome c oxidase biogenesis
under a recessive model. Variants were considered novel when not present in
dbSNP132 or 1000 Genomes databases. Abbreviations: COX = cytochrome c
oxidase; SNVs = single nucleotide variants; SC = synonymous coding; NSC = non-
synonymous coding; LOF = loss of function (frame-shift coding/stop gained/splice
site).
Chapter 5 | COX10 mutations link to severe adult COX deficiency
136
Figure 5.3: COX10 sequencing data for Patient 5.1 and amino acid alignment of the
human COX10 protein reference sequence versus sequences of various species.
COX10 Sanger sequencing of gDNA from the patient confirmed the presence of
c.1007A>T and c.1015C>T (A). COX10 Sanger sequencing of gDNA from the
unaffected parents confirmed the compound heterozygous nature of the mutations in
the patient (B).
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Figure 5.5: Micrographs of control and Patient 5.1 fibroblasts immunocytochemically
stained for MTCO1 (green fluorescence) and MitoTracker Red (red fluorescence),
and counterstained with the DNA fluorochrome 4’,6-diamidino-2-phenylindole (blue
fluorescence). The cells of Patient 5.1 show a general decrease in MTCO1 levels
compared to control cells.
5.4.4 Western blot analysis of one-dimensional blue-native
polyacrylamide gels
Analysis of western blots of blue-native polyacrylamide gels revealed undetectable
COX holoenzyme with no abnormal subassemblies (Figure 5.6).
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5.4.5 Haem spectrophotometry
Muscle haem absorption spectra confirmed reduction in haem aa3 levels with loss of
the haem aa3  band at 445 nm (Figure 5.7). The haem aa3  (605 nm) and  (520
nm) bands were masked by contaminating haemoglobin.
Figure 5.7: Air-oxidised versus sodium dithionite-reduced haem spectra of the
muscle mitochondrial proteins of Patient 5.1. There is loss of the haem aa3  band at
445 nm (arrow) in Patient 5.1 compared with the control.
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5.4.6 Yeast studies
The functional significance of the mutations was demonstrated by introducing
p.Asp336Val and p.Arg339Trp into the yeast Saccharomyces cerevisiae. Growth on
a nonfermentable carbon source confirmed that each mutation caused respiratory
deficiency individually, which was even more prominent when the mutations co-
existed (Figure 5.8A, B).
Figure 5.8: Growth of control and COX10 p.Asp336Val, COX10 p.Arg339Trp and
COX10 Asp336Val + Arg339Trp yeast strains on glucose (A) and glycerol+ethanol
(B) as carbon source. Both COX10 mutations cause respiratory deficiency as
demonstrated by impaired growth on the nonfermentable carbon source
glycerol+ethanol. When both mutations co-existed, the respiratory deficiency
appeared to be even more pronounced (A and B).
Chapter 5 | COX10 mutations link to severe adult COX deficiency
142
5.4.7 Modelling of COX10 protein from predicted contacts
The protein model (Figure 5.9) indicates that helices 7 and 9 of COX10 contain two
highly conserved histidine residues (360 and 418) in close proximity, suggesting that
the haem-binding site might be located in this C-terminal region. Substitutions
Thr196Lys and Asp204Lys, implicated in severe infantile mitochondrial disease,
affect hydrophilic residues in helix 2 which interact with other helices in the bundle.
The larger lysine side chain would disrupt these interactions and destabilize the
overall protein structure, thereby explaining the deleterious effects of both these
variants. The reported Pro225Leu substitution is in a long loop region predicted to
localize to the mitochondrial matrix between helices 2 and 3. Thus, this mutation may
cause dynamic changes by increasing local flexibility and disrupting interactions with
partner proteins. Residues 336 (Asp to Gly and Val) and 339 (Arg to Trp) are found
in a loop region which, based on the positive-inside rule of von Heijne (von Heijne
and Gavel, 1988), would be expected to be intra-organellar. These residues may
therefore participate in functional interactions taking place within the mitochondrial
matrix.
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Figure 5.9: Topology diagram and structural model of the COX10 protein. Locations
of known and here reported mutated residues highlighted in red, with
transmembrane segments labelled with Roman numerals (I-IX) (A). Structural model
of the COX10 protein showing locations of residues 336, 339, and 225 (B) and
residues 196, 204, 225, 336, and 339 looking up from the mitochondrial matrix at the
putative face of the bundle (C).
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5.5 Discussion
The structural and functional data presented, including biochemical and protein
analysis, yeast studies, and in silico protein modelling, confirm the pathogenic nature
of both mutations detected, and provide mechanistic insight for variability in
phenotypic presentation associated with COX deficiency.
To study the effect of both mutations on COX assembly BN-PAGE was used. This
showed undetectable COX holoenzyme and subassemblies in muscle. Lack of COX
assembly intermediates is consistent with previous reports of infantile COX10
dysfunction and reflects the requirement for COX10 at an early stage of COX
assembly (Antonicka et al., 2003). Insertion of haem A is thought to occur prior to
folding of MTCO1 during its association with subunits COX4 and COX5A.
Consequently, COX10 mutations do not cause accumulation of COX subassemblies
typical of SCO1 and SURF1 defects (Williams et al., 2004d). The absence of
assembly intermediates is probably related to impaired stability and downregulation
of MTCO1, which requires association with COX4 and COX5A and insertion of haem
A to prevent its rapid degradation by mitochondrial proteases (Arnold and Langer,
2002; Williams et al., 2004d). The yeast studies provide further support for
pathogenicity of each mutation; both variants caused respiratory deficiency in
isolation, and this was exaggerated further when the mutations co-existed.
Despite the limitations of this computational COX10 protein model, it is tempting to
hypothesise that the Asp336Gly substitution (previously reported as co-existing with
Asp336Val in a paediatric case with death at 4 months) generates more significant
structural changes within the COX10 protein than the novel Arg339Trp substitution
reported here. As such, the potentially less deleterious combination of Asp336Val
and Arg339Trp might contribute towards the milder clinical phenotype observed in
Patient 5.1.
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CHAPTER 6
6. NDUFA4 mutations underlie human cytochrome c
oxidase-deficient Leigh syndrome
6.1 Introduction
This chapter investigates the genetic basis of neurological disease in a large
consanguineous Pakistani family in whom four affected relatives had isolated COX
deficiency. The natural history was of an initial presentation with congenital lactic
acidosis and subsequent evolution into a Leigh syndrome phenotype with bulbar
dysfunction, dystonia and intermittent encephalopathy. A combined homozygosity
mapping and whole exome sequencing approach identified a homozygous splice
donor site mutation in NDUFA4, a gene previously considered to encode an
accessory subunit of complex I.
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6.2 Case histories
6.2.1 Patient 6.1 (III-4)
The proband, Patient 6.1 (III-4, Figure 6.1, Tables 6.1 and 6.2), was the fourth child
of healthy first cousin Pakistani parents. He presented with lactic acidosis at birth
following a normal pregnancy and full-term delivery. Birth weight was 2.7 kg. There
was initial normal motor development but gait was later considered ‘stiff’ and at 24
months he was diagnosed with a spastic diplegia. Speech was delayed and there
were moderate learning difficulties. Aged 13 years he suffered his first generalised
tonic-clonic seizure and subsequently developed treatment-resistant myoclonus. An
electroencephalogram indicated a right temporal focus with inter ictal discharges
over the right anterior temporal and frontocentral regions. At 17 years plasma lactate
was 2.4 mmol/L and CSF lactate 3.2 mmol/L. CSF protein was also elevated at 0.54
g/L, as was CSF alanine at 45 μg/L (reference 16-36). Brain CT (13 years) and MRI
(17 years) were both normal. However, a brain MRI aged 25 years demonstrated T2
hyperintensities in the deep white matter. NCS indicated there was a sensory axonal
peripheral neuropathy. Muscle biopsy aged 17 years showed non-specific changes,
including increased fibre size variation and intense peripheral staining of some fibres
on modified Gomori trichrome, although no true RRF. COX histochemistry was
surprisingly normal, and might reflect the existence of residual COX activity
measured by an endpoint (rather than kinetic) enzyme assay. EM revealed lipid
droplets in some fibres. Spectrophotometric assay of muscle confirmed significant
COX deficiency (COX/CS ratio 0.008; controls 0.014-0.034). Cultured skin fibroblasts
grown on glucose medium has normal COX activity (COX/CS ratio 2.2; controls >1).
Pyruvate dehydrogenase activity was normal in cultured skin fibroblasts, and
mutations in SURF1, POLG, C10orf2, and the entire mitochondrial genome were
excluded.
Most recent clinical examination aged 32 years showed short stature (5 ft 4 in) and a
spastic gait. Cranial nerves were normal. Upper and lower limb examination revealed
dystonic posturing and increased tone with pyramidal weakness (MRC grade 4/5).
Tendon reflexes were pathologically brisk in arms and legs and plantar responses
extensor.
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6.2.2 Patient 6.2 (III-3)
Patient 6.2 (III-3, Figures 6.1 and 6.2, Tables 6.1 and 6.2) was an older sibling of
Patient 6.1. She was born at term following a normal delivery. Birth weight was 2.3
kg. Growth was poor in the neonatal period but no underlying cause was identified.
She had a systolic murmur and mild pulmonary stenosis was found on cardiac
catheterisation. At 6 months lactic acidosis was noted, with plasma lactate levels
ranging from 3.5-6.6 mmol/L and elevated plasma alanine. There was also evidence
of proximal renal tubular acidosis. This was treated with oral sodium bicarbonate. At
10 months she had mild motor delay and she was later diagnosed with speech delay
and moderate learning difficulties. There is no history of seizures.
Neurophysiology showed evidence of a predominantly sensory axonal peripheral
neuropathy mainly affecting lower limbs, with no evidence of myopathy. Brain MRI
(Figure 6.2) showed multiple scattered foci of T2 hyperintensities within the deep
white matter of both cerebral hemispheres, medial thalami, at the level of the
superior cerebellar peduncles, corticospinal tracts of the pons, right middle cerebellar
peduncles, cerebellar hemispheres and descending tracts at the levels of the
medulla oblongata. She has not had a muscle biopsy.
Most recent clinical examination aged 34 years showed limited speech and
understanding. There was mild upper limb and gait dystonia, but neurological
assessment was otherwise normal.
6.2.3 Patient 6.3 (III-6)
Patient 6.3 (III-6, Figure 6.1, Tables 6.1 and 6.2) was a younger sibling of Patients
6.1 and 6.2. She presented at birth following an uneventful pregnancy with lactic
acidosis, which resolved with sodium bicarbonate, and intrauterine growth
retardation (birth weight was 1.9 kg). She was discharged one month later and
continued on oral sodium bicarbonate until aged 7 years. She was subsequently
diagnosed with mild learning difficulties, but was otherwise medically stable until the
age of 25 years when she developed hypertension and suffered a respiratory arrest
requiring tracheal intubation and admission to intensive care. Brain MRI
demonstrated T2 hyperintensities in the anterior lateral medulla, posterior pons, and
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the thalami, parietal white matter and basal ganglia. Muscle histology demonstrated
a mild increase in lipid but was otherwise normal, including COX histochemistry.
Spectrophotometric assay of muscle confirmed COX deficiency (COX/CS ratio
0.004; controls 0.014-0.034). She was eventually extubated and established on
nocturnal non-invasive ventilation. She required a protracted period of rehabilitation
and was discharged 8 months following her initial admission when she was alert and
conversing, although was dependent for most care needs. Unfortunately, she later
died aged 26 years of a second respiratory arrest caused by presumed extension of
her existing or new brainstem lesions.
6.2.4 Patient 6.4 (III-13)
Patient 6.4 (III-13, Figure 6.1, Tables 6.1 and 6.2) was the seventh child of healthy
Pakistani parents who are second cousins, and is probably a cousin of Patients 6.1,
6.2 and 6.3. His six siblings are all well. He was a second twin and was born by
forceps delivery for breech presentation at 37 weeks’ gestation. At birth he was
floppy and bradycardic and required cardiopulmonary resuscitation. Apgar scores
were 3 at 1 minute and 9 at 5 minutes. He had a mixed respiratory and metabolic
acidosis (pH 6.99, pCO2 8.74, bicarbonate 14 mmol/L, base deficit 14.8 mmol/L) and
was admitted briefly to the neonatal unit for headbox oxygen treatment, but his
respiratory symptoms had settled by 24 hours of age. At 4 months poor growth and
mild motor developmental delay were noted. At 2 years he was referred to the
metabolic unit because of poor growth, developmental delay and lactic acidosis. At 3
years he developed dystonic posturing of the left arm and respiratory distress due to
lactic acidosis, which responded to sodium bicarbonate (1 mmol/kg/day). He had
frequent upper respiratory infections during the first 5 years of life. Neurological
regression occurred from 4 years, with gradual but progressive loss of skills (walking,
speech, cognition) over the next four years until his death at 8 years and 9 months of
age.
Examination at 4 years revealed bilateral horizonatal nystagmus, optic atrophy, gait
ataxia, tremor, thin musculature and brisk tendon reflexes. At 8 years he also had a
four-limb dystonia. He never had seizures or myoclonus.
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Plasma lactate ranged from 2.1-8.5 mmol/L and CSF lactate was elevated at 6.4
mmol/L with a paired blood lactate of 5.8 mmol/L. ECHO was normal, and there was
no evidence of renal tubulopathy or hearing impairment. MRI brain at 2 years
demonstrated abnormal signal in the parietal white matter with no convincing
involvement of the basal ganglia or brainstem, whilst magnetic resonance
spectroscopy showed an increased lactate peak in the basal ganglia. Muscle
histology at 2 years revealed reduced histochemical staining of COX in all muscle
fibres and increased lipid in type I fibres. Respiratory chain enzyme activities were
not formally determined in muscle, but fibroblast COX activity was normal at 43
nmole/mg protein/min (reference range 30-90) with a normal COX/CS ratio of 1.7
(normal >1).
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Figure 6.1: Pedigree of consanguineous family harbouring the c.42+1G>C mutation in NDUFA4. Arrow indicates proband.
Members of the family whose genotype data were used in homozygosity mapping analyses are illustrated by chromosome 7
schematic. Those whose exomes were sequenced are marked with an asterisk (*). Filled symbols indicate affected individuals.
Square symbols indicate male gender. Round symbols indicate female gender. Symbols with diagonal strikethrough indicate
deceased. Broken line (┤├) indicates the possibility that III-13 is a more distant cousin.
Chapter 6 | NDUFA4 mutations underlie human COX-deficient Leigh syndrome
152
Figure 6.2: Brain MRI of Patient 6.2 characteristic of Leigh syndrome. MR T2-
weighted coronal image demonstrates multiple scattered T2 hyperintensities in deep
white matter of both cerebral hemispheres (arrow, 1), medial thalami (arrow, 2) and
at the level of the superior cerebellar peduncles (arrow, 3). Hyperintensities were
also evident in the corticospinal tracts of the pons, right middle cerebellar peduncles,
cerebellar hemispheres, and descending tracts at the level of the medulla oblongata
(not shown). Similar appearances were evident on the brain MRI of the other
affected patients.
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Table 6.1: Clinical characteristics of Patients 6.1, 6.2, 6.3 and 6.4 with homozygous c.42+1G>C splice donor site mutation in
NDUFA4
PATIENT AGE
(years)
CLINICAL
PHENOTYPE
CLINICAL MANIFESTATIONS
DD FTT LD Dystonia Myoclonus Ataxia UMN signs Seizures
6.1 (III-4) 34 CLA, LS L, M - + + + + + +
6.2 (III-3) 32 CLA, LS L + + + - - - -
6.3 (III-6) Died 26 CLA, LS L - + - - - - -
6.4 (III-13) Died 8 CLA, LS L, M + + + - + + -
Abbreviations: CLA = congenital lactic acidosis; DD = developmental delay; FTT = failure to thrive; L = language; LD = learning
difficulties; LS = Leigh syndrome; M = motor; UMN = upper motor neuron. Positive symbol (+) = present; Negative symbol (-) =
absent.
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Table 6.2: Laboratory, neurophysiological, imaging, histopathological and biochemical characteristics of Patients 6.1, 6.2, 6.3 and
6.4 with homozygous c.42+1G>C splice donor site mutations in NDUFA4
PATIENT PLASMA
LACTATE
CSF
LACTATE
NCS BRAIN MRI BRAIN
MRS
MUSCLE
PATHOLOGY
COX/CS COX
(k/mg/min)
Muscle
(0.014-
0.034)
Fibroblasts
(glucose)
(>1)
Fibroblasts
(galactose)
(3.35-3.88)
6.1 (III-4) 1.6-2.4 3.2 Sensory
axonal
neuropathy
Aged 17: Normal
Aged 25: T2 signal
deep WM
- lipid 0.008 2.2 1.07
6.2 (III-3) 3.5-6.6 - Sensory
axonal
neuropathy
Aged 32: T2 signal
deep WM, thalami,
brainstem, cerebellum
- - - - -
6.3 (III-6) 2.5-4.7 - - Aged 25: T2 signal
parietal WM, BG,
thalami, brainstem
- lipid 0.004 - -
6.4 (III-13) 2.1-8.5 6.4 - Aged 2 yrs: T2
signal parietal WM
Lactate
peak in BG
Global COX,
lipid
- 1.7 -
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Abbreviations: BG = basal ganglia; COX = cytochrome c oxidase; CS = citrate synthase; CSF = cerebrospinal fluid; NCS = nerve
conduction studies; MRI = magnetic resonance imaging; MRS = magnetic resonance spectroscopy; WM = white matter. Reference
ranges: plasma lactate 0.7-2.1 mmol/L; CSF lactate <2 mmol/L; COX/CS in muscle 0.014-0.034; COX/CS in glucose-grown
fibroblasts >1; COX/protein in galactose-grown fibroblasts 3.35-3.88 k/min/mg. Hyphen (-) = test not performed.
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6.3 Methods
6.3.1 Galactose-containing cell culture medium
For spectrophotometric analysis of respiratory chain enzyme activities and
immunocytochemistry of cultured skin fibroblasts, the glucose in the cell culture
medium was replaced with 4.5g/L of D-(+)-galactose for 6 days prior to harvesting.
See section 2.2 for cell culture methods.
6.3.2 Spectrophotometric analysis
Complex I, complex II+III and complex IV activities were measured in the muscle
tissue of Patient 6.1 and 6.3 in the UCLH NHNN NCG Neurometabolic diagnostic
laboratory by Dr Iain Hargreaves. Complex IV activity was measured using the
glucose-grown cultured skin fibroblasts of Patient 6.1 in the Oxford NCG
biochemistry laboratory by Dr Garry Brown. Complex I and IV activities of the
galactose-grown cultured skin fibroblasts of Patient 6.1 were measured as described
in section 2.3.2.
6.3.3 Homozygosity mapping
Homozygosity is defined as having two identical copies of the same allele. In an
outbred population, homozygosity at any particular locus occurs by chance alone.
However, the offspring of related parents, as occurs in consanguineous partnerships,
usually contain large regions in which multiple, consecutive polymorphic loci are
homozygous. In such circumstances, homozygosity is not by chance but by descent.
The more closely related the child is to their parents, the greater proportion of the
child’s genome is likely to be homozygous (parent/child or sibling parents will have
offspring with 25% of their genome homozygous-by-descent compared with first
cousin parents whose children have 6.25% of their genome homozygous-by-
descent), and therefore the higher probability of the child harbouring a rare
homozygous disease-causing mutation. Homozygosity mapping is a powerful tool
when searching for homozygous mutations in small, closed populations with a limited
gene pool. It was first described by Eric Lander in 1987 as a strategy for mapping
human genes caused by recessive traits using mapped restriction fragment length
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polymorphisms (RFLPs) and the DNA of affected children from consanguineous
marriages, with detection of the disease locus by virtue of the fact that the adjacent
region will preferentially be homozygous by descent in such inbred children (Lander
and Botstein, 1987). Modern techniques utilise microsatellite markers or SNP
microarrays rather than RFLPs. Panels of 300-400 microsatellite markers spaced at
5 megabase intervals or microarrays that can genotype over one million SNPs (the
affymetrix Genome-Wide Human SNP Array 6.0 features 1.8 million genetic markers,
including more than 906,600 SNPs and more than 946,000 probes for the detection
of copy number variation) are used to identify regions of homozygosity. Despite a
mean heterozygosity for individual SNPs of approximately 50% of microsatellites,
much smaller regions of homozygosity can be detected with SNP microarrays.
In this particular study, total gDNA was extracted from peripheral blood leucocytes in
the UCLH NHNN NCG Neurogenetics diagnostic laboratory as previously described
(see section 2.4.1). Subjects II-2, III-1, III-2, III-3, III-4, and III-6 were genotyped
using the Illumina 740K OmniExpress SNP array according to the manufacturer’s
instructions and previous publications (Paisan-Ruiz et al., 2009). All files were
visually examined by Dr Anna Sailer using GenomeViewer tool within BeadStudio
v3.1 Genotyping module (Illumina Inc., San Diego, CA), where two metrics were
assessed: log R ratio and B allele frequency. The log R ratio gives an indirect
measure of copy number of each SNP by plotting the ratio of observed to expected
hybridisation intensity. B allele frequency plots the proportion of times an allele is
called B at each SNP locus: thus the expected values are 1.0 (B/B), 0.5 (A/B) and
0.0 (A/A). These two statistics allow visualisation of copy number changes and
homozygosity mapping. After quality control, the first analysis was visual inspection
to determine whether any large insertions/deletions were present, and whether any
extended regions of homozygosity were shared by affected individuals and absent in
unaffected family members. Subsequent, more detailed analysis used PennCNV to
collate the CNV data into Excel tables and to examine the CNV data to look for
unique smaller insertions/deletions. The genotyping data with AA, AB and BB were
then saved as excel files for affected and unaffected individuals so that shared
regions could be easily analysed.
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6.3.4 Whole exome sequencing
Genomic DNA (1-3 μg) was sheared to 100–400 bp using a Covaris E210 or LE220
(Covaris, Woburn, MA, USA). Sheared DNA was subjected to Illumina paired-end
DNA library preparation and enriched for target sequences (Agilent Technologies;
Human All Exon 50 Mb - ELID S02972011) according to manufacturer’s
recommendations (Agilent Technologies; SureSelectXT Automated Target
Enrichment for Illumina Paired-End Multiplexed Sequencing). Enriched libraries were
sequenced using the HiSeq platform (IIIumina, Inc., San Diego, CA, USA) as paired-
end 75 base reads according to the manufacturer’s protocol (see section 2.4.5).
6.3.5 Whole exome sequencing bioinformatic analysis
Autosomal recessive inheritance was assumed in view of the consanguineous
lineage, because parents were unaffected, and because all reports of COX
deficiency result from loss-of-function genetic defects. The filtering pathway
searched for novel (not reported to dbSNP132 and/or 1000 Genomes), homozygous
(in view of parental consanguinity), functional SNVs and/or coding indels shared by
both affected siblings. Genes predicted to play a role in COX biogenesis were initially
searched. However, using this strategy no candidate genes were identified across
the entire exome. The stringency of the filtering strategy was subsequently relaxed to
include all known nuclear-encoded mitochondrial genes, still assuming recessive
inheritance (Pagliarini et al., 2008b).
6.3.6 Automated Sanger sequence analysis of NDUFA4
Confirmation and segregation of the c.42+1G>C mutation and screening of 20
additional COX-deficient probands for mutations in NDUFA4 was assessed using
standard dideoxynucleotide chain termination. Amplitaq Gold 360 Mastermix
(Applied Biosystems) was used for all PCRs. Oligonucleotides for NDUFA4 PCR
amplification and sequence analysis in gDNA are listed in Table 6.3 below. M13
universal sequences to prime sequencing reactions were added to the 5' end of the
primers (5’-tgtaaaacgacggccagt to forward primers and 5’-ccagtatcgacaaaggac to
reverse primers) in order to simplify the sequencing reaction setup. Amplification of
NDUFA4 fragments for sequencing of complementary DNA (cDNA) was performed
using a forward primer annealing in exon 1 (5’-GTCAGGCCAAGAAGCATCC-3’) and
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a reverse primer annealing in exon 4 (5-ACACCTAATGTCGTTCGACTT-3’). Primers
were designed using Primer3 (http://frodo.wi.mit.edu/primer3/), and Sanger
sequencing was performed using M13 primers and BigDye Terminator v.1.1 cycle
sequencing kit (Applied Biosystems). The samples were run on a 3730xl DNA
Analyzer, assembled and analysed using Seqscape v2.5 software (Applied
Biosystems).
Table 6.3: Oligonucleotides for NDUFA4 PCR amplification and sequence analysis
in genomic DNA
Forward primers (5’ to 3’) Reverse primers (5’ to 3’)
Exon 1 GACCAGGTCAGGACGAACAT GGTGAATGGCAGGCAGTCTG
Exon 2 ATCTCTCGTTGGCCAGTGTT ACCAAGAGCCGTGTACATTT
Exon 3 AAAGGTTTTGTGAAAGCCAGA AAGTCGGAATAGGGGTCTCT
Exon 4 CATTGAAGGCTGGAATTTTAGG CGTATGTATTGTTGACCTTGACCT
6.3.7 RNA extraction
RNA was extracted from whole blood using the Qiagen/PreAnalytix blood RNA
system and from cultured cells using the Qiagen/RNeasy Mini Kit following the
manufacturer’s instructions.
6.3.8 RNA to complementary DNA conversion
Complementary DNA was synthesised from ~1 g RNA in a 20 l reaction using the
Applied Biosystems high capacity cDNA reverse transcription kit, following the
manufacturer's instructions.
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6.3.9 Polyacrylamide-gel electrophoresis of amplified
complementary DNA
Amplified cDNA fragments were resolved on a denaturing 7% polyacrylamide gel
and stained with silver as previously described (Sambrook and Russell, 2001).
7% gel
40% acrylamide/bis (37.5:1) 5.25 ml
5x TBE (54 g Tris, 27.5 g boric acid, 20 ml 0.5 M EDTA [pH 8.0] per litre) 6 ml
Urea 12.6 g
10% ammonium persulphate 100 l
TEMED 40 l
ddH2O (to a final volume of 30 ml)
The mixture, except for ammonium persulphate and TEMED, was placed on a roller
until the urea had dissolved and then ddH2O was added to a final volume of 30 ml.
Whilst shaking, the plates were cleaned with ddH2O, ethanol, and with ddH2O again.
The gel casting apparatus (Model AE-6210, Atto Corporation) was then assembled,
but not sealed, until ready to add the last two reagents. Once the urea had dissolved
the gel mix was filtered into a small beaker. Once ready to pour between the plates
10% APS and TEMED were added whilst on a stirrer. The gel was poured and the
comb inserted at an angle to avoid trapping bubbles and left to set for 20-30 min.
Sufficient TBE buffer was poured into the gel tank to cover the ‘feet’ at the bottom.
Once the gel had set it was removed from the casting apparatus along with the
rubber spacer and placed in the tank with the bevelled plate facing towards the back.
TBE was subsequently poured into the rear of the tank almost to the top of the plates.
The comb was removed and the wells flushed with a syringe containing buffer using
a loading tip to remove any acrylamide. In order to heat the gel it was run for two
hours prior to loading at a constant 50 mA (the voltage was set to 600 V to ensure
the amps remained constant). The products were initially run on an agarose gel to
determine the optimum loading concentration which was found to be 1 l along with
2 l of the denaturing loading buffer (98% formamide, 0.05% xylene cyanol [2%],
0.05% bromophenol blue [2%]). Prior to loading each sample was denatured briefly
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at 95°C and each lane was flushed to remove any urea. In order to visualise the
PCR products of 250 bp the gel was run for approximately 2 h 30 min.
6.3.10 Silver staining of polyacrylamide gel
The following solutions were made up to 300 ml using clean bottles rinsed with nitric
acid (one part nitric acid to three parts ddH2O):
Solution 1
(5-10 min, Fix)
Solution 2
(5 min)
Solution 3
(until bands visible
on light box)
Solution 4
(10-15 min, Stop)
10% ethanol
(30 ml)
0.5 g silver nitrate 4.5 g sodium hydroxide 2.25 g sodium
carbonate
0.5% acetic acid
(1.5 ml)
450 l formaldehyde
(added after solution 2
was used)
The gel was taken out of the tank and the non-bevelled plate was removed by lifting
the plate and teasing the gel off using a clean Gilson tip. The gel was then
submerged in solution 1 in a large plastic tray (also washed and rinsed with nitric
acid). The gel was then washed in each of the solutions in order for the times
specified above using a shaker, rinsing with ddH2O between each solution. The gel
was scanned on an Epson Perfection V700 Photo scanner and subsequently
wrapped in Clingfilm and stored at -4°C.
6.3.11 Fluorescent polymerase chain reaction
Fluorescent PCR of cDNA was performed, in order to quantify the wild-type versus
mutant cDNA, using a forward primer annealing in exon 1 (5’-
GTCAGGCCAAGAAGCATCC-3’) and a 6-FAM-labelled reverse primer annealing in
exon 4 (5’-ACACCTAATGTCGTTCGACTT-3’), in order to measure the relative
quantities of wild-type and mutant transcripts. PCR products were electrophoresed
on an Applied Biosystems 3730xl capillary analyzer with a LIZ500 internal size-
standard (Applied Biosystems). Data was analysed using GeneMapper v3.7 software
(Applied Biosystems).
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6.3.12 Western blot analysis of SDS denaturing polyacrylamide gels
Protein steady-state levels were evaluated using western blot analysis of SDS-
denaturing polyacrylamide gels probed with antibodies directed against NDUFA4
(1:1,000, Stratech Scientific Ltd, AssaybioTech cat. no. C16821) and MTCO2 (clone
12C4F12, Abcam).
6.3.13 Immunocytochemistry
Immunocytochemistry of the NDUFA4/MTCO1 and NDUFA4/MitoTracker Red CM-
H2XRos (Life Technologies) stained cells was carried as described in Chapter 2.
Anti-MTCO1 (clone 1D6E11A8, Abcam) was detected with goat anti-mouse IgG
Alexa Fluor 488 (Life Technologies), anti-NDUFA4 (1:300, Stratech Scientific Ltd,
AssaybioTech cat. no. C16821) with goat anti rabbit-IgG Alexa 594 or 488 (Life
Technologies) and nuclei were counterstained with 1 g of 4’,6-diamidino-2-
phenylindole (Sigma) per ml of Citifluor-glycerol-PBS solution (Agar Scientific).
6.3.14 In-gel activity and western blot analysis of one- and two-
dimensional blue-native polyacrylamide gels
To establish the optimal concentration of DDM required to analyse NDUFA4 as part
of the COX holoenzyme, western blot analysis of 8-16% polyacrylamide gradient
blue-native gels loaded with 10 g of mitochondrial protein extracted from control
muscle tissue using serial dilutions of DDM (0.01%, 0.02%, 0.04%, 0.08%, 0.16%,
and 0.32%) for mitochondrial membrane protein extraction was performed (Schägger,
1995; Williams et al., 2004d). Blots were developed with antibodies directed against
NDUFA4 and MTCO1. Mitochondrial membrane proteins (10 g), extracted using
0.08% DDM in order to verify co-localisation of the NDUFA4 protein with complex IV,
were subsequently applied and run on 3-12% polyacrylamide gradient blue-native
gels. For two-dimensional analysis, a single lane was excised from the gel,
denatured with 1% SDS and 2% -mecaptoethanol and resolved by denaturing
electrophoresis in the second dimension on an SDS 15% polyacrylamide gel, prior to
immunoblotting. Blots were probed with specific antibodies against complex I (anti-
NDUFA9; clone 20C11B11B11, Abcam), complex III (anti-UQCRC2; clone
13G12AF12BB11, Abcam), complex IV (anti-MTCO1, anti-MTCO2) and NDUFA4.
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Native markers were obtained by reprobing one-dimensional blots for SDHA (anti-
SDHA clone 2E3GC1FB2AE2, Abcam) to detect complex II (~125 kDa) and ATP5A1
(anti-ATP5A1 clone 7H10BD4F9, Abcam) to detect holo-complex V (~600 kDa), the
F1 portion of complex V (~400 kDa) and the free subunit (55 kDa).
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6.4 Results
6.4.1 Spectrophotometric analysis
Despite the normal COX activity measured using glucose-grown cultured skin
fibroblasts, a repeat assay using whole cell lysate of cultured skin fibroblasts grown
on galactose-containing medium did demonstrate reduced COX activity (1.07
k/min/mg; control mean±standard deviation [n=5]: 3.60±0.24 k/min/mg) (Table 6.2).
Complex I activity in fibroblasts grown under the same conditions was normal (37.3
nmol/min/mg; control mean±standard deviation [n=5]: 19.4±7.2 nmol/min/mg).
6.4.2 Homozygosity mapping and whole exome sequencing
bioinformatic analysis
To identify areas of shared homozygosity amongst affected relatives, six family
members were genotyped (three affected and three unaffected, Figure 6.1A). Two
large regions of shared homozygosity mapped to chromosome 7p (nucleotides
9,219,283-13,801,764, containing 15 protein-coding genes; and nucleotides
19,034,191-29,250,335, containing 92 protein-coding genes, Table 6.4). As no
candidate genes for COX deficiency were present in either region, it was initially
concluded that a small area of homozygosity had been overlooked. Whole exome
sequencing was therefore subsequently performed in two affected family members:
Patient 6.1 (III-4); and Patient 6.3 (III-6).
A total of 78,004 shared variants were identified (Table 6.5). Of these, 19,389 were
shared homozygous SNVs and indels and 190 of these were novel variants. Thirteen
of these homozygous variants were predicted to be functional. The only gene within
this group predicted to encode a protein product known to localise to the
mitochondrion was NDUFA4, which contained a homozygous splice donor site
mutation (c.42+1G>C). NDUFA4 was also a gene within one of the previously
identified regions of homozygosity.
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Table 6.4: Two large regions of homozygosity shared by Patients 6.1 (III-4), 6.2 (III-
3) and 6.3 (III-6)
Region 1 (Ch 7p: 9,219,283-13,801,764) containing genes (15)
PER4, NDUFA4, PHF14, BC040327,THSD7A, KIAA0960, TMEM106B, VWDE,
AK027618, AK075525, BC075797, CR592342, KIAA1905, SCIN, ARL4A
Region 2 (Ch 7p: 19,034,191-29,250,335) containing genes (92)
CR623750, TWIST1, BC043576, FERD3L, TWISTNB, TMEM196, ABCB5, SP8,
ITGB8, MACC1, RPL23P8, SP4, DNAH11, CDCA7L, RAPGEF5, MGC87042,
AK123961, LOC541472, IL6, C7orf30, TOMM7, SNORD93, KLHL7, NUPL2,
AK057873, GPNMB, BC065766, IGF2BP3, IMP-3, TRA2A, hAWMS1, CLK2P,
CCDC126, C7orf46, STK31, FAM126A, DRCTNNB1A, AK054880, RPS2P32,
DKFZp434E052, DFNA5, NPY, MPP6, CYCS, ICERE-1, OSBPL3, C7orf31, NPVF,
SNX10, MIR148A, NFE2L3, HNRNPA2B1, CBX3, hp1-gamma, SNX10,
LOC441204, KIAA0087, C7orf71, LOC285941, SKAP2, HOXA2, HOXA3,
AK311383, BC035889, HOXA5, HOXA6, AX747263, DQ655986, AK096334,
HOXA7, HOXA9, MIR196B, HOXA10, HOXA11, HOXA11AS, HOXA13, AK093987,
HIBADH, EVX1, TSL-A, TAX1BP1, BC034444, NS5ATP1, JAZF1, LOC402644,
CREB5, BC087859, KIAA0644, DQ601810, CPVL, AK124888, CHN2
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Table 6.5: Identification of shared candidate genes for cytochrome c oxidase
deficiency in Patient 6.1 (III-4) and 6.3 (III-6) using exome resequencing
Filter III-4 III-6 Shared variants
Total number of variants 140456 140859 78004
Total number of homozygous variants 50868 50832 28320
Number of homozygous PASS SNVs and
indels
26379 25289 19389
Novel homozygous PASS SNVs and
indels
442 412 190
Functional novel homozygous PASS
SNVs and indels
46 40 13
Functional novel homozygous PASS
SNVs and indels with predicted
mitochondrial localisation
2 2 1
IARS FTSJ2
NDUFA4 NDUFA4 NDUFA4
Abbreviations: indel = insertion/deletion; PASS = variants that have passed the
Genome Analysis Toolkit (GATK) filter criteria; SNV(s) = single nucleotide variant(s).
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6.4.3 Automated Sanger sequence analysis of NDUFA4
Sanger sequencing demonstrated that all four affected individuals were homozygous
for the mutation (Figure 6.3A, Patient 6.2 shown), whilst three unaffected family
members (II-2, III-1, and III-2) were heterozygous (Figure 6.1A). A further 20
probands with isolated COX deficiency were screened for mutations in NDUFA4 but
no further variants were identified.
6.4.4 Transcriptional analysis of c.42+1G>C mutation
To study the effect the c.42+1G>C mutation had on mRNA splicing, NDUFA4 cDNA
fragments were amplified, after generation from reverse transcription of mRNA
extracted from whole blood and cultured skin fibroblasts. The PCR products were
resolved on a denaturing 7% polyacrylamide gel followed by silver staining. This
revealed two fragments in blood: (1) a band measuring 241 bp, corresponding to the
wild-type transcript, which was present in all samples but at much lower levels in the
affected subjects (III-3 and III-4) compared with an unaffected carrier (II-2) and the
control; and (2) a band at 245 bp which was absent in the control sample but present
at high levels in the affected subjects with lower levels detectable in the unaffected
carrier. Cultured skin fibroblasts demonstrated a 245 bp fragment in the patient
studied (III-4), with no evidence of wild-type transcript (Figure 6.3B). Low-level wild-
type cDNA sequence was observed in the sequencing electropherograms of both
affected individuals (Figure 6.3C, Patient 6.2 shown), which was also demonstrated
by fluorescent PCR using FAM-labelled primers (Figure 6.4). These data indicate
that the c.42+1G>C mutation does not appear to completely abolish correct splicing
of NDUFA4 exon 1 to exon 2 in blood. Sanger sequencing of the PCR products
revealed that the first 4 bp of intron 1 are retained following activation of a cryptic
splice site 4 bp downstream of the c.42+1G>C mutation (Figure 6.3A, C). This
frameshift is predicted to introduce a premature stop codon (TAA) 105 bp
downstream in exon 3. If translated, the resultant protein would consist of 14 in-
frame amino acids followed by 35 out-of-frame amino acids (compared to the 81
amino acid wild-type protein).
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Figure 6.3: Schematic showing activated cryptic splice site downstream to the
c.42+1G>C mutation causes a frameshift and introduces a premature stop codon in
mRNA, and silver-stained polyacrylamide gel of Patient 6.1 and 6.2 complementary
DNA. Schematic demonstrating location of the c.42+1G>C mutation within NDUFA4
intron 1 and homozygous mutation in forward genomic DNA sequencing of an
affected subject (A). Position of cryptic splice site activated adjacent to the next GT
dinucleotide 4 base-pairs (bp) downstream of c.42+1G>C is marked with an asterisk
(*). Silver-stained polyacrylamide gel of amplified complementary DNA extracted
from blood and cultured skin fibroblasts alongside a 249 bp molecular weight marker
(M) (B). In blood, Patient 6.2 (III-3) and Patient 6.1 (III-4) (affected siblings) have a
strongly staining (mutant) band at 245 bp and a faintly staining (wild-type) band at
241 bp, whilst II-2 (unaffected father) has a strongly staining band at 241 bp and a
faintly staining band at 245 bp. In cultured skin fibroblasts, III-4 only has a band at
245 bp. The control blood (C1) and cultured skin fibroblasts (C2) only have a band at
241 bp. Schematic depicting the mutant NDUFA4 transcript retaining 4 bp of intron 1,
with sequencing electropherograms below (reverse sequencing shown) (C). Close
inspection of the mixed electropherogram 5' of exon 2 in III-4 confirmed that wild-
type sequence was present at low levels (also seen in Patient 6.2, data not shown).
Mutant sequence can also be seen in II-2. Abbreviations: 1F and 4R = exonic primer
binding sites; UAA = premature stop codon.
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Figure 6.4: Fluorescent PCR of Patient 6.1 and 6.2 complementary DNA using a 6-
FAM-labelled reverse primer annealing in exon 4. Patients 6.2 (III-3) and 6.1 (III-4)
(affected siblings) have a large peak measuring 209 bp representing mutant PCR
product and a small peak measuring 205 bp representing wild-type PCR product in
blood. Patient 6.1 (III-4) has only mutant PCR product detectable in fibroblasts.
Subject II-2 (unaffected father) has a large wild-type peak (205 bp) and a small
mutant peak (209 bp) present. Control (C) shows wild-type peak (205 bp) only.
Abbreviations: b = blood; f = fibroblasts.
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6.4.5 Western blot of SDS denaturing polyacrylamide gels and
immunocytochemistry
NDUFA4 protein was undetectable in all affected subjects examined (muscle tissue
of III-4, III-6 and III-13, cultured skin fibroblasts of III-4). Steady-state level of the
mitochondrially encoded COX subunit MTCO2 was markedly reduced in the muscle
tissue of one patient compared with the mean MTCO2 value of four controls
(MTCO2 level in III-6 56% of controls). The steady-state MTCO2 subunit levels in III-
6 and III-13 were comparable to the control muscle tissue samples (Figure 6.5A).
Immunocytochemistry also showed absent NDUFA4 protein in cultured skin
fibroblasts (III-4) with normal mitochondrially encoded COX subunit MTCO1 (Figure
6.5B). MitoTracker confirmed co-localisation of NDUFA4 in control fibroblasts (Figure
6.6).
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Figure 6.5: Western blot analysis of an SDS polyacrylamide gel and micrographs of
control and Patient 6.1 fibroblasts immunocytochemically stained for NDUFA4 and
MTCO1. SDS polyacrylamide gel loaded with 10 g of mitochondrial protein pellets
extracted from muscle tissue of Patients 6.1 (III-4), 6.3 (III-6) and 6.4 (III-13), and
cultured skin fibroblasts of Patients 6.1 (III-4) compared with controls (C1-8) (A).
Blots were developed with antibodies directed against SDHA, MTCO2 and NDUFA4.
The antibody to complex II subunit SDHA was used to confirm equal protein loading.
Micrographs of control and Patient 6.1 (III-4) fibroblasts immunocytochemically
stained for NDUFA4 (red fluorescence) and MTCO1 (green fluorescence) and
counterstained with the DNA fluorochrome 4’,6-diamidino-2-phenylindole (blue
fluorescence) (B). Note that NDUFA4 is absent from patient cells whilst MTCO1
levels are comparable to the control cells.
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Figure 6.6: Micrographs of control and Patient 6.1 (III-4) fibroblasts
immunocytochemically stained for MitoTracker (red fluorescence) and NDUFA4
(green fluorescence) and counterstained with the DNA fluorochrome 4’,6-diamidino-
2-phenylindole (blue fluorescence). Note that NDUFA4 co-localises with MitoTracker
in control cells whist it is absent from patient cells.
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6.4.6 In-gel activity and western blot analysis of one- and two-
dimensional blue-native polyacrylamide gels
In-gel activity staining of blue-native gels supported spectrophotometric analysis of
respiratory chain enzyme with normal complex I and reduced complex IV in the
muscle tissue of Patients 6.1 (III-4) and 6.3 (III-6) (Figure 6.7A). Recent work
suggests an interaction of NDUFA4 with complex IV which is disrupted when high
concentrations (>1.5%) of DDM, the standard detergent used to purify complex IV for
crystallisation purposes, are used (Balsa et al., 2012a). To establish the optimal
concentration of DDM required to analyse NDUFA4 as part of COX holoenzyme,
western blot analysis of blue-native polyacrylamide gels loaded with 10 g of
mitochondrial enriched protein pellets extracted from control muscle tissue using
serial dilutions of DDM for mitochondrial membrane protein extraction was performed
(Schägger, 1995; Williams et al., 2004d). Blots were developed with antibodies
directed against NDUFA4 and MTCO1. This analysis demonstrated that dissociation
of NDUFA4 subunit from the COX enzyme complex occurred when >0.08% DDM
was used to extract mitochondrial membrane proteins, whilst 0.08% DDM allowed
detection of NDUFA4 as part of the COX enzyme complex (Figure 6.7B). Western
blot analysis of respiratory chain enzymes extracted using 0.08% DDM in order to
verify interaction of the NDUFA4 protein with complex IV was subsequently
performed (Figure 6.7C). Analysis of one-dimensional blots of blue-native gels
showed complex IV holoenzyme was present in the muscle tissue of III-4 with no
abnormal subassemblies, whilst one- and two-dimensional blots confirmed
association of NDUFA4 with complex IV in the control.
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Figure 6.7: In-gel activity and western blot analysis of one- and two-dimensional
blue-native polyacrylamide gels. In-gel activity of complex I and IV in 3-12%
polyacrylamide blue-native gels loaded with 70 g of mitochondrial enriched protein
pellets extracted from control (C1-3) and the muscle tissue of Patient 6.1 (III-4) and
6.3 (III-6) (A). Complex I activity is comparable amongst the control and Patient 6.1
and 6.3. However, significant reduction in complex IV activity is demonstrated in
patient muscle tissue. Smearing of complex I can be seen in C3 and Patient 6.1 due
to high amount of protein loaded. The measured staining intensity is indicated below
each lane. Western blot analysis of blue-native polyacrylamide gels loaded with 10
g of mitochondrial protein pellets extracted from control muscle tissue (B). The
following concentrations of n-dodecyl -D-maltoside (DDM) were used to extract
mitochondrial membrane proteins: 0.01%; 0.02%; 0.04%; 0.08%; 0.16%; 0.32%.
Proteins were run on 8-16% polyacrylamide gradient blue-native gels to visualize the
free NDUFA4 protein subunit (left panel), and were also probed for MTCO1 to
examine the complex IV associations (right panel). Mitochondrial membrane proteins
(10 g), extracted using 0.08% DDM in order to verify co-localization of the NDUFA4
protein with complex IV (also see Figure 6.7B), were applied and run on 3-12%
polyacrylamide gradient blue-native gels using the muscle tissue of Patient 6.1 and a
control (C). For two-dimensional analysis a single lane was excised from the gel,
denatured, and resolved by denaturing electrophoresis in the second dimension on
an SDS polyacrylamide gel, prior to immunoblotting. One-dimensional native blots
are shown above two-dimensional denatured blots to aid identification of protein
spots. Blots were probed with specific antibodies against complex I (anti-NDUFA9),
complex III (anti-UQCRC2), complex IV (anti-MTCO1, anti-MTCO2) and NDUFA4.
Native markers were obtained by reprobing one-dimensional blots for SDHA to
detect complex II (~125 kDa) and ATP5A1 to detect holo-complex V (~600 kDa), the
F1 portion of complex V (~400 kDa) and the free subunit (55 kDa). Abbreviations: CI
= complex I; CIII2 = complex III dimer; CIV = complex IV; a = MTCO1; b = MTCO2; c
= NDUFA4; d = UQCRC2; e = NDUFA9.
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6.5 Discussion
The work presented in this chapter focuses on a large consanguineous Pakistani
family with COX-deficient Leigh Syndrome of unknown genetic aetiology. Through a
combined homozygosity mapping and whole exome sequencing approach, a
homozygous splice donor site mutation was identified in NDUFA4, a gene previously
considered to encode a subunit of respiratory chain complex I. Transcriptional
studies demonstrated the c.42+1G>C transversion significantly reduces wild-type
NDUFA4 mRNA and produces an aberrant transcript which predicts a translated
protein comprising 14 in-frame amino acids followed by 35 out-of-frame amino acids.
Western blot analysis of denaturing gels and immunocytochemistry revealed
undetectable steady-state NDUFA4 protein levels indicating that this mutation
causes a loss-of-function effect in the homozygous state.
The existence of some very low level wild-type NDUFA4 transcripts in patients
harbouring the c.42+1G>C mutation might explain the slower natural history and the
comparatively milder clinical phenotype observed; most previously reported patients
with nuclear-encoded COX deficiency exhibit severe phenotypes resulting in early
childhood death. Interestingly, only mutant transcript alone was detected in cultured
skin fibroblasts, despite apparently normal fibroblast COX activity observed in patient
III-4 using a glucose-containing culture medium. Cells cultured with galactose as a
carbon source are not able to produce ATP through glycolysis and are entirely
dependent on OXPHOS for their ATP synthesis (Petrova-Benedict et al., 1992).
Biochemical assays were therefore repeated with cells grown in galactose-containing
medium for 6 days in order to accentuate the underlying defect in OXPHOS. In
contrast to III-4 fibroblasts grown in glucose containing medium, III-4 fibroblasts
grown in galactose-containing medium showed a clear COX deficiency. These
observations indicate that current diagnostic procedures which typically use glucose
as a carbon source in the culture medium may not detect a reduction in COX activity.
Balsa and colleagues (2012) found that >1.5% of DDM disrupted the binding of
NDUFA4 with complex IV in HeLa cell mitochondria, whilst in the experiments
reported here >0.08% of DDM disrupted the binding in human muscle mitochondrial
preparations. The discrepancy in the concentration of DDM required to dissociate
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NDUFA4 from the COX enzyme complex may be explained by differences in the
buffer conditions or tissue-types used. DDM extractions were performed in 1 M -
amino-n-caproic acid, 50 mM bistris (pH 7.0) (Schägger, 1995). The buffer conditions
used by Balsa and colleagues were not specified.
These data confirm that NDUFA4 is not required for assembly of the other COX
subunits since COX enzyme complex with no abnormal subassemblies were
detected on native gels of patient mitochondrial membrane proteins. In addition, the
observation that COX activity is retained following its purification using
concentrations of DDM known to disrupt NDUFA4 (Sinjorgo et al., 1987) implies that
NDUFA4 is not directly required for catalysis per se. However, deficiency of NDUFA4
clearly impairs COX activity in muscle tissue and cultured skin fibroblasts in patients
harbouring homozygous loss-of-function NDUFA4 mutations. NDUFA4 is probably a
subunit of COX rather than an assembly factor because blots of two-dimensional
blue-native polyacrylamide gels demonstrated a clear association between NDUFA4
and the COX enzyme complex. It is likely that NDUFA4 is required during the
biogenesis of COX to become an active enzyme and remains loosely associated
with the enzyme complex. In addition, a critical interaction must occur between
NDUFA4 and the remaining COX subunits during biogenesis of the enzyme complex
which is essential for overall COX activity. For example, it is possible that NDUFA4
facilitates folding of MTCO1 or is involved in addition or modification of prosthetic
groups that affects downstream catalysis but not assembly of the enzyme. The
precise nature of this interaction requires further study.
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CHAPTER 7
7. Discussion
The aims of this thesis were to characterise new clinical phenotypes and to identify
the underlying causative pathogenic mutations in both known and novel nuclear
genes in adult patients with clinically and/or biochemically suspected mitochondrial
disease. To investigate the latter, three main experimental strategies were adopted:
1) in patients where long PCR and/or Southern blotting genetic analysis had
demonstrated impaired mtDNA maintenance, as evidenced by multiple mtDNA
deletions, the candidate nuclear gene RRM2B was sequenced, after POLG and
C10orf2 mutations were excluded; 2) in a non-consanguineous pedigree where
spectrophotometric analysis of the RC enzymes indicated complex IV deficiency,
and mutations in mtDNA and a number of candidate nuclear genes had been
excluded, a whole-exome sequencing approach in the affected individual was
utilised; 3) in a consanguineous kinship with biochemical evidence of isolated
complex IV deficiency, in whom mutations in mtDNA and other candidate nuclear
genes were excluded, a combined homozygosity mapping and whole-exome
sequencing approach was applied.
This work contributes to current understanding of both the phenotypic presentation
and molecular basis of mitochondrial disease. Firstly, the characterisation of new
disease phenotypes associated with mutations in both mitochondrial (MT-ATP6) and
nuclear (POLG and COX10) genes expands the clinical spectrum of mitochondrial
dysfunction and should increase the probability that a genetic diagnosis is achieved
in such patients; MT-ATP6/8 sequencing is now routinely performed in the UCLH
NHNN NCG Neurogenetics diagnostic laboratory in patients with CMT2 following the
findings reported in Chapter 3 that mutations in these genes can cause an isolated
axonal neuropathy. Secondly, the finding that COX10 mutations link to adult COX
deficiency highlights the remarkable variability in clinical severity associated with
human COX deficiency. It also raises important questions concerning the precise
biological mechanisms underpinning the relatively mild clinical phenotype exhibited
by the patient despite harbouring a severe biochemical defect. Understanding these
cellular compensatory processes could potentially facilitate future treatment
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strategies for human COX deficiency. Thirdly, the discovery that dysfunction of the
NDUFA4 protein, previously assigned to be a complex I subunit, causes human COX
deficiency confirms its essential role in COX function and builds upon existing
published work using cell lines which suggests NDUFA4 is actually a component of
complex IV.
7.1 Novel adult mitochondrial clinical phenotypes
7.1.1 m.9185T>C in MT-ATP6 causes axonal Charcot-Marie-Tooth
disease
One of the major unresolved challenges in neuromuscular disease is the
determination of the genetic basis of inherited axonal neuropathy (CMT2). Although
a genetic diagnosis is achieved in the majority of inherited demyelinating
neuropathies (CMT1), this is not the case in inherited axonal neuropathies (Reilly
and Shy, 2009; Reilly et al., 2011). Molecular defects are only detected in ~35% of
patients with CMT2 and 15% of patients with dHMN (Saporta et al., 2011; Dierick et
al., 2008). There is overlap both clinically and genetically between CMT2 and dHMN,
and mutations in HSPB1, HSPB8, TRPV4, BSCL2 and GARS are all reported to
cause either phenotype (Tang et al., 2005; Irobi et al., 2004; Evgrafov et al., 2004;
Auer-Grumbach et al., 2005; Antonellis et al., 2003; Zimoń et al., 2010), but are only
identified in a small minority of cases.
In Chapter 3, four unrelated families with CMT2 caused by the known pathogenic
m.9185T>C mutation in the mitochondrial-encoded MT-ATP6 gene are described. It
is notable that all of the patients presented had previously been assessed by
experienced clinicians, and based on detailed clinical and electrophysiological
evaluation were considered to have CMT2. All but one of these cases was
homoplasmic for the m.9185T>C mutation. However, despite three of the four
pedigrees exhibiting a matrilineal pattern of inheritance, an underlying mitochondrial
basis for disease had not previously been considered due to the relatively peripheral
nerve-specific disease phenotype. The patients presented could be broadly divided
into four clinical severity-related groups according to their m.9185T>C mutant load:
(Group 1) unaffected individuals (<64% mutant load); (Group 2) individuals without
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symptoms or signs of peripheral neuropathy but with UMN signs (64-79% mutant
load); (Group 3) individuals with signs and symptoms of an UMN axonopathy (80-
91% mutant load); (Group 4) affected individuals with motor-predominant CMT2 with
or without UMN signs (92-100% mutant load).
The m.9185T>C variant was originally reported in a seven year-old patient who
developed sudden onset ptosis, ophthalmoparesis and fatigue having previously
been well (Moslemi et al., 2005). Although isolated axonal neuropathy is
documented at 85% m.9185T>C heteroplasmy, higher mutant loads have been
reported to cause a more severe neurological phenotype, including NARP and early
and late-onset LS (Castagna et al., 2007; Childs et al., 2007; Moslemi et al., 2005;
Saneto and Singh, 2010). Families 3.2, 3.3 and 3.4 exhibited surprising tissue-
specificity of disease expression considering they had homoplasmic m.9185T>C
mutant levels detected in blood, urine, skin and muscle. Unlike previous reports that
suggest disease expression requires more than 85% mutant load (Moslemi et al.,
2005; Castagna et al., 2007), we found the threshold for disease manifestation to be
lower in our cohort; for example, one asymptomatic individual (Figure 3.3, Family 3.2,
Patient III-5) displayed pyramidal tract signs with a mutant load of 73%.
It is unclear why some patients harbouring homoplasmic levels of m.9185T>C should
develop a tissue-specific peripheral neuropathic phenotype, whilst other reported
patients and families with similar mutant loads develop a multi-system neurological
syndrome such as LS. Variable clinical severity in patients with similar mutant loads
has been reported with a number of known pathogenic mtDNA mutations. It is
possible this variability relates to subtle differences in tissue heteroplasmy; however,
no correlation has been shown between the presence of neuropathy and muscle
m.3243A>G mutant levels despite the disease phenotype being more severe in the
patients with neuropathy (Kärppä et al., 2003). This finding suggests there may be
additional factors that increase the susceptibility of certain patients to neuropathy,
such as activation of nuclear encoded genes that enhance pathways which partially
compensate for aberrant complex V function or reduced ATP production. This
hypothesis requires further study. The precise molecular mechanisms linking
respiratory chain dysfunction to axonal degeneration are not determined. One
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possibility is that axonal degeneration relates to loss of the axon membrane potential
as a consequence of failure of the energy-dependent Na+/K+ ATPase pump,
comparable to ischaemia. However, a recent study did not show detectable changes
in nerve excitability in patients with mitochondrial disease, as would be expected if
there was significant axonal depolarisation due to failure of energy-dependent
systems (Ng et al., 2010a).
The data presented adds to the increasing evidence that mitochondrial dysfunction is
an important cause of CMT2. MT-ATP6 mutations should be considered early in the
diagnostic evaluation of patients with inherited axonal neuropathies.
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7.1.2 Distal myopathy associated with novel POLG mutations
POLG mutations account for up to 25% of mitochondrial disease (Chinnery and
Zeviani, 2008) and more than 150 different pathogenic mutations are reported
(http://tools.niehs.nih.gov/polg/). They are a heterogeneous group which frequently
affect multiple organ systems and exhibit variable clinical severity and age of onset.
Patients with identical molecular defects can be almost as diverse as patients with
different POLG mutations (Neeve et al., 2012). Genetic, environmental and
epigenetic factors are thought to modify the disease course and contribute to the
broad phenotypic spectrum. Despite this clinical heterogeneity, however, age at
presentation and overlapping clinical symptoms allow the major clinical syndromes to
be divided into distinct groups (Table 7.1).
Skeletal limb myopathy is common (79%) in adult patients with POLG mutations but
invariably occurs with PEO and affects proximal musculature (Horvath et al., 2006).
The distal myopathic phenotype seen in both Patient 4.1 and 4.2 discussed in
Chapter 4 was striking and has not previously been described in association with
POLG-related multiple mtDNA deletions. Patient 4.1 presented with isolated upper
limb distal myopathy during adolescence before developing PEO when the
differential diagnosis would have included the distal-predominant hereditary
myopathies, particularly those with upper limb onset. Welander distal myopathy can
present with early wrist and finger extensor weakness. However, the early age of
onset would be highly unusual for this condition (Chinnery, 2010). Isolated finger and
wrist extensor weakness has also been reported in an adult with compound
heterozygous POLG mutations (c.1156C>T; p.Arg386Cys and c.2794C>T;
p.His932Tyr) associated with mtDNA depletion but no detectable mtDNA deletions
(Giordano et al., 2010).
POLG mutations should be considered prior to muscle biopsy in patients presenting
with distal muscle weakness, even when more classical clinical features of
mitochondrial disease are absent.
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Table 7.1: Major clinical syndromes associated with POLG mutations
Age of onset Syndrome Reference
Neonate/infancy Hepatocerebral (Ferrari et al., 2005; de Vries
et al., 2007)
Infancy/childhood Alpers-Huttenlocher (AHS) (Naviaux and Nguyen, 2004)
Adolescence/adulthood Ataxia neuropathy
syndrome (ANSa)
(Hakonen et al., 2005)
Myoclonus, epilepsy,
myopathy, sensory ataxia
(MEMSA)
(Van Goethem et al., 2004)
Progressive external
ophthalmoplegia (PEO)b,c
(Van Goethem et al., 2001b)
Table adapted from (Stumpf et al., 2013). aANS previously termed mitochondrial
recessive ataxia syndrome (MIRAS), sensory ataxic neuropathy with dysarthria and
ophthalmoplegia (SANDO), and spinocerebellar ataxia epilepsy syndrome (SCAE).
bPEO labelled PEO+ when associated with additional symptoms including: peripheral
neuropathy, ataxia, hearing loss, depression, premature menopause, hypogonadism,
Parkinsonism, cataracts, or gastrointestinal dysmotility. cDominant and recessive
mutations in POLG have been associated with PEO.
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7.1.3 RRM2B-related Kearns-Sayre syndrome
KSS is a multisystem disorder defined clinically by the triad of PEO and pigmentary
retinopathy with onset before the age of 20 years plus at least one of: cardiac
conduction block; CSF protein concentration greater than 1 g/L; cerebellar ataxia
(Berenberg et al., 1977; Kearns, 1965; Kearns and Sayre, 1958; Rowland, 1975;
Rowland et al., 1983). Frequent additional signs include sensorineural hearing loss,
renal tubular acidosis, dementia, seizures, short stature and endocrine disturbance
(diabetes mellitus, hypoparathyroidism and growth hormone deficiency). A
progressive skeletal myopathy is also frequently seen. The most common MRI
appearances are cerebral and cerebellar atrophy with bilateral, often symmetrical,
hyperintense lesions in the subcortical white matter, thalamus, basal ganglia and
brainstem (Lerman-Sagie et al., 2005; Wray et al., 1995; Saneto et al., 2008).
Interestingly, there appears to be little correlation between neurological deficits and
the severity of the MRI features (Chu et al., 1999). KSS is most commonly
associated with single large-scale deletions of mtDNA (Yamashita et al., 2008).
In Chapter 4, Patient 4.3 had a clinical phenotype compatible with KSS. This finding
expanded the clinical spectrum of RRM2B-related adult mitochondrial disease
beyond that of PEO and ‘PEO plus’ syndromes. Additional cases of RRM2B-related
KSS have since been reported (Pitceathly et al., 2012), thus providing support for
this important association, although the majority of cases remain sporadic.
It is now estimated that RRM2B mutations represent the third most common cause
of Mendelian PEO and multiple mtDNA deletions in adults (13%), following mutations
in POLG (27%) and C10orf2 (14%) (Pitceathly et al., 2012). The first reported human
diseases linked to mutations in RRM2B were associated with mtDNA depletion
(Acham-Roschitz et al., 2009; Bornstein et al., 2008; Bourdon et al., 2007a; Kollberg
et al., 2009; Spinazzola et al., 2009b) and caused severe, early-onset, multisystem
disease with infant mortality. RRM2B mutations have since been recognised to
cause adult-onset syndromes. This was first demonstrated in a patient with MNGIE
and mtDNA depletion (Shaibani et al., 2009). Tyynsimaa et al. later published a large
adPEO family with multiple mtDNA deletions whose disease was not explained by
mutations in any of the known adPEO genes (Tyynismaa et al., 2009). A
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heterozygous nonsense mutation in exon 9 or RRM2B was detected resulting in a
truncated protein that was postulated to cause a dominant-negative or gain-of-
function effect on the heterotetrameric structure of the RNR enzyme. The
mechanistic importance of truncating exon 9 mutations was further expanded by
Fratter et al. where three further novel pathogenic variants in exon 9 were shown to
cause familial adPEO in seven unrelated probands. In addition, clinically more
severe, recessively-inherited, compound heterozygous mutations were
demonstrated (Fratter et al., 2011). More recently, a clear relationship between
phenotypic severity and genotype in patients harbouring pathogenic RRM2B
mutations has been established (Pitceathly et al., 2012). Individuals harbouring
recessively-inherited compound heterozygous RRM2B mutations, as with Patient 4.3
in Chapter 4, present at an earlier age (mean age 7 years) with a more severe and
multisystem disorder, whilst patients with single heterozygous mutations, implying
autosomal dominant transmission, have a later age of disease onset (mean age 46
years) and develop a predominantly myopathic phenotype comprising PEO, ptosis,
proximal muscle weakness and bulbar dysfunction. The distinction between
recessively- and dominantly-inherited mutations is also evident on histochemical
analysis of skeletal muscle tissue, in which COX-deficient fibres are more
widespread in patients with recessively-inherited compound heterozygous mutations.
In conclusion, the work presented in Chapter 4 confirms RRM2B mutations as one of
the leading causes of adult-onset mitochondrial disease associated with disruption of
mtDNA maintenance and reported the first case of KSS associated with nuclear
genomic dysfunction.
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7.1.4 COX10 linked adult cytochrome c oxidase deficiency
In Chapter 5, an adult with severe COX deficiency caused by compound
heterozygous COX10 mutations, detected using whole exome sequencing, is
described.
To date, four infants with early-onset COX-deficient mitochondrial disease caused by
COX10 mutations have been reported (Valnot et al., 2000; Antonicka et al., 2003;
Coenen et al., 2004) (Table 7.2). Presentation was with progressive neurological
decline from the neonatal period up to six months of age. Clinical findings included a
combination of seizures, ataxia, hypotonia, pyramidal signs, renal tubulopathy,
hypertrophic cardiomyopathy, SNHL and anaemia. None survived beyond two years.
Although some clinical features exhibited by these children are shared with the adult
presented in Chapter 5, specifically renal tubulopathy and SNHL, the adult
phenotype is considerably milder, and might be considered a ‘slow motion’
multisystem version of the more severe fatal infantile disease.
The protein modelling data presented in Chapter 5 suggests there are milder
structural consequences to the adult patient’s mutations as compared with previously
reported amino acid substitutions. The difference in clinical severity might also relate
to a nuclear modifier or epigenetic phenomenon which partially compensates for the
underlying biochemical defect. It is also possible that our patient has never been
exposed to a physiological stress sufficient to trigger a severe metabolic
decompensation.
The normality of the patient’s oxygen polarographic studies, a technique which has
not previously been reported in patients with COX10 mutations, was surprising given
the severe histochemical and spectrophotometric reduction in COX activity and
might provide some evidence for the patient’s ability to tolerate her biochemical
defect. This finding could reflect the capacity of any residual assembled COX to
partially compensate for the underlying biochemical defect. Polarography measures
RC function at physiological levels when electron flux through complex IV is at a
controlled/low rate. This scenario mimics the cellular environment in which only
suboptimal substrate concentrations are usually available. In contrast,
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spectrophotometric assay of RC function records the optimal enzyme activity under
conditions where there is maximum electron flux. The residual COX activity in the
patient could be sufficient to maintain electron transport and proton translocation
activities under non-strenuous conditions, explaining the normal polarographic
results. However, during times of physiological stress it is not possible to upregulate
COX activity to meet the higher energy demands required due to impaired COX10
function. This is reflected by the reduced COX activity on spectrophotometric assay.
In conclusion, research presented in this thesis has provided some evidence to
explain the variable clinical severity seen with COX10 mutations. Furthermore,
COX10 genetic analysis should be added to the diagnostic armamentarium for adult
mitochondrial disease associated with COX deficiency. It remains essential that
additional unrelated adult cases with COX10 mutations are identified to help fully
understand the extreme variation in clinical severity associated with COX10
dysfunction.
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Table 7.2: Clinical and molecular data of published cases with genetically confirmed COX10 mutations
Source Clinical Phenotype Brain MRI Age of
Onset
(months)
Age of
Death
(months)
Genotype
(Valnot et al.,
2000)
Ataxia, muscle weakness,
hypotonia, ptosis, UMN signs,
seizures, proximal renal tubulopathy
- 18 24 Homozygous:
c.612C>A; p.Asp204Lys
(Antonicka et al.,
2003)
Hypoglycaemia, lactic acidosis,
hypotonia, poor feeding, SNHL,
macrocytic anemia, HCM
- 0.25 5 Compound heterozygous:
c.791C>A; p.Thr196Lys and
c.878C>T; p.Pro225Leu
(Antonicka et al.,
2003)
Leigh syndrome: anemia,
splenomegaly, hypotonia, lactic
acidosis, central respiratory failure
Symmetrical
BG lesions
1.5 4 Compound heterozygous:
c.1007A>T; p.Asp336Val and
c.1007A>G; p.Asp336Gly
(Coenen et al.,
2004)
Leigh syndrome: FTT, hypotonia,
ataxia, UMN signs, lactic acidosis
Thalamic
lesions
5 9 Homozygous:
T>C transition in start codon
(ATG)
Abbreviations: BG = basal ganglia; MRI = magnetic resonance imaging; UMN = upper motor neuron; FTT = failure to thrive; HCM =
hypertrophic cardiomyopathy; SNHL = sensorineural hearing loss.
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7.2 NDUFA4 is a new complex IV subunit
The association of NDUFA4 mutations and human COX deficiency presented in
Chapter 6 indicates an important role of the NDUFA4 protein in COX function, and
confirms that NDUFA4 is a COX polypeptide subunit despite its previously accepted
role as an accessory component of complex I (Carroll et al., 2002). It is likely that
NDUFA4 is necessary during biogenesis of COX in order to generate the active
enzyme, and subsequently remains loosely associated with the COX enzyme
complex. This interaction is clearly essential for overall COX activity, as evidenced
by the severe isolated COX deficiency exhibited by individuals harbouring loss-of-
function NDUFA4 mutations, and requires further study. The findings presented are
supported by mouse and human cell line evidence that the NDUFA4 protein is an
additional COX subunit (Balsa et al., 2012b).
These findings have important implications for understanding the precise biological
function of the NDUFA4 protein and its interaction with the other COX polypeptide
subunits and assembly factors. Analysis of the NDUFA4 gene should therefore be
considered in all patients with unexplained COX deficiency.
Finally, it is important to emphasise that careful clinical observation and biochemical
stratification were central to this discovery, thus highlighting the importance of
patients in unravelling fundamental aspects of normal cellular biology, so called
‘back-translation.’
7.3 Future research
Over the next decade, NGS is likely to unravel the molecular basis of all the
remaining genetically undefined Mendelian disorders. However, it is essential that
physicians continue to clinically characterise novel and unusual phenotypes related
to known disease-causing genes, as highlighted by work described in Chapters 3
(CMT2/MT-ATP6), 4 (distal myopathy/POLG and KSS/RRM2B), and 5 (adult COX
deficiency/COX10), in order to facilitate rapid recognition of patients with genetic
disorders and improve upon current knowledge concerning the natural history of their
disease.
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Understanding the biological mechanisms underpinning the phenotypic diversity
associated with dysfunction of identical protein products is likely to contribute
towards the development of new treatment strategies for the benefit of patients. One
example of this phenomenon is the remarkable variability in clinical severity
associated with COX deficiency, as evidenced by the adult described in Chapter 5
harbouring COX10 mutations.
This work raises a number of potential areas that require further study. Firstly, it is
important an attempt is made to identify additional unrelated cases harbouring the
here reported novel mutation to unequivocally prove its pathogenicity. Identification
of adult patients would also help determine whether the phenotype is related to
specific combinations of mutations or the location of a mutation within a specific
COX10 protein domain, and if there are other genetic, epigenetic and/or
environmental factors which influence the variability in clinical severity. Secondly,
determination of the COX10 crystal structure would greatly improve the predicted
structural implications different mutations confer on the COX10 protein structure.
Thirdly, genetic analysis of both the mitochondrial genome and other components of
COX, specifically those acting in concert with COX10 such as MT-CO1, might reveal
genetic modifiers of the clinical phenotype. In addition, establishing chromosomal
haplotype and mtDNA haplogroup would help establish whether there is a protective
or deleterious influence from these factors, as is seen with mtDNA haplogroups U
and Parkinson’s disease in the Russian Tatar population (Khusnutdinova et al.,
2008). An obvious challenge to this work concerns the limited number of patients
with COX10 mutations available for further study. However, it remains possible a
shared common mechanism underlies the variability in clinical severity associated
with COX deficiency caused by other molecular defects. Collation of the data from all
of these patients might therefore be informative. Mitochondrial cybrid studies could
then be utilised to further investigate these factors. Finally, it is important to consider
whether variable tissue-specific requirements for COX10 (and COX) might explain
why certain clinical characteristics are shared by patients harbouring COX10
mutations (see Table 7.2). This phenomenon is exemplified by the normal COX
activity frequently observed in the cultured skin fibroblasts of patients harbouring
mutations in many of the complex IV assembly factors (excluding SURF1), despite
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patients exhibiting severe biochemical defects in muscle tissue (Williams et al.,
2004b). One explanation for this might be that fibroblasts require less of certain
assembly factors to produce functional COX than muscle tissue, or that fibroblasts
are less reliant on OXPHOS to maintain cellular function. Alternatively, the laboratory
conditions under which fibroblasts are cultured might influence their COX activity
when measured using spectrophotometric analysis. This was demonstrated in
Chapter 6 when fibroblasts grown on galactose-containing medium expressed a
biochemical defect which was not present in cells grown on glucose-containing
medium.
The work presented in Chapter 6 highlights the importance of comprehensively
reappraising previously published and accepted research data. The original
attribution of NDUFA4 to complex I was made with the caveat that it was
inconsistently detected in preparations of complex I, and its presence correlated with
COXVIB. There was also existing work from yeast that the number of COX subunits
isolated using different purification methods varied as a result of their dissociation
from the COX enzyme complex depending on the strength of detergent used
(Taanman and Capaldi, 1992). Data presented in this thesis supports recent
evidence gained from mouse and human cell lines that NDUFA4 is an important
component of COX, and confirms that NDUFA4 mutations cause human disease.
However, the precise function of NDUFA4 remains unclear. In the first instance, the
crystal structure of COX requires redefinition. X-ray crystallography should be
performed using concentrations of DDM 0.08% in order to visualise the NDUFA4
subunit as part of the enzyme complex. This would provide insight into the
interaction formed between NDUFA4 and the other polypeptide subunits, from which
functional implications could then be inferred. There are significant challenges to
using this approach; particularly the potential risk of contamination with unrelated
protein products when such low concentrations of detergent are used during the
crystallisation process. It is also essential that additional families harbouring
NDUFA4 mutations are identified to further understand the function of NDUFA4, fully
characterise the phenotypic spectrum of NDUFA4-related disease, and establish any
genotype/phenotype correlations.
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In conclusion, this thesis expands the clinical phenotypic spectrum associated with
mutations in both the mitochondrial and nuclear genome and provides evidence that
NDUFA4 mutations link to human disease, thus confirming the essential role of the
NDUFA4 protein as a complex IV subunit.
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